

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 5
MAY 2014**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2014

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Cumulative Supplement 5

May 2014

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement.....	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend.....	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List.....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution.....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists.....	A-1
B. Patent and Exclusivity Terms.....	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

**CUMULATIVE SUPPLEMENT 5
May 2014**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
WEST WARD INC (WEST WARD)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS CORP)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS LLC)	WATSON LABORATORIES INC (WATSON LABS INC)
WATSON LABORATORIES INC (WATSON LABS)	ACTAVIS LABORATORIES INC (ACTAVIS LABS FL INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucml29689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2013</u>	<u>MAR 2014</u>	<u>JUN 2014</u>	<u>SEPT 2014</u>	<u>DEC 2014</u>
DRUG PRODUCTS LISTED	15711	15885			
SINGLE SOURCE	2517 (16.0%)	2540 (16.0%)			
MULTISOURCE	13194 (84.0%)	13345 (84.0%)			
THERAPEUTICALLY EQUIVALENT	13055 (83.1%)	13208 (83.1%)			
NOT THERAPEUTICALLY EQUIVALENT	139 (0.9%)	137 (0.9%)			
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	20	12			
NUMBER OF APPLICANTS	866	873			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration.

CFTG Change. A first time generic for the innovator product. A TE Code is added.

CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1 Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.

CPOT Change. Potency amount/unit.

CRLD Change. Reference Listed Drug.

CTEC Change. Therapeutic Equivalence Code.

CTNA Change. Trade Name.

DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL
 ACAMPROSATE CALCIUM

AB MYLAN PHARMS INC 333MG A200142 001 Mar 11, 2014 Feb NEWA

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL
 ACEBUTOLOL HYDROCHLORIDE

>D> AB WATSON LABS EQ 200MG BASE A074007 001 Oct 18, 1995 May DISC
 >A> @ EQ 200MG BASE A074007 001 Oct 18, 1995 May DISC
 >D> AB EQ 400MG BASE A074007 002 Oct 18, 1995 May DISC
 >A> @ EQ 400MG BASE A074007 002 Oct 18, 1995 May DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL
 PHRENILIN FORTE

@ VALEANT 650MG;50MG A088831 001 Jun 19, 1985 Apr DISC

TABLET;ORAL

BUTAPAP
 @ MIKART 650MG;50MG A089988 001 Oct 26, 1992 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
 ESGIC-PLUS

@ MIKART 500MG;50MG;40MG A040085 001 Mar 28, 1996 Apr DISC

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 @ MIKART 750MG;50MG;40MG A040496 001 Dec 23, 2003 Apr DISC
 @ MIRROR PHARMS 325MG;50MG;40MG A040864 001 Dec 01, 2008 Mar DISC
 AA + VINTAGE PHARMS 325MG;50MG;40MG A040511 001 Aug 27, 2003 Mar CRLD
 @ 500MG;50MG;40MG A040513 001 Aug 25, 2003 Apr DISC
 @ WATSON LABS 500MG;50MG;40MG A040267 001 Jul 30, 1998 Jan DISC
 ESGIC-PLUS
 @ MIKART 500MG;50MG;40MG A089451 001 May 23, 1988 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
 PHRENILIN WITH CAFFEINE AND CODEINE

@ VALEANT 325MG;50MG;40MG;30MG A074911 001 Aug 22, 2001 Mar DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MALLINCKRODT 500MG/15ML;7.5MG/15ML A040418 001 Jun 27, 2001 Jan DISC
 @ MIKART 500MG/15ML;7.5MG/15ML A081051 001 Aug 28, 1992 Apr DISC
 @ PHARM ASSOC 500MG/15ML;7.5MG/15ML A040182 001 Mar 13, 1998 Apr DISC
 AA VINTAGE PHARMS 325MG/15ML;7.5MG/15ML A040894 001 Jul 19, 2011 Feb CAHN
 @ 500MG/15ML;7.5MG/15ML A040520 001 Oct 30, 2003 Apr DISC

TABLET;ORAL

ANEXSIA

@ MALLINCKRODT 500MG;5MG A089160 001 Apr 23, 1987 Jan DISC
 @ 750MG;10MG A040468 001 Oct 31, 2002 Jan DISC

ANEXSIA 7.5/650

@ MALLINCKRODT 650MG;7.5MG A089725 001 Sep 30, 1987 Jan DISC

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ AMNEAL PHARMS NY 500MG;5MG A040729 001 Aug 25, 2006 Apr DISC
 @ 500MG;7.5MG A040748 001 Aug 25, 2006 Apr DISC
 @ 500MG;10MG A040813 001 Feb 23, 2007 Apr DISC
 @ 650MG;7.5MG A040754 001 Aug 25, 2006 Apr DISC
 @ 650MG;10MG A040757 001 Aug 25, 2006 Apr DISC
 @ 750MG;7.5MG A040769 001 Aug 28, 2006 Apr DISC
 @ CARACO 500MG;5MG A090265 001 Dec 23, 2008 Apr DISC
 @ 500MG;7.5MG A090265 002 Dec 23, 2008 Apr DISC
 @ 500MG;10MG A090265 003 Dec 23, 2008 Apr DISC
 @ 650MG;7.5MG A090380 001 Dec 23, 2008 Apr DISC
 @ 650MG;10MG A090380 002 Dec 23, 2008 Apr DISC
 @ 660MG;10MG A090380 003 Dec 23, 2008 Apr DISC
 @ 750MG;7.5MG A090380 004 Dec 23, 2008 Apr DISC
 @ MALLINCKRODT 500MG;5MG A040084 002 Jun 01, 1995 Jan DISC
 @ 500MG;7.5MG A040201 001 Feb 27, 1998 Jan DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
	@	500MG; 10MG	A040201	002	Feb 27, 1998	Jan DISC
	@	650MG; 10MG	A040084	004	Oct 16, 1996	Jan DISC
	@	660MG; 10MG	A040084	003	Jul 29, 1996	Jan DISC
	@	750MG; 7.5MG	A040084	001	Jun 01, 1995	Jan DISC
	@ MIKART	500MG; 7.5MG	A089699	001	Aug 25, 1989	Apr DISC
	@	650MG; 7.5MG	A089689	001	Jun 29, 1988	Apr DISC
	@	650MG; 10MG	A081223	001	May 29, 1992	Apr DISC
AA	VINTAGE PHARMS	300MG; 5MG	A090415	001	Jan 24, 2011	Feb CAHN
AA		300MG; 7.5MG	A090415	002	Jan 24, 2011	Feb CAHN
AA		300MG; 10MG	A090415	003	Jan 24, 2011	Feb CAHN
	@	500MG; 2.5MG	A040144	002	Apr 25, 1997	Apr DISC
	@	500MG; 5MG	A089971	001	Dec 02, 1988	Apr DISC
	@	500MG; 7.5MG	A040144	001	Feb 22, 1996	Apr DISC
	@	500MG; 10MG	A040356	001	May 31, 2000	Apr DISC
	@	650MG; 7.5MG	A040155	001	Apr 14, 1997	Jan DISC
	@	650MG; 10MG	A040143	001	Feb 22, 1996	Apr DISC
	@	660MG; 10MG	A040358	001	May 31, 2000	Apr DISC
	@	750MG; 7.5MG	A040157	001	Apr 12, 1996	Jan DISC
	@ WATSON LABS	500MG; 2.5MG	A081079	001	Aug 30, 1991	Apr DISC
	@	500MG; 5MG	A089883	001	Dec 01, 1988	Apr DISC
	@	500MG; 7.5MG	A081080	001	Aug 30, 1991	Jan DISC
	@	650MG; 7.5MG	A040094	001	Sep 29, 1995	Apr DISC
	@	650MG; 10MG	A040094	002	Sep 29, 1995	Apr DISC
	@	660MG; 10MG	A040094	003	Aug 08, 2000	Apr DISC
	@	750MG; 7.5MG	A081083	001	Aug 30, 1991	Jan DISC
	@	750MG; 10MG	A040094	004	Mar 22, 1999	Apr DISC
	@ WATSON LABS FLORIDA	660MG; 10MG	A040495	001	May 28, 2003	Apr DISC
	LORTAB					
	@ UCB INC	500MG; 5MG	A087722	001	Jul 09, 1982	Apr DISC
	@	500MG; 10MG	A040100	001	Jan 26, 1996	Apr DISC
	ZYDONE					
	@ VINTAGE PHARMS LLC	400MG; 5MG	A040288	001	Nov 27, 1998	Apr DISC
	@	400MG; 7.5MG	A040288	002	Nov 27, 1998	Apr DISC
	@	400MG; 10MG	A040288	003	Nov 27, 1998	Apr DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

	@ DURAMED PHARMS BARR	500MG; 5MG	A040289	001	Mar 16, 1999	Apr DISC
	@ MALLINCKRODT	500MG; 5MG	A040257	001	Aug 04, 1998	Jan DISC
	@ VINTAGE PHARMS	500MG; 5MG	A040106	001	Jul 30, 1996	Apr DISC
	@ WATSON LABS	500MG; 5MG	A040234	001	Oct 30, 1997	Jan DISC
	ROXILOX					
	@ ROXANE	500MG; 5MG	A040061	001	Jul 03, 1995	Apr DISC
	TYLOX					
	@ JANSSEN PHARMS	500MG; 5MG	A088790	001	Dec 12, 1984	Apr DISC

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

	@ AMNEAL PHARMS NY	500MG; 7.5MG	A040789	001	Nov 27, 2007	Apr DISC
	@	650MG; 10MG	A040789	002	Nov 27, 2007	Apr DISC
	@ COASTAL PHARMS	500MG; 7.5MG	A090177	005	Oct 20, 2008	Apr DISC
	@	650MG; 10MG	A090177	006	Oct 20, 2008	Apr DISC
	@ MALLINCKRODT	500MG; 7.5MG	A040550	001	Jun 30, 2004	Apr DISC
	@	650MG; 10MG	A040550	002	Jun 30, 2004	Apr DISC
	@ MIKART	400MG; 5MG	A040687	001	Apr 27, 2006	Apr DISC
	@	400MG; 7.5MG	A040698	001	Apr 27, 2006	Apr DISC
	@	400MG; 10MG	A040692	001	Apr 27, 2006	Apr DISC
	@	500MG; 10MG	A040676	001	Apr 19, 2006	Apr DISC
	@ WATSON LABS	500MG; 7.5MG	A040371	001	Dec 29, 2000	Jan DISC
	@	650MG; 10MG	A040371	002	Dec 29, 2000	Jan DISC
	PERCOCET					
	@ VINTAGE PHARMS LLC	500MG; 7.5MG	A040341	001	Jul 26, 1999	Jan DISC
	@	650MG; 10MG	A040341	002	Jul 26, 1999	Jan DISC

TABLET, EXTENDED RELEASE; ORAL

XARTEMIS XR

+	MALLINCKRODT INC	325MG; 7.5MG	N204031	001	Mar 11, 2014	Mar NEWA
---	------------------	--------------	---------	-----	--------------	----------

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

@ GAVIS PHARMS 650MG;EQ 25MG BASE

A076202 001 Aug 02, 2002 Apr DISC

@ WATSON LABS 650MG;EQ 25MG BASE

A074699 001 Mar 24, 2000 Apr DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB ALLIED PHARMA INC 325MG;37.5MG

A202076 001 Mar 30, 2012 Apr CAHN

AB APOTEX INC 325MG;37.5MG

A078778 001 Apr 07, 2014 Mar NEWA

>D> AB WATSON LABS 325MG;37.5MG

A076914 001 Jul 26, 2006 May DISC

>A> @ 325MG;37.5MG

A076914 001 Jul 26, 2006 May DISC

>D> ACETOHEXAMIDE

>D> TABLET; ORAL

>D> ACETOHEXAMIDE

>D> WATSON LABS 250MG

A071893 001 Nov 25, 1987 May DISC

>A> @ 250MG

A071893 001 Nov 25, 1987 May DISC

>D> + 500MG

A071894 001 Nov 25, 1987 May DISC

>A> @ 500MG

A071894 001 Nov 25, 1987 May DISC

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN INNOPHARMA LICENSING 10%

A204674 001 Feb 11, 2014 Jan NEWA

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+ AUXILIUM PHARMS LLC 8MG;60MG

N019806 001 Mar 25, 1994 Apr CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB CADILA PHARMS LTD 200MG

A201445 001 Mar 06, 2014 Feb NEWA

TABLET; BUCCAL

SITAVIG

+ INNOCUTIS HOLDINGS 50MG

N203791 001 Apr 12, 2013 Apr CMFD

+ 50MG

N203791 001 Apr 12, 2013 Apr CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

+ BEDFORD EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Feb CRLD

@ HIKMA MAPLE EQ 1GM BASE/VIAL

A074913 002 Oct 15, 1997 Feb DISC

@ EQ 500MG BASE/VIAL

A074913 001 Oct 15, 1997 Feb DISC

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

AP AGILA SPECLTS 3MG/ML

A078640 001 Mar 21, 2014 Mar NEWA

AP 3MG/ML

A078686 001 May 13, 2009 Feb CAHN

AP HOSPIRA INC 3MG/ML

A203883 001 Mar 24, 2014 Mar NEWA

AP SAGENT STRIDES 3MG/ML

A090212 001 Mar 28, 2014 Mar NEWA

ALBUTEROL SULFATE

SOLUTION; INHALATION

ACCUNEB

>D> AN + DEY EQ 0.021% BASE

N020949 002 Apr 30, 2001 May CAHN

>D> AN + EQ 0.042% BASE

N020949 001 Apr 30, 2001 May CAHN

>A> AN + MYLAN SPECLT EQ 0.021% BASE

N020949 002 Apr 30, 2001 May CAHN

>A> AN + EQ 0.042% BASE

N020949 001 Apr 30, 2001 May CAHN

TABLET; ORAL

ALBUTEROL SULFATE

>D> AB WATSON LABS EQ 2MG BASE

A072764 001 Aug 28, 1991 May DISC

>A> @ EQ 2MG BASE

A072764 001 Aug 28, 1991 May DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDESOLUTION; INHALATION
DUONEB

>D>	AN	+	DEY	EQ 0.083% BASE;0.017%	N020950	001	Mar 21, 2001	May	CAHN
>A>	AN	+	MYLAN SPECLT	EQ 0.083% BASE;0.017%	N020950	001	Mar 21, 2001	May	CAHN

>D> ALISKIREN HEMIFUMARATE; VALSARTAN

>D> TABLET; ORAL

>D> VALTURNA

>D>			NOVARTIS	EQ 150MG BASE;160MG	N022217	001	Sep 16, 2009	May	DISC
>A>		@		EQ 150MG BASE;160MG	N022217	001	Sep 16, 2009	May	DISC
>D>		+		EQ 300MG BASE;320MG	N022217	002	Sep 16, 2009	May	DISC
>A>		@		EQ 300MG BASE;320MG	N022217	002	Sep 16, 2009	May	DISC

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB			VINTAGE PHARMS	0.25MG	A090248	001	Sep 17, 2010	Feb	CAHN
AB				0.5MG	A090248	002	Sep 17, 2010	Feb	CAHN
AB				1MG	A090248	003	Sep 17, 2010	Feb	CAHN
AB				2MG	A090248	004	Sep 17, 2010	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB			ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006	Jan	CAHN
		@		0.5MG	A077979	001	Feb 28, 2007	Jan	CAHN
AB				1MG	A077725	002	Jul 31, 2006	Jan	CAHN
		@		1MG	A077979	002	Feb 28, 2007	Jan	CAHN
AB				2MG	A077725	004	Jul 31, 2006	Jan	CAHN
		@		2MG	A077979	003	Feb 28, 2007	Jan	CAHN
AB				3MG	A077725	003	Jul 31, 2006	Jan	CAHN
		@		3MG	A077979	004	Feb 28, 2007	Jan	CAHN

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

		@	AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr	CAHN
AP				0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr	CAHN
		+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr	CAHN
AP				0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr	CAHN
		+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr	CAHN
AP				0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr	CAHN
		+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB		+	SANDOZ	100MG	A071293	001	Feb 18, 1987	Feb	CRLD
AB			USL PHARMA	100MG	A070589	001	Aug 05, 1986	Feb	CRLD

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

>D>		@	JHP PHARMS LLC	50MG/ML	A076394	001	Apr 25, 2003	May	CAHN
>A>		@	PAR STERILE PRODUCTS	50MG/ML	A076394	001	Apr 25, 2003	May	CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHORIDE

>A>	AB		ACCORD HLTHCARE	10MG	A202446	001	Jun 04, 2014	May	NEWA
>A>	AB			25MG	A202446	002	Jun 04, 2014	May	NEWA
>A>	AB			50MG	A202446	003	Jun 04, 2014	May	NEWA
>A>	AB			75MG	A202446	004	Jun 04, 2014	May	NEWA
>A>	AB			100MG	A202446	005	Jun 04, 2014	May	NEWA
>A>	AB			150MG	A202446	006	Jun 04, 2014	May	NEWA

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

@	PURACAP PHARM	EQ 2.5MG BASE
@		EQ 5MG BASE
@		EQ 10MG BASE

A078131	001	Sep 04, 2007	Feb	DISC
A078131	002	Sep 04, 2007	Feb	DISC
A078131	003	Sep 04, 2007	Feb	DISC

TABLET;ORAL

AMLODIPINE BESYLATE

AB	VIVIMED LABS	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr CAHN
AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr CAHN
AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	DR REDDYS LABS LTD	EQ 2.5MG BASE;EQ 10MG BASE	A203874	001	Mar 07, 2014	Feb NEWA
AB		EQ 2.5MG BASE;EQ 20MG BASE	A203874	002	Mar 07, 2014	Feb NEWA
AB		EQ 2.5MG BASE;EQ 40MG BASE	A203874	003	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 10MG BASE	A203874	004	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 20MG BASE	A203874	005	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 40MG BASE	A203874	006	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 80MG BASE	A203874	007	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 10MG BASE	A203874	008	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 20MG BASE	A203874	009	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 40MG BASE	A203874	010	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 80MG BASE	A203874	011	Mar 07, 2014	Feb NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	UCSF RODIOPHARM	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204496	001	Mar 28, 2014	Mar NEWA
AP	WA UNIV SCH MED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204506	001	Feb 07, 2014	Jan NEWA

AMOXICILLIN

TABLET, EXTENDED RELEASE;ORAL

MOXATAG

+	PRAGMA PHARMS LLC	775MG	N050813	001	Jan 23, 2008	Apr CAHN
---	-------------------	-------	---------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	SANDOZ	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A202588	001	Mar 04, 2014	Feb NEWA
----	--------	--	---------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	GASTROENTERO	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Mar CDFR
---	--------------	--	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003	Apr CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003	Apr CMFD
AB		5MG;5MG;5MG;5MG	A040456	003	May 06, 2003	Apr CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003	Apr CMFD

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Mar NEWA
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062719	002	May 12, 1987	Feb CAHN
AP		EQ 2GM BASE/VIAL	A062797	002	Jul 12, 1993	Feb CAHN
AP		EQ 10GM BASE/VIAL	A201404	001	Dec 20, 2013	Jan CPOT
AP		EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Feb CAHN
AP		EQ 250MG BASE/VIAL	A062719	001	May 12, 1987	Feb CAHN
AP		EQ 500MG BASE/VIAL	A062719	003	May 12, 1987	Feb CAHN
AP	STRIDES ARCOLAB LTD	EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Mar NEWA
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Mar NEWA
AP		EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Mar NEWA
AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Mar NEWA

ATAZANAVIR SULFATE

		CAPSULE;ORAL							
		ATAZANAVIR SULFATE							
AB	TEVA PHARMS USA	EQ 100MG BASE	A 091673	001	Apr 22, 2014	Apr	NEWA		
AB		EQ 150MG BASE	A 091673	002	Apr 22, 2014	Apr	NEWA		
AB		EQ 200MG BASE	A 091673	003	Apr 22, 2014	Apr	NEWA		
AB		EQ 300MG BASE	A 091673	004	Apr 22, 2014	Apr	NEWA		
		REYATAZ							
AB	BRISTOL MYERS SQUIBB	EQ 100MG BASE	N 021567	001	Jun 20, 2003	Apr	CFTG		
AB		EQ 150MG BASE	N 021567	002	Jun 20, 2003	Apr	CFTG		
AB		EQ 200MG BASE	N 021567	003	Jun 20, 2003	Apr	CFTG		
AB	+	EQ 300MG BASE	N 021567	004	Oct 16, 2006	Apr	CFTG		

ATENOLOL

		TABLET;ORAL							
		ATENOLOL							
AB	MYLAN	50MG	A 073457	003	Jan 24, 1992	Apr	CMS1		

ATOVAQUONE

		SUSPENSION;ORAL							
		ATOVAQUONE							
AB	AMNEAL PHARMS	750MG/5ML	A 202960	001	Mar 18, 2014	Mar	NEWA		
		MEPRON							
AB	+	GLAXOSMITHKLINE LLC	750MG/5ML	N 020500	001	Feb 08, 1995	Mar	CFTG	

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

		TABLET;ORAL							
		ATOVAQUONE AND PROGUANIL HYDROCHLORIDE							
>A>	AB	MYLAN PHARMS INC	62.5MG;25MG	A 202362	001	May 27, 2014	May	NEWA	
>A>	AB		250MG;100MG	A 202362	002	May 27, 2014	May	NEWA	
		MALARONE PEDIATRIC							
>D>		GLAXOSMITHKLINE	62.5MG;25MG	N 021078	002	Jul 14, 2000	May	CTEC	
>A>	AB		62.5MG;25MG	N 021078	002	Jul 14, 2000	May	CTEC	

ATROPINE SULFATE

		INJECTABLE;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
		ATROPINE SULFATE ANSYR PLASTIC SYRINGE							
>D>		HOSPIRA	0.05MG/ML	N 021146	002	Jul 09, 2001	May	CRLD	
>A>	+		0.05MG/ML	N 021146	002	Jul 09, 2001	May	CRLD	

AZELASTINE HYDROCHLORIDE

		SPRAY;NASAL							
		AZELASTINE HYDROCHLORIDE							
AB	PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY	A 202743	001	May 08, 2014	Apr	NEWA		

AZILSARTAN KAMEDOXOMIL

		TABLET;ORAL							
		EDARBI							
		ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL	N 200796	001	Feb 25, 2011	Feb	CAHN	
	+		EQ 80MG MEDOXOMIL	N 200796	002	Feb 25, 2011	Feb	CAHN	

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

		TABLET;ORAL							
		EDARBYCLOR							
		ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL;12.5MG	N 202331	001	Dec 20, 2011	Feb	CAHN	
	+		EQ 40MG MEDOXOMIL;25MG	N 202331	002	Dec 20, 2011	Feb	CAHN	

BACITRACIN

		OINTMENT;OPHTHALMIC							
		BACITRACIN							
	+	PERRIGO CO TENNESSEE	500 UNITS/GM	A 061212	001		Feb	CTEC	

BENDROFLUMETHIAZIDE; NADOLOL

		TABLET;ORAL							
		NADOLOL AND BENDROFLUMETHIAZIDE							
AB	MYLAN	5MG;40MG	A 078688	001	Feb 15, 2008	Jan	CTNA		
AB		5MG;80MG	A 078688	002	Feb 15, 2008	Jan	CTNA		

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

	GEL; TOPICAL							
	BENZACLIN							
AB	+	VALEANT BERMUDA	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Mar	CRLD
	+		5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Mar	CTEC

BEPOTASTINE BESILATE

	SOLUTION/DROPS; OPHTHALMIC							
	BEPREVE							
	+	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Apr	CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

	LOTION; TOPICAL							
	LOTRISONE							
AB	+	MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Jan	CAHN

BETHANECHOL CHLORIDE

	TABLET; ORAL							
	DUVOID							
	@	WELLSPRING PHARM	10MG	A086262	001		Mar	DISC
	@		25MG	A086263	001		Mar	DISC
	@		50MG	A085882	003		Mar	DISC

BIMATOPROST

	SOLUTION/DROPS; OPHTHALMIC							
	LUMIGAN							
>D>	+	ALLERGAN	0.03%	N021275	001	Mar 16, 2001	May	DISC
>A>	@		0.03%	N021275	001	Mar 16, 2001	May	DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

	CAPSULE; ORAL							
	PYLERA							
	+	FOREST LABS INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Apr	CAHN
	+	FOREST RES INST INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

	TABLET; ORAL							
	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE							
>D> AB		WATSON LABS	2.5MG; 6.25MG	A075469	001	Sep 25, 2000	May	DISC
>A>	@		2.5MG; 6.25MG	A075469	001	Sep 25, 2000	May	DISC
>D> AB			5MG; 6.25MG	A075469	002	Sep 25, 2000	May	DISC
>A>	@		5MG; 6.25MG	A075469	002	Sep 25, 2000	May	DISC
>D> AB			10MG; 6.25MG	A075469	003	Sep 25, 2000	May	DISC
>A>	@		10MG; 6.25MG	A075469	003	Sep 25, 2000	May	DISC

BROMFENAC SODIUM

	SOLUTION/DROPS; OPHTHALMIC							
	BROMDAY							
AT	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr	CAHN
AT	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Jan	CFTG
	BROMFENAC SODIUM							
AT1		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Jan	CTEC
AT		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jan	NEWA
AT1		LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jan	CTEC
	XIBROM							
	@	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr	CAHN

BUDESONIDE

	CAPSULE; ORAL							
	BUDESONIDE							
AB		BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Mar	NEWA
	SPRAY, METERED; NASAL							
	BUDESONIDE							
AB		APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Apr	NEWA
	RHINOCORT							
	+	ASTRAZENECA	0.032MG/INH	N020746	001	Oct 01, 1999	Apr	CFTG
	TABLET, EXTENDED RELEASE; ORAL							
	UCERIS							
	+	SALIX PHARMS INC	9MG	N203634	001	Jan 14, 2013	Feb	CAHN
	+	SANTARUS INC	9MG	N203634	001	Jan 14, 2013	Mar	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
 BUPROPION HYDROCHLORIDE
 AB3 ZYDUS PHARMS USA INC 300MG A201567 001 Jan 17, 2014 Jan NEWA

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
 BUSPIRONE HYDROCHLORIDE
 AB ZYDUS PHARMS USA INC 5MG A078888 001 Feb 07, 2014 Jan NEWA
 AB 10MG A078888 002 Feb 07, 2014 Jan NEWA
 AB 15MG A078888 003 Feb 07, 2014 Jan NEWA
 AB 30MG A078888 004 Feb 07, 2014 Jan NEWA

BUTOCONAZOLE NITRATE

CREAM;VAGINAL
 GYNAZOLE-1
 >D> @ KV PHARM 2% N019881 001 Feb 07, 1997 May CAHN
 >A> @ LUMARA HEALTH INC 2% N019881 001 Feb 07, 1997 May CAHN

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION
 BUTORPHANOL TARTRATE
 >D> AP HIKMA FARMACEUTICA 2MG/ML A078247 001 Apr 29, 2009 May DISC
 >A> @ 2MG/ML A078247 001 Apr 29, 2009 May DISC

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS
 CAFFEINE CITRATE
 AP EXELA PHARMA SCIENCE EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A077233 001 Sep 21, 2006 Feb CAHN
 SOLUTION;ORAL
 CAFFEINE CITRATE
 AA EXELA PHARMA SCS LLC EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A077304 001 Sep 21, 2006 Feb CAHN

CALCIPOTRIENE

SOLUTION;TOPICAL
 CALCIPOTRIENE
 >D> AT HI TECH PHARMA 0.005% A077579 001 Nov 19, 2009 May DISC
 >A> @ 0.005% A077579 001 Nov 19, 2009 May DISC
 AT + TOLMAR 0.005% A077029 001 Nov 20, 2009 Apr CRLD
 DOVONEX
 @ LEO PHARM 0.005% N020611 001 Mar 03, 1997 Apr DISC

CALCITRIOL

INJECTABLE;INJECTION
 CALCITRIOL
 @ TEVA PARENTERAL 0.002MG/ML A075823 002 Mar 31, 2003 Feb DISC

CAPTOPRIL

TABLET;ORAL
 CAPTOPRIL
 >D> @ CLONMEL HLTHCARE 12.5MG A074423 001 Feb 13, 1996 May CAHN
 >D> @ 25MG A074423 002 Feb 13, 1996 May CAHN
 >D> @ 50MG A074423 003 Feb 13, 1996 May CAHN
 >D> @ 100MG A074423 004 Feb 13, 1996 May CAHN
 >A> @ DAVA PHARMS INC 12.5MG A074423 001 Feb 13, 1996 May CAHN
 >A> @ 25MG A074423 002 Feb 13, 1996 May CAHN
 >A> @ 50MG A074423 003 Feb 13, 1996 May CAHN
 >A> @ 100MG A074423 004 Feb 13, 1996 May CAHN
 @ WATSON LABS 12.5MG A074451 001 Feb 13, 1996 Mar DISC
 @ 25MG A074451 002 Feb 13, 1996 Mar DISC
 @ 50MG A074451 003 Feb 13, 1996 Mar DISC
 @ 100MG A074451 004 Feb 13, 1996 Mar DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL
 CAPOZIDE 25/15
 @ APOTHECON 25MG;15MG N018709 001 Oct 12, 1984 Mar DISC
 CAPOZIDE 25/25
 @ APOTHECON 25MG;25MG N018709 002 Oct 12, 1984 Mar DISC

TABLET;ORAL

		CAPOZIDE 50/15							
		@ APOTHECON	50MG;15MG		N018709	004	Oct 12, 1984	Mar	DISC
		CAPOZIDE 50/25							
		@ APOTHECON	50MG;25MG		N018709	003	Oct 12, 1984	Mar	DISC
		CAPTOPRIL AND HYDROCHLOROTHIAZIDE							
AB	+	MYLAN	25MG;25MG		A074896	002	Dec 29, 1997	Mar	CRLD
AB	+		50MG;15MG		A074896	004	Dec 29, 1997	Mar	CRLD

CARBIDOPA

		TABLET;ORAL							
		CARBIDOPA							
AB		AMERIGEN PHARMS LTD	25MG		A203261	001	Mar 10, 2014	Feb	NEWA
		LODOSYN							
AB	+	ATON	25MG		N017830	001		Feb	CFTG

CARBINOXAMINE MALEATE

		SOLUTION;ORAL							
		CARBINOXAMINE MALEATE							
AA		VINTAGE PHARMS	4MG/5ML		A040814	001	Feb 26, 2008	Feb	CAHN
		TABLET;ORAL							
		CARBINOXAMINE MALEATE							
AA		VINTAGE PHARMS	4MG		A040639	002	May 30, 2008	Feb	CAHN

CARBOPLATIN

>D>		INJECTABLE;INJECTION							
>D>		CARBOPLATIN							
>D>	AP	BEDFORD	50MG/VIAL		A076099	001	Oct 14, 2004	May	DISC
>A>		@	50MG/VIAL		A076099	001	Oct 14, 2004	May	DISC
>D>	AP		150MG/VIAL		A076099	002	Oct 14, 2004	May	DISC
>A>		@	150MG/VIAL		A076099	002	Oct 14, 2004	May	DISC
>D>	AP		450MG/VIAL		A076099	003	Oct 14, 2004	May	DISC
>A>		@	450MG/VIAL		A076099	003	Oct 14, 2004	May	DISC
>D>	AP	CIPLA LTD	50MG/VIAL		A077383	001	Jan 27, 2006	May	DISC
>A>		@	50MG/VIAL		A077383	001	Jan 27, 2006	May	DISC
>D>	AP		150MG/VIAL		A077383	002	Jan 27, 2006	May	DISC
>A>		@	150MG/VIAL		A077383	002	Jan 27, 2006	May	DISC
>D>	AP		450MG/VIAL		A077383	003	Jan 27, 2006	May	DISC
>A>		@	450MG/VIAL		A077383	003	Jan 27, 2006	May	DISC
>D>	AP	FRESENIUS KABI USA	50MG/VIAL		A076235	001	Oct 14, 2004	May	DISC
>A>		@	50MG/VIAL		A076235	001	Oct 14, 2004	May	DISC
>D>	AP		150MG/VIAL		A076235	002	Oct 14, 2004	May	DISC
>A>		@	150MG/VIAL		A076235	002	Oct 14, 2004	May	DISC
>D>	AP		450MG/VIAL		A076235	003	Oct 14, 2004	May	DISC
>A>		@	450MG/VIAL		A076235	003	Oct 14, 2004	May	DISC
>D>	AP	ONCO THERAPIES LTD	50MG/VIAL		A091510	001	May 29, 2012	May	DISC
>A>		@	50MG/VIAL		A091510	001	May 29, 2012	May	DISC
>D>	AP		150MG/VIAL		A091510	002	May 29, 2012	May	DISC
>A>		@	150MG/VIAL		A091510	002	May 29, 2012	May	DISC
>D>	AP		450MG/VIAL		A091510	003	May 29, 2012	May	DISC
>A>		@	450MG/VIAL		A091510	003	May 29, 2012	May	DISC
>D>	AP	SANDOZ	50MG/VIAL		A076959	001	Mar 18, 2005	May	DISC
>A>		@	50MG/VIAL		A076959	001	Mar 18, 2005	May	DISC
>D>	AP		150MG/VIAL		A076959	002	Mar 18, 2005	May	DISC
>A>		@	150MG/VIAL		A076959	002	Mar 18, 2005	May	DISC
>D>	AP		450MG/VIAL		A076959	003	Mar 18, 2005	May	DISC
>A>		@	450MG/VIAL		A076959	003	Mar 18, 2005	May	DISC
>D>	AP	+ WATSON LABS	50MG/VIAL		A076162	001	Oct 14, 2004	May	DISC
>A>		@	50MG/VIAL		A076162	001	Oct 14, 2004	May	DISC
>D>	AP	+	150MG/VIAL		A076162	002	Oct 14, 2004	May	DISC
>A>		@	150MG/VIAL		A076162	002	Oct 14, 2004	May	DISC
>D>	AP	+	450MG/VIAL		A076162	003	Oct 14, 2004	May	DISC
>A>		@	450MG/VIAL		A076162	003	Oct 14, 2004	May	DISC
		INJECTABLE;IV (INFUSION)							
		CARBOPLATIN							
AP	+	PHARMACHEMIE BV	50MG/5ML (10MG/ML)		A077269	001	Oct 14, 2004	Feb	CAHN
AP	+		150MG/15ML (10MG/ML)		A077269	002	Oct 14, 2004	Feb	CAHN
AP	+		450MG/45ML (10MG/ML)		A077269	003	Oct 14, 2004	Feb	CAHN
AP	+		600MG/60ML (10MG/ML)		A077269	004	Dec 28, 2007	Feb	CAHN

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA SCIEGEN PHARMS INC 350MG A203374 001 Jan 27, 2014 Jan NEWA

CEFACTOR

FOR SUSPENSION; ORAL
CEFACTOR

AB + YUNG SHIN PHARM EQ 375MG BASE/5ML A065412 004 Feb 17, 2012 Jan CRLD

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL
CEFADROXIL

@ ANI PHARMS INC EQ 125MG BASE/5ML A062698 001 Mar 01, 1989 Jan CAHN
 @ EQ 250MG BASE/5ML A062698 002 Mar 01, 1989 Jan CAHN
 @ EQ 250MG BASE/5ML A065278 001 Jan 20, 2006 Jan CAHN
 @ EQ 500MG BASE/5ML A062698 003 Mar 01, 1989 Jan CAHN
 @ EQ 500MG BASE/5ML A065278 002 Jan 20, 2006 Jan CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

@ STERI PHARMA EQ 1GM BASE/VIAL A063208 001 Dec 27, 1991 Mar DISC

CEFTAZIDIME

INJECTABLE; INJECTION
FORTAZ

>A> AP + COVIS INJECTABLES 1GM/VIAL N050578 002 Jul 19, 1985 May CAHN
 >A> AP + 2GM/VIAL N050578 003 Jul 19, 1985 May CAHN
 >A> AP + 6GM/VIAL N050578 004 Jul 19, 1985 May CAHN
 >A> AP + 500MG/VIAL N050578 001 Jul 19, 1985 May CAHN
 >D> AP + COVIS PHARMA 1GM/VIAL N050578 002 Jul 19, 1985 May CAHN
 >D> AP + 2GM/VIAL N050578 003 Jul 19, 1985 May CAHN
 >D> AP + 6GM/VIAL N050578 004 Jul 19, 1985 May CAHN
 >D> AP + 500MG/VIAL N050578 001 Jul 19, 1985 May CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

@ COVIS INJECTABLES EQ 10MG BASE/ML N050634 001 Apr 28, 1989 Apr CAHN
 + EQ 20MG BASE/ML N050634 002 Apr 28, 1989 Apr CAHN
 + EQ 40MG BASE/ML N050634 003 Apr 28, 1989 Apr CAHN

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION
CEFTRIAZONE

AP AGILA SPECLTS EQ 10GM BASE/VIAL A091068 001 Jan 07, 2013 Feb CAHN
 SAMSON MEDCL EQ 100GM BASE/VIAL A090057 001 Apr 25, 2014 Apr NEWA

CEFUROXIME SODIUM

INJECTABLE; IM-IV
ZINACEF

AB + COVIS INJECTABLES EQ 750MG BASE/VIAL N050558 002 Oct 19, 1983 Apr CAHN

INJECTABLE; INJECTION
ZINACEF

AP + COVIS INJECTABLES EQ 1.5GM BASE/VIAL N050558 003 Oct 19, 1983 Apr CAHN
 AP + EQ 7.5GM BASE/VIAL N050558 004 Oct 23, 1986 Apr CAHN

ZINACEF IN PLASTIC CONTAINER

>A> @ COVIS INJECTABLES EQ 15MG BASE/ML N050643 001 Apr 28, 1989 May CAHN
 >A> + EQ 30MG BASE/ML N050643 002 Apr 28, 1989 May CAHN
 >D> + COVIS PHARMA EQ 30MG BASE/ML N050643 002 Apr 28, 1989 May CAHN
 >D> @ COVIS PHARMA SARL EQ 15MG BASE/ML N050643 001 Apr 28, 1989 May CAHN

CELECOXIB

CAPSULE; ORAL
CELEBREX

>D> GD SEARLE 50MG N020998 004 Dec 15, 2006 May CFTG
 >A> AB 50MG N020998 004 Dec 15, 2006 May CFTG
 >D> 100MG N020998 001 Dec 31, 1998 May CFTG
 >A> AB 100MG N020998 001 Dec 31, 1998 May CFTG
 >D> 200MG N020998 002 Dec 31, 1998 May CFTG

CAPSULE;ORAL
 CELEBREX

>A>	AB		200MG	N020998	002	Dec 31, 1998	May	CFTG
>D>		+	400MG	N020998	003	Aug 29, 2002	May	CFTG
>A>	AB		400MG	N020998	003	Aug 29, 2002	May	CFTG
>A>								
>A>	AB		50MG	A078857	001	May 30, 2014	May	NEWA
>A>	AB		50MG	A076898	001	May 30, 2014	May	NEWA
>A>	AB		100MG	A076898	002	May 30, 2014	May	NEWA
>A>	AB		200MG	A076898	003	May 30, 2014	May	NEWA
>A>	AB		400MG	A076898	004	May 30, 2014	May	NEWA

CEPHALEXIN

CAPSULE;ORAL
 CEPHALEXIN
 @ STEVENS J EQ 250MG BASE A062870 001 Mar 17, 1988 Mar DISC

CERITINIB

CAPSULE;ORAL
 ZYKADIA
 + NOVARTIS PHARMS CORP 150MG N205755 001 Apr 29, 2014 Apr NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL
 CEVIMELINE HYDROCHLORIDE
 >A> AB PACK PHARMS LLC 30MG A203775 001 Jun 04, 2014 May NEWA

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL
 CHLORDIAZEPOXIDE HYDROCHLORIDE

>D>	AB		5MG	A086383	001		May	DISC
>A>		@	5MG	A086383	001		May	DISC
>D>	AB		10MG	A086294	001		May	DISC
>A>		@	10MG	A086294	001		May	DISC
>D>	AB		25MG	A086382	001		May	DISC
>A>		@	25MG	A086382	001		May	DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA			4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Apr	NEWA
AA		+	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Apr	CFTG

CHLORPROPAMIDE

TABLET;ORAL
 CHLORPROPAMIDE

		@ ANI PHARMS INC	100MG	A088768	001	Oct 11, 1984	Jan	CAHN
		@	100MG	A088812	001	Oct 19, 1984	Jan	CAHN
		@	100MG	A088840	001	Oct 25, 1984	Feb	CAHN
		@	100MG	A088918	001	Oct 16, 1984	Jan	CAHN
AB		@	100MG	A088921	001	Apr 12, 1985	Jan	CAHN
		@	100MG	A089446	001	Nov 17, 1986	Jan	CAHN
		@	250MG	A088813	001	Oct 19, 1984	Jan	CAHN
		@	250MG	A088919	001	Oct 16, 1984	Jan	CAHN
AB		@	250MG	A088922	001	Apr 12, 1985	Jan	CAHN
		@	250MG	A089447	001	Nov 17, 1986	Jan	CAHN
		@ TEVA PHARMS USA	250MG	A087353	001		Apr	CAHN
		@ ANI PHARMS INC	250MG	A088641	001	Oct 11, 1984	Jan	CAHN
		@ TEVA PHARMS USA	250MG	A088641	001	Oct 11, 1984	Apr	CAHN

CHLORZOXAZONE

TABLET;ORAL
 CHLORZOXAZONE

>D>	AA		500MG	A040137	001	Aug 09, 1996	May	DISC
>A>		@	500MG	A040137	001	Aug 09, 1996	May	DISC
>D>	AA		500MG	A081040	001	Aug 22, 1989	May	DISC
>A>		@	500MG	A081040	001	Aug 22, 1989	May	DISC

CICLOPIROX

CREAM;TOPICAL
CICLOPIROX

AB	TARO	0.77%	A076790	001	Apr 12, 2005	Mar	CMFD
	@	0.77%	A076790	001	Apr 12, 2005	Feb	DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL
CIMETIDINE HYDROCHLORIDE

AA	ANI PHARMS INC	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996	Jan	CAHN
	@	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998	Feb	CAHN
	@	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998	Jan	CAHN

CIPROFLOXACIN

FOR SUSPENSION;ORAL
CIPRO

AB	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	Feb	CFTG
AB	+	500MG/5ML	N020780	002	Sep 26, 1997	Feb	CFTG
	CIPROFLOXACIN						
AB	LUPIN LTD	250MG/5ML	A200563	001	Mar 05, 2014	Feb	NEWA
AB		500MG/5ML	A200563	002	Mar 05, 2014	Feb	NEWA

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

AT	WATSON LABS INC	EQ 0.3% BASE	A076673	001	Jan 21, 2005	Apr	CAHN
----	-----------------	--------------	---------	-----	--------------	-----	------

CISPLATIN

INJECTABLE;INJECTION
CISPLATIN

AP	PHARMACHEMIE BV	1MG/ML	A074656	001	May 16, 2000	Feb	CAHN
----	-----------------	--------	---------	-----	--------------	-----	------

CITALOPRAM HYDROBROMIDE

TABLET;ORAL
CITALOPRAM HYDROBROMIDE

>D>	AB	WATSON LABS	EQ 10MG BASE	A077034	001	Jun 30, 2005	May	DISC
>A>		@	EQ 10MG BASE	A077034	001	Jun 30, 2005	May	DISC
>D>	AB		EQ 20MG BASE	A077034	002	Jun 30, 2005	May	DISC
>A>		@	EQ 20MG BASE	A077034	002	Jun 30, 2005	May	DISC
>D>	AB		EQ 40MG BASE	A077034	003	Jun 30, 2005	May	DISC
>A>		@	EQ 40MG BASE	A077034	003	Jun 30, 2005	May	DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Feb	NEWA
----	---------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL
CLINDESSE

>D>	+	KV PHARM	EQ 2% BASE	N050793	001	Nov 30, 2004	May	CAHN
>A>	+	LUMARA HEALTH INC	EQ 2% BASE	N050793	001	Nov 30, 2004	May	CAHN

SOLUTION;TOPICAL
CLINDAMYCIN PHOSPHATE

>D>	AB	ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	May	CAHN
	AB		EQ 1% BASE	A062811	001	Sep 01, 1988	Apr	CMFD
>A>	AB	G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988	May	CAHN
	@	VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989	Feb	CAHN

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL
CLONIDINE

AB	WATSON LABS INC	0.1MG/24HR	A090873	001	May 06, 2014	Apr	NEWA
AB		0.2MG/24HR	A090873	002	May 06, 2014	Apr	NEWA
AB		0.3MG/24HR	A090873	003	May 06, 2014	Apr	NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP		ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014	Feb	NEWA
AP			5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014	Feb	NEWA

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

>D>	AB	WATSON LABS	0.3MG	A070963	001	Jul 08, 1986	May	DISC
>A>		@	0.3MG	A070963	001	Jul 08, 1986	May	DISC

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

AB		ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Mar	NEWA
AB			0.2MG	A202983	002	Apr 02, 2014	Mar	NEWA

CLOPIDOGREL

TABLET; ORAL

CLOPIDOGREL

AB		AMNEAL PHARMS	75MG	A203751	001	Apr 11, 2014	Mar	NEWA
----	--	---------------	------	---------	-----	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB		APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	Feb	NEWA
AB		MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014	Jan	NEWA

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

>D>	AB	WATSON LABS	3.75MG	A071852	001	Feb 09, 1988	May	DISC
>A>		@	3.75MG	A071852	001	Feb 09, 1988	May	DISC
>D>	AB		7.5MG	A071853	001	Feb 09, 1988	May	DISC
>A>		@	7.5MG	A071853	001	Feb 09, 1988	May	DISC
>D>	AB		15MG	A071854	001	Feb 09, 1988	May	DISC
>A>		@	15MG	A071854	001	Feb 09, 1988	May	DISC

CLOZAPINE

TABLET; ORAL

CLOZAPINE

AB		IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003	Mar	CTEC
AB			200MG	A076809	001	Dec 16, 2005	Mar	CTEC
AB		MYLAN	12.5MG	A075417	003	Apr 15, 2010	Mar	NEWA
AB			50MG	A075417	004	Apr 15, 2010	Mar	NEWA
AB			200MG	A075417	005	Apr 15, 2010	Mar	NEWA

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP		SAGENT PHARMS	EQ 150MG BASE/VIAL	A201365	001	Feb 19, 2014	Feb	NEWA
AP	+	PAR STERILE PRODUCTS	EQ 150MG BASE/VIAL	N050108	002		Apr	CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+		PAR STERILE PRODUCTS	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001		Apr	CAHN
---	--	----------------------	---	---------	-----	--	-----	------

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL

		@ CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005	Feb	CAHN
		VAPRISOL IN 5% DEXTROSE	IN PLASTIC CONTAINER					
+		CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Feb	CAHN

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

>D>	AN	DEY	10MG/ML	A074209	001	Apr 26, 1994	May	CAHN
>A>	AN	MYLAN SPECLT	10MG/ML	A074209	001	Apr 26, 1994	May	CAHN
>D>	AN	WATSON LABS	10MG/ML	A076469	001	Jun 17, 2005	May	DISC
>A>		@	10MG/ML	A076469	001	Jun 17, 2005	May	DISC

>A>	<u>DALBAVANCIN HYDROCHLORIDE</u>							
>A>	INJECTABLE;IV (INFUSION)							
>A>	DALVANCE							
>A>	+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	May	NEWA
	<u>DANTROLENE SODIUM</u>							
	CAPSULE;ORAL							
	DANTRIUM							
AB		PAR STERILE PRODUCTS	25MG	N017443	001		Mar	CAHN
AB			50MG	N017443	003		Mar	CAHN
AB	+		100MG	N017443	002		Mar	CAHN
	INJECTABLE;INJECTION							
	DANTRIUM							
AP	+	PAR STERILE PRODUCTS	20MG/VIAL	N018264	001		Apr	CAHN
		REVONTO						
AP		US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007	Mar	CTNA
	<u>DAPAGLIFLOZIN</u>							
	TABLET;ORAL							
	FARXIGA							
		ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb	CAHN
	+		10MG	N202293	002	Jan 08, 2014	Feb	CAHN
		BRISTOL MYERS SQUIBB	5MG	N202293	001	Jan 08, 2014	Jan	NEWA
	+		10MG	N202293	002	Jan 08, 2014	Jan	NEWA
	<u>DECITABINE</u>							
	POWDER;INTRAVENOUS							
	DECITABINE							
	+	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014	Jan	NEWA
	<u>DEFEROXAMINE MESYLATE</u>							
	INJECTABLE;INJECTION							
	DEFEROXAMINE MESYLATE							
>D>	AP	WATSON LABS	2GM/VIAL	A076806	002	Mar 31, 2006	May	DISC
>A>		@	2GM/VIAL	A076806	002	Mar 31, 2006	May	DISC
>D>	AP		500MG/VIAL	A076806	001	Mar 31, 2006	May	DISC
>A>		@	500MG/VIAL	A076806	001	Mar 31, 2006	May	DISC
	<u>DESIPRAMINE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	DESIPRAMINE HYDROCHLORIDE							
	@	ANI PHARMS INC	25MG	A071800	001	Dec 08, 1987	Jan	CAHN
	@		50MG	A071801	001	Dec 08, 1987	Jan	CAHN
	@		75MG	A071802	001	Dec 08, 1987	Jan	CAHN
	@		100MG	A071803	001	May 29, 1997	Feb	CAHN
	@		150MG	A071804	001	May 29, 1997	Feb	CAHN
	<u>DESLORATADINE</u>							
>A>	SOLUTION;ORAL							
>A>	CLARINEX							
>A>	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	May	CDFR
>D>	SYRUP;ORAL							
>D>	CLARINEX							
>D>	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	May	CDFR
	<u>DESMOPRESSIN ACETATE</u>							
	SPRAY, METERED;NASAL							
	DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)							
AB		SUN PHARMA GLOBAL	0.01MG/SPRAY	A078271	001	Dec 23, 2013	Jan	CMS2
	<u>DESONIDE</u>							
	AEROSOL, FOAM;TOPICAL							
	VERDESO							
>A>	+	AQUA PHARMS	0.05%	N021978	001	Sep 19, 2006	May	CAHN
>D>	+	STIEFEL LABS INC	0.05%	N021978	001	Sep 19, 2006	May	CAHN

DESOXIMETASONE

 OINTMENT;TOPICAL
 DESOXIMETASONE
AB VERSAPHARM INC 0.25% A201005 001 Apr 24, 2014 Apr NEWA

DESVENLAFAXINE

 TABLET, EXTENDED RELEASE;ORAL
 DESVENLAFAXINE
BC SUN PHARMA GLOBAL 50MG N205583 001 Jan 28, 2014 Jan NEWA
BC + 100MG N205583 002 Jan 28, 2014 Jan NEWA

DESVENLAFAXINE FUMARATE

 TABLET, EXTENDED RELEASE;ORAL
 DESVENLAFAXINE FUMARATE
+ SUN PHARMA GLOBAL EQ 50MG BASE N205583 001 Jan 28, 2014 Feb CTEC
+ EQ 100MG BASE N205583 002 Jan 28, 2014 Feb CTEC

DEXCHLORPHENIRAMINE MALEATE

 TABLET;ORAL
 DEXCHLORPHENIRAMINE MALEATE
 @ ANI PHARMS INC 2MG A088682 001 Jan 17, 1986 Jan CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

 CAPSULE, EXTENDED RELEASE;ORAL
 DEXMETHYLPHENIDATE HYDROCHLORIDE
>A> AB TEVA PHARMS USA 15MG A078908 004 May 19, 2014 May NEWA
>A> AB 30MG A202731 003 May 19, 2014 May NEWA
>A> AB WATSON LABS INC 15MG A079108 003 May 19, 2014 May NEWA

DEXTROAMPHETAMINE SULFATE

 TABLET;ORAL
 DEXTROAMPHETAMINE SULFATE
AA COREPHARMA 5MG A090652 001 Mar 07, 2014 Feb NEWA
AA 10MG A090652 002 Mar 07, 2014 Feb NEWA

DIAZEPAM

 CONCENTRATE;ORAL
 DIAZEPAM
AA LANNETT HOLDINGS INC 5MG/ML A204433 001 Apr 14, 2014 Mar NEWA
 DIAZEPAM INTENSOL
AA + ROXANE 5MG/ML A071415 001 Apr 03, 1987 Mar CFTG
 TABLET;ORAL
 DIAZEPAM
 @ DAVA PHARMS INC 2MG A070226 001 Sep 26, 1985 Mar DISC

DICLOFENAC POTASSIUM

 FOR SOLUTION;ORAL
 CAMBIA
+ DEPOMED INC 50MG N022165 001 Jun 17, 2009 Jan CAHN

DICLOFENAC SODIUM

 SOLUTION;TOPICAL
 DICLOFENAC SODIUM
>A> AT APOTEX INC 1.5% A202027 001 May 27, 2014 May NEWA
 PENNSAID
>D> + MALLINCKRODT 1.5% N020947 001 Nov 04, 2009 May CFTG
>A> AT + 1.5% N020947 001 Nov 04, 2009 May CFTG
 + MALLINCKRODT INC 2% N204623 001 Jan 16, 2014 Jan NEWA

DICLOFENAC SODIUM; MISOPROSTOL

 TABLET, DELAYED RELEASE;ORAL
 DICLOFENAC SODIUM AND MISOPROSTOL
AB EAGLE PHARMS 50MG;0.2MG A200540 001 Mar 14, 2014 Mar NEWA
AB 75MG;0.2MG A200540 002 Mar 14, 2014 Mar NEWA

DICYCLOMINE HYDROCHLORIDE

	CAPSULE; ORAL						
	BENTYL						
AB	+ FOREST LABS INC	10MG	N007409	003	Oct 15, 1984	Apr	CAHN
	INJECTABLE; INJECTION						
	BENTYL						
AP	+ FOREST LABS INC	10MG/ML	N008370	001	Oct 15, 1984	Apr	CAHN
	BENTYL PRESERVATIVE FREE						
AP	+ FOREST LABS INC	10MG/ML	N008370	002	Oct 15, 1984	Apr	CAHN
	TABLET; ORAL						
	BENTYL						
AB	+ FOREST LABS INC	20MG	N007409	001	Oct 15, 1984	Apr	CAHN

DIGOXIN

	INJECTABLE; INJECTION						
	LANOXIN						
AP	+ COVIS INJECTABLES	0.25MG/ML	N009330	002		Apr	CAHN
	LANOXIN PEDIATRIC						
	+ COVIS INJECTABLES	0.1MG/ML	N009330	004		Apr	CAHN
	TABLET; ORAL						
	LANOXIN						
	COVIS PHARMA	0.0625MG	N020405	001	Sep 30, 1997	Jan	CMFD
		0.1875MG	N020405	003	Sep 30, 1997	Jan	CMFD

DILTIAZEM HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL						
	DILTIAZEM HYDROCHLORIDE						
	@ NESHER PHARMS	120MG	A076563	002	Sep 12, 2006	Mar	DISC
	@	180MG	A076563	003	Sep 12, 2006	Mar	DISC
	@	240MG	A076563	004	Sep 12, 2006	Mar	DISC
	@	300MG	A076563	005	Sep 12, 2006	Mar	DISC
	@	360MG	A076563	006	Sep 12, 2006	Mar	DISC
	@	420MG	A076563	001	Sep 12, 2006	Mar	DISC
	INJECTABLE; INJECTION						
	DILTIAZEM HYDROCHLORIDE						
	@ AGILA SPECLTS	5MG/ML	A075375	001	Sep 30, 1999	Feb	CAHN

DIPYRIDAMOLE

	TABLET; ORAL						
	DIPYRIDAMOLE						
	@ GLENMARK GENERICS	25MG	A088999	001	Feb 05, 1991	Mar	DISC
	@	50MG	A089000	001	Feb 05, 1991	Mar	DISC
	@	75MG	A089001	001	Feb 05, 1991	Mar	DISC
>D>	AB	WATSON LABS	A087160	001	Jun 07, 1996	May	DISC
>A>	@	50MG	A087160	001	Jun 07, 1996	May	DISC

DISULFIRAM

	TABLET; ORAL						
	DISULFIRAM						
AB	ROXANE	250MG	A202652	001	Feb 05, 2014	Jan	NEWA
AB		500MG	A202652	002	Feb 05, 2014	Jan	NEWA

DIVALPROEX SODIUM

	TABLET, EXTENDED RELEASE; ORAL						
	DIVALPROEX SODIUM						
>A>	AB	AUROBINDO PHARMA LTD EQ 250MG VALPROIC ACID	A202419	001	Jun 02, 2014	May	NEWA
>A>	AB	EQ 500MG VALPROIC ACID	A202419	002	Jun 02, 2014	May	NEWA

DOBUTAMINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	DOBUTAMINE HYDROCHLORIDE						
>D>	AP	WATSON LABS EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993	May	DISC
>A>	@	EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993	May	DISC

DOCETAXEL

	INJECTABLE; INJECTION						
	DOCETAXEL						
	PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Mar	NEWA
		80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Mar	NEWA
		130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Mar	NEWA

INJECTABLE; INJECTION
DOCETAXEL

200MG/20ML (10MG/ML) N202356 004 Mar 13, 2014 Mar NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB MACLEODS PHARMS LTD 23MG A202631 001 Jan 22, 2014 Jan NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION
DOXAPRAM HYDROCHLORIDE

>D> AP WATSON LABS 20MG/ML A073529 001 Jan 30, 1992 May DISC
>A> @ 20MG/ML A073529 001 Jan 30, 1992 May DISC

DOXAZOSIN MESYLATE

TABLET; ORAL
DOXAZOSIN MESYLATE

>A> AB ACCORD HLTHCARE EQ 1MG BASE A202824 001 Jun 11, 2014 May NEWA
>A> AB EQ 2MG BASE A202824 002 Jun 11, 2014 May NEWA
>A> AB EQ 4MG BASE A202824 003 Jun 11, 2014 May NEWA
>A> AB EQ 8MG BASE A202824 004 Jun 11, 2014 May NEWA

DOXERCALCIFEROL

INJECTABLE; INJECTION
DOXERCALCIFEROL

AP SANDOZ 4MCG/2ML (2MCG/ML) A091333 001 May 05, 2014 Apr NEWA
AP 4MCG/2ML (2MCG/ML) A200926 001 Feb 04, 2014 Jan NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

AP PHARMACHEMIE BV 2MG/ML A063336 001 Feb 28, 1995 Feb CAHN
AP 10MG/VIAL A063097 001 May 21, 1990 Feb CAHN
AP 20MG/VIAL A063097 002 May 21, 1990 Feb CAHN
AP 50MG/VIAL A063097 003 May 21, 1990 Feb CAHN
AP 200MG/100ML A063336 004 Feb 28, 1995 Feb CAHN

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

AB LUPIN LTD EQ 50MG BASE A204234 001 Mar 05, 2014 Feb NEWA
AB EQ 75MG BASE A204234 002 Mar 05, 2014 Feb NEWA
AB EQ 100MG BASE A204234 003 Mar 05, 2014 Feb NEWA
>D> AB WATSON LABS EQ 50MG BASE A065041 001 Apr 28, 2000 May DISC
>A> @ EQ 50MG BASE A065041 001 Apr 28, 2000 May DISC
>D> AB EQ 100MG BASE A065041 002 Apr 28, 2000 May DISC
>A> @ EQ 100MG BASE A065041 002 Apr 28, 2000 May DISC

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE; ORAL
DORYX

AB MAYNE PHARMA EQ 150MG BASE N050795 003 Jun 20, 2008 Feb CRLD
+ EQ 200MG BASE N050795 005 Apr 11, 2013 Feb CRLD

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL
NIKKI

>A> AB LUPIN LTD 3MG;0.02MG A201661 001 May 27, 2014 May NEWA

DROXIDOPA

CAPSULE; ORAL
NORTHERA

CHELSEA THERAPS INC 100MG N203202 001 Feb 18, 2014 Feb NEWA
200MG N203202 002 Feb 18, 2014 Feb NEWA
+ 300MG N203202 003 Feb 18, 2014 Feb NEWA

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

>A>	AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A202949	001	Jun 09, 2014	May	NEWA
>A>	AB		EQ 30MG BASE	A202949	002	Jun 09, 2014	May	NEWA
>A>	AB		EQ 60MG BASE	A202949	003	Jun 09, 2014	May	NEWA
>A>	AB	APOTEX INC	EQ 20MG BASE	A202045	001	Jun 11, 2014	May	NEWA
>A>	AB		EQ 30MG BASE	A202045	002	Jun 11, 2014	May	NEWA
>A>	AB		EQ 60MG BASE	A202045	003	Jun 11, 2014	May	NEWA
>A>	AB	BRECKENRIDGE PHARM	EQ 20MG BASE	A203088	001	Jun 11, 2014	May	NEWA
>A>	AB		EQ 30MG BASE	A203088	002	Jun 11, 2014	May	NEWA
>A>	AB		EQ 60MG BASE	A203088	003	Jun 11, 2014	May	NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		ANCHEN PHARMS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Feb	NEWA
		JALYN						
AB	+	GLAXOSMITHKLINE	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Feb	CFTG

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL
ECOZA

+		VELDANA MEDICAL SA	1%	N205175	001	Oct 24, 2013	Feb	CAHN
---	--	--------------------	----	---------	-----	--------------	-----	------

CREAM;TOPICAL
SPECTAZOLE

@		MERZ PHARMS LLC	1%	N018751	001	Dec 23, 1982	Jan	CAHN
---	--	-----------------	----	---------	-----	--------------	-----	------

ENALAPRIL MALEATE

TABLET;ORAL
ENALAPRIL MALEATE

>D>	AB	WATSON LABS	2.5MG	A075501	001	Aug 22, 2000	May	DISC
>A>		@	2.5MG	A075501	001	Aug 22, 2000	May	DISC
>D>	AB		5MG	A075501	002	Aug 22, 2000	May	DISC
>A>		@	5MG	A075501	002	Aug 22, 2000	May	DISC
>D>	AB		10MG	A075501	003	Aug 22, 2000	May	DISC
>A>		@	10MG	A075501	003	Aug 22, 2000	May	DISC
>D>	AB		20MG	A075501	004	Aug 22, 2000	May	DISC
>A>		@	20MG	A075501	004	Aug 22, 2000	May	DISC

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN

+		PAR STERILE PRODUCTS	1MG/ML	N204200	001	Dec 07, 2012	Apr	CAHN
---	--	----------------------	--------	---------	-----	--------------	-----	------

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENALIN

+		PAR STERILE PRODUCTS	30MG/30ML (1MG/ML)	N204640	001	Dec 18, 2013	Apr	CAHN
---	--	----------------------	--------------------	---------	-----	--------------	-----	------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
EPIRUBICIN HYDROCHLORIDE

>D>	AP	HOSPIRA	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007	May	DISC
>A>		@	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007	May	DISC
		@ MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Mar	DISC
		@	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Mar	DISC

ERGOLOID MESYLATES

>D>		TABLET;SUBLINGUAL						
>D>		ERGOLOID MESYLATES						
>D>		WATSON LABS	0.5MG	A087233	001		May	DISC
>A>		@	0.5MG	A087233	001		May	DISC

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL
ERLOTINIB HYDROCHLORIDE

>A>		MYLAN PHARMS INC	EQ 25MG BASE	A091002	001	Jun 11, 2014	May	NEWA
>A>	AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	May	NEWA
>A>	AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	May	NEWA
		TARCEVA						
>D>		OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	May	CFTG
>A>	AB		EQ 25MG BASE	N021743	001	Nov 18, 2004	May	CFTG

		TABLET; ORAL							
		TARCEVA							
>D>			EQ 100MG BASE	N021743	002	Nov 18, 2004	May	CFTG	
>A>	AB		EQ 100MG BASE	N021743	002	Nov 18, 2004	May	CFTG	
>D>		+	EQ 150MG BASE	N021743	003	Nov 18, 2004	May	CFTG	
>A>	AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	May	CFTG	
<u>ERYTHROMYCIN</u>									
		SWAB; TOPICAL							
		ERYTHROMYCIN							
>D>	AT	+	FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	May	DISC
>A>			@	2%	A065320	001	Jul 25, 2006	May	DISC
<u>ERYTHROMYCIN LACTOBIONATE</u>									
		INJECTABLE; INJECTION							
		ERYTHROCIN							
>D>	AP	+	HOSPIRA	EQ 1GM BASE/VIAL	A062638	002	Oct 31, 1986	May	CTEC
>A>		+		EQ 1GM BASE/VIAL	A062638	002	Oct 31, 1986	May	CTEC
<u>ERYTHROMYCIN STEARATE</u>									
		TABLET; ORAL							
		ERYTHROMYCIN STEARATE							
			@ ANI PHARMS INC	EQ 250MG BASE	A061461	001		Feb	CAHN
			@	EQ 250MG BASE	A061591	001		Jan	CAHN
			@	EQ 500MG BASE	A061461	002		Feb	CAHN
			@	EQ 500MG BASE	A063179	001	May 15, 1990	Feb	CAHN
<u>ESCITALOPRAM OXALATE</u>									
		TABLET; ORAL							
		ESCITALOPRAM OXALATE							
AB			TEVA PHARMS USA	EQ 5MG BASE	A076765	001	Mar 14, 2012	Feb	CAHN
AB				EQ 10MG BASE	A076765	002	Mar 14, 2012	Feb	CAHN
AB				EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb	CAHN
<u>ESOMEPRAZOLE MAGNESIUM</u>									
		CAPSULE, DELAYED RELEASE; ORAL							
		NEXIUM							
			ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Mar	NEWA
<u>ESTRADIOL</u>									
		GEL; TOPICAL							
		ESTROGEL							
>D>			@ ASCEND	0.06%	N021166	001	Feb 09, 2004	May	CAHN
>A>			@ ASCEND THERAPS US	0.06%	N021166	001	Feb 09, 2004	May	CAHN
		GEL; TRANSDERMAL							
		DIVIGEL							
			VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007	Apr	CAHN
				0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007	Apr	CAHN
			+	0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007	Apr	CAHN
		GEL, METERED; TRANSDERMAL							
		ESTROGEL							
>D>		+	ASCEND	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	May	CAHN
>A>		+	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	May	CAHN
		SPRAY; TRANSDERMAL							
		EVAMIST							
>D>		+	KV PHARM	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May	CAHN
>A>		+	LUMARA HEALTH INC	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May	CAHN
<u>ESTRADIOL CYPIONATE</u>									
		INJECTABLE; INJECTION							
		DEPO-ESTRADIOL							
>D>	AO	+	PHARMACIA AND UPJOHN	5MG/ML	A085470	003		May	CTEC
>A>		+		5MG/ML	A085470	003		May	CTEC
>D>			ESTRADIOL CYPIONATE						
>D>	AO		WATSON LABS	5MG/ML	A085620	001		May	DISC
>A>			@	5MG/ML	A085620	001		May	DISC

ESTRADIOL VALERATEINJECTABLE; INJECTION
DELESTROGEN

AO	+	PAR STERILE PRODUCTS	10MG/ML		N009402	002		Apr	CAHN
AO	+		20MG/ML		N009402	004		Apr	CAHN
AO	+		40MG/ML		N009402	003		Apr	CAHN

ESTROPIPATE

TABLET; ORAL

>D>		ESTROPIPATE							
>D>	AB	WATSON LABS	6MG		A081216	001	Sep 23, 1993	May	DISC
>A>		@	6MG		A081216	001	Sep 23, 1993	May	DISC
		OGEN 5							
>D>	AB	PHARMACIA AND UPJOHN	6MG		A083220	004		May	CTEC
>A>			6MG		A083220	004		May	CTEC

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

AB		DR REDDYS LABS LTD	1MG		A091024	001	Apr 15, 2014	Mar	NEWA
AB			2MG		A091024	002	Apr 15, 2014	Mar	NEWA
AB			3MG		A091024	003	Apr 15, 2014	Mar	NEWA
AB		GLENMARK GENERICS	1MG		A091166	001	Apr 15, 2014	Mar	NEWA
AB			2MG		A091166	002	Apr 15, 2014	Mar	NEWA
AB			3MG		A091166	003	Apr 15, 2014	Mar	NEWA
AB		LUPIN LTD	1MG		A091124	001	Sep 13, 2011	Mar	CMFD
AB			2MG		A091124	002	Sep 13, 2011	Mar	CMFD
AB			3MG		A091124	003	Sep 13, 2011	Mar	CMFD
>A>	AB	ORCHID HLTHCARE	1MG		A091113	001	Jun 10, 2014	May	NEWA
>A>	AB		2MG		A091113	002	Jun 10, 2014	May	NEWA
>A>	AB		3MG		A091113	003	Jun 10, 2014	May	NEWA
AB		ROXANE	1MG		A091153	001	Apr 15, 2014	Mar	NEWA
AB			2MG		A091153	002	Apr 15, 2014	Mar	NEWA
AB			3MG		A091153	003	Apr 15, 2014	Mar	NEWA
AB		TEVA	1MG		A091169	001	May 23, 2011	Jan	CMFD
AB			2MG		A091169	002	May 23, 2011	Jan	CMFD
AB			3MG		A091169	003	May 23, 2011	Jan	CMFD

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

+	ORGANON USA INC	0.015MG/24HR;0.12MG/24HR			N021187	001	Oct 03, 2001	Apr	CPOT
---	-----------------	--------------------------	--	--	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1		HAUPT PHARMA	0.02MG;0.1MG		A201108	001	Feb 05, 2014	Jan	NEWA
-----	--	--------------	--------------	--	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

AB	+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR		N021180	001	Nov 20, 2001	Mar	CFTG
	+		0.035MG/24HR;0.15MG/24HR		N021180	001	Nov 20, 2001	Mar	CPOT
AB		XULANE							
AB		MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR		A200910	001	Apr 16, 2014	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

>D>	AB	WATSON LABS	0.035MG;1MG		A071480	001	Apr 12, 1988	May	DISC
>A>		@	0.035MG;1MG		A071480	001	Apr 12, 1988	May	DISC
		NORETHINDRONE AND ETHINYL ESTRADIOL							
>D>		WATSON LABS	0.035MG;0.4MG		A078379	001	Feb 23, 2010	May	DISC
>A>		@	0.035MG;0.4MG		A078379	001	Feb 23, 2010	May	DISC
>D>	AB		0.035MG;1MG		A070685	001	Jan 29, 1987	May	DISC
>A>		@	0.035MG;1MG		A070685	001	Jan 29, 1987	May	DISC
>D>		NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)							
>D>		WATSON LABS	0.035MG,0.035MG;0.5MG,1MG		A071043	001	Apr 01, 1988	May	DISC
>A>		@	0.035MG,0.035MG;0.5MG,1MG		A071043	001	Apr 01, 1988	May	DISC
>D>		NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)							
>D>		WATSON LABS	0.035MG,0.035MG;0.5MG,1MG		A071041	001	Sep 24, 1991	May	DISC

TABLET;ORAL-21

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

>A> @ 0.035MG,0.035MG;0.5MG,1MG A071041 001 Sep 24, 1991 May DISC

TABLET;ORAL-28

NORETHIN 1/35E-28

>D> AB WATSON LABS 0.035MG;1MG A071481 001 Apr 12, 1988 May DISC

>A> @ 0.035MG;1MG A071481 001 Apr 12, 1988 May DISC

>D> NORETHINDRONE AND ETHINYL ESTRADIOL

>D> AB WATSON LABS 0.035MG,0.035MG,0.035MG;0.5MG,0.75 A076393 001 Feb 04, 2010 May DISC

>A> @ 0.035MG,0.035MG,0.035MG;0.5MG,0.75 A076393 001 Feb 04, 2010 May DISC

MG,1MG

>D> NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

>D> WATSON LABS 0.035MG,0.035MG;0.5MG,1MG A071042 001 Sep 24, 1991 May DISC

>A> @ 0.035MG,0.035MG;0.5MG,1MG A071042 001 Sep 24, 1991 May DISC

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB FAMY CARE LTD 0.025MG;0.8MG A203371 001 Apr 23, 2014 Apr NEWA

AB + WARNER CHILCOTT 0.025MG;0.8MG N022573 001 Dec 22, 2010 Apr CFTG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21

GILDESS 1.5/30

AB VINTAGE PHARMS LLC 0.03MG;1.5MG A077075 002 Jul 24, 2012 Mar NEWA

GILDESS 1/20

AB VINTAGE PHARMS LLC 0.02MG;1MG A077077 002 Jul 24, 2012 Mar NEWA

LARIN 1.5/30

AB NOVAST LABS LTD 0.03MG;1.5MG A202996 001 Mar 20, 2014 Mar NEWA

>D> LOESTRIN 21 1.5/30

>D> AB WARNER CHILCOTT LLC 0.03MG;1.5MG N017875 001 May DISC

>A> @ 0.03MG;1.5MG N017875 001 May DISC

>D> LOESTRIN 21 1/20

>D> AB WARNER CHILCOTT LLC 0.02MG;1MG N017876 001 May DISC

>A> @ 0.02MG;1MG N017876 001 May DISC

TABLET;ORAL-28

LOESTRIN FE 1.5/30

>D> AB + WARNER CHILCOTT LLC 0.03MG;1.5MG N017355 001 May DISC

>A> @ 0.03MG;1.5MG N017355 001 May DISC

>D> LOESTRIN FE 1/20

>D> AB WARNER CHILCOTT 0.02MG;1MG N017354 001 May DISC

>A> @ 0.02MG;1MG N017354 001 May DISC

MICROGESTIN FE 1.5/30

>D> AB WATSON LABS 0.03MG;1.5MG A075548 001 Feb 05, 2001 May CRLD

>A> AB + 0.03MG;1.5MG A075548 001 Feb 05, 2001 May CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

>D> AB WATSON LABS 0.025MG,0.025MG,0.025MG;0.18MG,0.2 A090479 001 Mar 09, 2011 May DISC

>A> @ 0.025MG,0.025MG,0.025MG;0.18MG,0.2 A090479 001 Mar 09, 2011 May DISC

15MG,0.25MG

>D> AB 0.035MG,0.035MG,0.035MG;0.18MG,0.2 A076626 001 Aug 17, 2006 May DISC

>A> @ 0.035MG,0.035MG,0.035MG;0.18MG,0.2 A076626 001 Aug 17, 2006 May DISC

15MG,0.25MG

>D> AB 0.035MG;0.25MG A076627 001 Aug 17, 2006 May DISC

>A> @ 0.035MG;0.25MG A076627 001 Aug 17, 2006 May DISC

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

LOW-OGESTREL-21

>D> AB + WATSON LABS 0.03MG;0.3MG A075288 001 Jul 28, 1999 May DISC

>A> @ 0.03MG;0.3MG A075288 001 Jul 28, 1999 May DISC

TABLET;ORAL-28

LOW-OGESTREL-28

>D> AB WATSON LABS 0.03MG;0.3MG A075288 002 Jul 28, 1999 May DISC

>A> @ 0.03MG;0.3MG A075288 002 Jul 28, 1999 May DISC

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE
ETHIODOL

+ GUERBET	99%	N009190	001		Apr	CMFD
LIPIODOL						
+ GUERBET	99%	N009190	001		Apr	CTNA

ETODOLAC

CAPSULE;ORAL
ETODOLAC

@ ANI PHARMS INC	200MG	A074899	001	Jul 08, 1997	Feb	CAHN
@	200MG	A075126	001	Sep 16, 1999	Jan	CAHN
@	300MG	A074899	002	Jul 08, 1997	Feb	CAHN
AB	300MG	A075126	002	Sep 16, 1999	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL
ETODOLAC

>A> AB	ZYDUS PHARMS USA INC	400MG	A091134	001	Jan 23, 2014	May	NEWA
>A> AB		500MG	A091134	002	Jan 23, 2014	May	NEWA
>A> AB		600MG	A091134	003	Jan 23, 2014	May	NEWA

ETOMIDATE

INJECTABLE;INJECTION
ETOMIDATE

AP	AGILA SPECLTS	2MG/ML	A078289	001	Jan 02, 2009	Feb	CAHN
----	---------------	--------	---------	-----	--------------	-----	------

ETOPOSIDE

INJECTABLE;INJECTION
ETOPOSIDE

>D> AP	@ PHARMACHEMIE BV	20MG/ML	A074227	001	Feb 22, 1996	Feb	CAHN
>A>	TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994	May	DISC
>A>	@	20MG/ML	A074284	001	Feb 10, 1994	May	DISC

EXENATIDE SYNTHETIC

INJECTABLE;SUBCUTANEOUS
BYETTA

+ ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Mar	CAHN
+	600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Mar	CAHN

FAMOTIDINE

FOR SUSPENSION;ORAL
FAMOTIDINE

>A> AB	HI-TECH PHARMA CO	40MG/5ML	A201995	001	May 30, 2014	May	NEWA
	INJECTABLE;INJECTION						
	FAMOTIDINE PRESERVATIVE FREE						
AP	BEDFORD LABS	10MG/ML	A075825	001	Apr 17, 2001	Feb	CAHN

FENOFIBRATE

TABLET;ORAL
FENOGLIDE

	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Feb	CAHN
+		120MG	N022118	002	Aug 10, 2007	Feb	CAHN
	TRIGLIDE						
>D>	SKYEPHARMA AG	50MG	N021350	001	May 07, 2005	May	DISC
>A>	@	50MG	N021350	001	May 07, 2005	May	DISC

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

@ NOVEN	100MCG/HR	A077775	004	Oct 16, 2009	Apr	DISC
FENTANYL-25						
@ NOVEN	25MCG/HR	A077775	001	Oct 16, 2009	Apr	DISC
FENTANYL-50						
@ NOVEN	50MCG/HR	A077775	002	Oct 16, 2009	Apr	DISC
FENTANYL-75						
@ NOVEN	75MCG/HR	A077775	003	Oct 16, 2009	Apr	DISC

FENTANYL CITRATE

>D>	TABLET;BUCCAL							
>D>	FENTANYL CITRATE							
>D> AB	WATSON LABS	EQ 0.1MG BASE	A 079075	001	Jan 07, 2011	May	DISC	
>A>	@	EQ 0.1MG BASE	A 079075	001	Jan 07, 2011	May	DISC	
>D> AB		EQ 0.2MG BASE	A 079075	002	Jan 07, 2011	May	DISC	
>A>	@	EQ 0.2MG BASE	A 079075	002	Jan 07, 2011	May	DISC	
>D> AB		EQ 0.4MG BASE	A 079075	003	Jan 07, 2011	May	DISC	
>A>	@	EQ 0.4MG BASE	A 079075	003	Jan 07, 2011	May	DISC	
>D> AB		EQ 0.6MG BASE	A 079075	004	Jan 07, 2011	May	DISC	
>A>	@	EQ 0.6MG BASE	A 079075	004	Jan 07, 2011	May	DISC	
>D> AB		EQ 0.8MG BASE	A 079075	005	Jan 07, 2011	May	DISC	
>A>	@	EQ 0.8MG BASE	A 079075	005	Jan 07, 2011	May	DISC	
>A>	TABLET;SUBLINGUAL							
>A>	FENTANYL CITRATE							
>A>	@ WATSON LABS	EQ 0.1MG BASE	A 079075	001	Jan 07, 2011	May	CDFR	
>A>	@	EQ 0.2MG BASE	A 079075	002	Jan 07, 2011	May	CDFR	
>A>	@	EQ 0.4MG BASE	A 079075	003	Jan 07, 2011	May	CDFR	
>A>	@	EQ 0.6MG BASE	A 079075	004	Jan 07, 2011	May	CDFR	
>A>	@	EQ 0.8MG BASE	A 079075	005	Jan 07, 2011	May	CDFR	

FLORBETABEN F-18SOLUTION;INTRAVENOUS
NEURACEQ

+ PIRAMAL IMAGING 30ML (1.4-135mCi/ML) N204677 001 Mar 19, 2014 Mar NEWA

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ TEVA PHARMS 200MG/100ML (2MG/ML) A 076837 001 Jan 13, 2005 Apr DISC

@ 400MG/200ML (2MG/ML) A 076837 002 Jan 13, 2005 Apr DISC

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

>A> AP MUSTAFA NEVZAT ILAC 50MG/2ML (25MG/ML) A 090724 001 Sep 27, 2010 May CAHN

>D> AP MYLAN INSTITUTIONAL 50MG/2ML (25MG/ML) A 090724 001 Sep 27, 2010 May CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP ESSENTIAL ISOTOPES 20-300mCi/ML A 203946 001 Feb 05, 2014 Jan NEWA

AP LANTHEUS MEDICAL 20-200mCi/ML A 203664 001 Feb 04, 2014 Jan NEWA

AP UCSF RODIOPHARM 20-300mCi/ML A 203902 001 May 09, 2014 Apr NEWA

@ WEILL MEDCL COLL 10-100mCi/ML N 021768 001 Aug 05, 2004 Feb DISC

AP WUSM CYCLOTRON 20-300mCi/ML A 203935 001 Feb 05, 2014 Jan NEWA

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB HIKMA PHARMS 0.1MG A 091302 001 Jul 22, 2011 Jan CAHN

AB 0.1MG A 091302 001 Jul 22, 2011 Jan CAHN

AB 0.1MG A 091302 001 Jul 22, 2011 Jan CAHN

AB 0.1MG A 091302 001 Jul 22, 2011 Jan CAHN

FLUNISOLIDE

AEROSOL, METERED;INHALATION

AEROSPAN HFA

+ MEDA PHARMS INC EQ 78MG BASE/INH N 021247 001 Jan 27, 2006 Mar CAHN

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

+ MEDIMETRIKS PHARMS 0.025%;EQ 3.5MG BASE/GM A 060700 001 Apr CMFD

FLUOCINONIDE

SOLUTION;TOPICAL

FLUOCINONIDE

>D> AT ACTAVIS MID ATLANTIC 0.05% A 071535 001 Dec 02, 1988 May CAHN

>A> AT G AND W LABS INC 0.05% A 071535 001 Dec 02, 1988 May CAHN

SOLUTION;TOPICAL
LIDEX

AT CNTY LINE PHARMS 0.05% N018849 001 Apr 06, 1984 Apr CMFD

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB2 ANI PHARMS INC EQ 10MG BASE A076287 001 May 20, 2008 Jan CAHN
AB2 EQ 20MG BASE A076287 002 May 20, 2008 Jan CAHN

TABLET;ORAL

SARAFEM

AB1 WARNER CHILCOTT LLC EQ 10MG BASE N021860 001 May 19, 2006 Jan CFTG
AB1 EQ 15MG BASE N021860 002 May 19, 2006 Jan CFTG
AB1 + EQ 20MG BASE N021860 003 May 19, 2006 Jan CFTG
SELFEMRA
AB1 TEVA PHARMS USA EQ 10MG BASE A200151 001 Feb 03, 2014 Jan NEWA
AB1 EQ 15MG BASE A200151 002 Feb 03, 2014 Jan NEWA
AB1 EQ 20MG BASE A200151 003 Feb 03, 2014 Jan NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

@ ANI PHARMS INC 2.5MG/5ML A081310 001 Apr 29, 1993 Feb CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

>D> AB MYLAN PHARMS INC 15MG A070345 002 Nov 27, 1985 May CTEC
>A> 15MG A070345 002 Nov 27, 1985 May CTEC
>D> AB + 30MG A070345 001 Nov 27, 1985 May CTEC
>A> + 30MG A070345 001 Nov 27, 1985 May CTEC
>D> AB WATSON LABS 15MG A071205 001 Nov 25, 1986 May DISC
>A> @ 15MG A071205 001 Nov 25, 1986 May DISC
>D> AB 30MG A071068 001 Nov 25, 1986 May DISC
>A> @ 30MG A071068 001 Nov 25, 1986 May DISC
>D> AB 30MG A072369 001 Mar 30, 1989 May DISC
>A> @ 30MG A072369 001 Mar 30, 1989 May DISC

FOLIC ACID

TABLET;ORAL

FOLIC ACID

AA CADILA PHARMS LTD 1 MG A202437 001 Jan 27, 2014 Jan NEWA

FOLLITROPIN ALFA/BETA

INJECTABLE;SUBCUTANEOUS

GONAL-F RFF PEN

>D> + EMD SERONO 300 IU/0.5ML N021684 001 May 25, 2004 May CTNA
>D> + 450 IU/0.75ML N021684 002 May 25, 2004 May CTNA
>D> + 900 IU/1.5ML N021684 003 May 25, 2004 May CTNA
>A> GONAL-F RFF REDI-JECT
>A> + EMD SERONO 300 IU/0.5ML N021684 001 May 25, 2004 May CTNA
>A> + 450 IU/0.75ML N021684 002 May 25, 2004 May CTNA
>A> + 900 IU/1.5ML N021684 003 May 25, 2004 May CTNA

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS

ARIIXTRA

>A> AP + AGI 2.5MG/0.5ML N021345 001 Dec 07, 2001 May CAHN
>A> AP + 5MG/0.4ML N021345 002 May 28, 2004 May CAHN
>A> AP + 7.5MG/0.6ML N021345 003 May 28, 2004 May CAHN
>A> AP + 10MG/0.8ML N021345 004 May 28, 2004 May CAHN
>D> AP + GLAXOSMITHKLINE 2.5MG/0.5ML N021345 001 Dec 07, 2001 May CAHN
>D> AP + 5MG/0.4ML N021345 002 May 28, 2004 May CAHN
>D> AP + 7.5MG/0.6ML N021345 003 May 28, 2004 May CAHN
>D> AP + 10MG/0.8ML N021345 004 May 28, 2004 May CAHN

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

>D> AB WATSON LABS 10MG A077531 001 Aug 31, 2006 May DISC
>A> @ 10MG A077531 001 Aug 31, 2006 May DISC
>D> AB 20MG A077531 002 Aug 31, 2006 May DISC

TABLET;ORAL

FOSINOPRIL SODIUM

>A>	@	20MG	A 077531	002	Aug 31, 2006	May	DISC
>D>	AB	40MG	A 077531	003	Aug 31, 2006	May	DISC
>A>	@	40MG	A 077531	003	Aug 31, 2006	May	DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		EMCURE PHARMS INDIA	10MG;12.5MG	A 079025	001	Sep 17, 2010	Feb	CAIN
AB	+		20MG;12.5MG	A 079025	002	Sep 17, 2010	Feb	CAIN

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	+	EMCURE PHARMS INDIA	20MG;12.5MG	A 079025	002	Sep 17, 2010	Jan	CRLD
----	---	---------------------	-------------	----------	-----	--------------	-----	------

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

CEREBYX

AP		PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N 020450	001	Aug 05, 1996	Feb	CMFD
		FOSPHENYTOIN SODIUM						
AP		AGILA SPECLTS	EQ 50MG PHENYTOIN NA/ML	A 078736	001	Jun 08, 2010	Feb	CAHN

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

AP		CLARIS LIFESCIENCES	10MG/ML	A 202747	001	Jan 27, 2014	Jan	NEWA
----	--	---------------------	---------	----------	-----	--------------	-----	------

TABLET;ORAL

FUROSEMIDE

AB		CARACO	20MG	A 091258	001	Apr 01, 2014	Mar	NEWA
AB			40MG	A 091258	002	Apr 01, 2014	Mar	NEWA
AB			80MG	A 091258	003	Apr 01, 2014	Mar	NEWA
>D>	AB	WATSON LABS	20MG	A 070412	001	Feb 26, 1986	May	DISC
>A>	@		20MG	A 070412	001	Feb 26, 1986	May	DISC
>D>	AB		20MG	A 070449	001	Nov 22, 1985	May	DISC
>A>	@		20MG	A 070449	001	Nov 22, 1985	May	DISC
>D>	AB		20MG	A 071379	001	Jan 02, 1987	May	DISC
>A>	@		20MG	A 071379	001	Jan 02, 1987	May	DISC
>D>	AB		40MG	A 070450	001	Nov 22, 1985	May	DISC
>A>	@		40MG	A 070450	001	Nov 22, 1985	May	DISC
>D>	AB		80MG	A 070528	001	Jan 07, 1986	May	DISC
>A>	@		80MG	A 070528	001	Jan 07, 1986	May	DISC
>D>	AB		80MG	A 071594	001	Feb 09, 1988	May	DISC
>A>	@		80MG	A 071594	001	Feb 09, 1988	May	DISC

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

>D>	AB	WATSON LABS	100MG	A 075485	003	May 11, 2007	May	DISC
>A>	@		100MG	A 075485	003	May 11, 2007	May	DISC
>D>	AB		300MG	A 075485	002	May 11, 2007	May	DISC
>A>	@		300MG	A 075485	002	May 11, 2007	May	DISC
>D>	AB		400MG	A 075485	001	May 11, 2007	May	DISC
>A>	@		400MG	A 075485	001	May 11, 2007	May	DISC

TABLET;ORAL

GABAPENTIN

AB		ACI HEALTHCARE LTD	600MG	A 203244	002	Jul 12, 2013	Feb	CAHN
AB			800MG	A 203244	001	Jul 12, 2013	Feb	CAHN

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

>D>	@	YABAO BIOPHARMS	EQ 4MG BASE	A 077604	001	Feb 06, 2009	May	CAHN
>D>	@		EQ 8MG BASE	A 077604	002	Feb 06, 2009	May	CAHN
>D>	@		EQ 12MG BASE	A 077604	003	Feb 06, 2009	May	CAHN
>A>	@	YABAO PHARM	EQ 4MG BASE	A 077604	001	Feb 06, 2009	May	CAHN
>A>	@		EQ 8MG BASE	A 077604	002	Feb 06, 2009	May	CAHN
>A>	@		EQ 12MG BASE	A 077604	003	Feb 06, 2009	May	CAHN

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

>D>	AB	WATSON LABS	600MG	A074442	001	Apr 28, 1995	May	DISC
>A>		@	600MG	A074442	001	Apr 28, 1995	May	DISC

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS
COPAXONE

+	TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Jan	NEWA
---	-----------------	---------	---------	-----	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE

>D>	AB	WATSON LABS	1MG	A077280	001	Feb 03, 2006	May	DISC
>A>		@	1MG	A077280	001	Feb 03, 2006	May	DISC
>D>	AB		2MG	A077280	002	Feb 03, 2006	May	DISC
>A>		@	2MG	A077280	002	Feb 03, 2006	May	DISC
>D>	AB		4MG	A077280	003	Feb 03, 2006	May	DISC
>A>		@	4MG	A077280	003	Feb 03, 2006	May	DISC

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

>D>	AB	WATSON LABS	5MG	A074370	001	Nov 22, 1994	May	DISC
>A>		@	5MG	A074370	001	Nov 22, 1994	May	DISC
>D>	AB		10MG	A074370	002	Nov 22, 1994	May	DISC
>A>		@	10MG	A074370	002	Nov 22, 1994	May	DISC

GLYCOPYRROLATE

TABLET; ORAL
GLYCOPYRROLATE

AA	STASON PHARMS	1MG	A091182	001	Feb 03, 2014	Jan	NEWA
AA		2MG	A091182	002	Feb 03, 2014	Jan	NEWA
AA	VINTAGE PHARMS	1MG	A090020	001	Oct 19, 2011	Feb	CAHN
AA		2MG	A090020	002	Oct 19, 2011	Feb	CAHN

GUANABENZ ACETATE

TABLET; ORAL
GUANABENZ ACETATE

	ANI PHARMS INC	EQ 4MG BASE	A074149	001	Apr 07, 1995	Jan	CAHN
	@	EQ 4MG BASE	A074267	001	Jun 01, 1994	Mar	CAHN
+		EQ 8MG BASE	A074149	002	Apr 07, 1995	Jan	CAHN
	@	EQ 8MG BASE	A074267	002	Jun 01, 1994	Mar	CAHN

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL
HALOBETASOL PROPIONATE

AB	TARO	0.05%	A076994	001	Dec 16, 2004	Apr	CMFD
----	------	-------	---------	-----	--------------	-----	------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Feb	CMFD
AO		EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Feb	CMFD

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011	Mar	NEWA
+	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983	Mar	CRLD
+	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Mar	CRLD
+		5,000 UNITS/ML	N201370	002	Jul 21, 2011	Mar	CRLD
+		10,000 UNITS/ML	N201370	003	Jul 21, 2011	Mar	CRLD
	HEPARIN SODIUM IN PLASTIC CONTAINER						
+	FRESENIUS KABI USA	1,000 UNITS/ML	N017029	013	Dec 05, 1985	Mar	CTEC
+		10,000 UNITS/ML	N017029	015	Dec 05, 1985	Mar	CTEC
+		20,000 UNITS/ML	N017029	016	Dec 05, 1985	Mar	CTEC
	HEPARIN SODIUM PRESERVATIVE FREE						
+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar	NEWA
+	HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987	Mar	CTEC

INJECTABLE; INJECTION
HEPARIN SODIUM PRESERVATIVE FREE

+	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Mar	CRLD
---	--------	----------------	---------	-----	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HYDROCHLORIDE

>D>	AA	WATSON LABS	25MG	A084504	001		May	DISC
>A>		@	25MG	A084504	001		May	DISC
>D>	AA		50MG	A084503	001		May	DISC
>A>		@	50MG	A084503	001		May	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

AB		CARACO	12.5MG	A090651	001	Apr 07, 2014	Mar	NEWA
----	--	--------	--------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		PRINSTON INC	12.5MG; 150MG	A203072	001	May 09, 2014	Apr	NEWA
AB			12.5MG; 300MG	A203072	002	May 09, 2014	Apr	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>D>	AB	WATSON LABS	12.5MG; 50MG	A200180	001	Jan 12, 2011	May	DISC
>A>		@	12.5MG; 50MG	A200180	001	Jan 12, 2011	May	DISC
>D>	AB		12.5MG; 100MG	A200180	002	Jan 12, 2011	May	DISC
>A>		@	12.5MG; 100MG	A200180	002	Jan 12, 2011	May	DISC
>D>	AB		25MG; 100MG	A200180	003	Jan 12, 2011	May	DISC
>A>		@	25MG; 100MG	A200180	003	Jan 12, 2011	May	DISC

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE

		MYLAN	15MG; 250MG	A070265	002	Jan 23, 1986	Mar	CMS1
--	--	-------	-------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		HERITAGE PHARMS INC	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Apr	CAHN
AB			12.5MG; 15MG	A202150	002	Mar 07, 2014	Apr	CAHN
AB			25MG; 15MG	A202150	003	Mar 07, 2014	Apr	CAHN
AB		INDICUS PHARMA	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Feb	NEWA
AB			12.5MG; 15MG	A202150	002	Mar 07, 2014	Feb	NEWA
AB			25MG; 15MG	A202150	003	Mar 07, 2014	Feb	NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	25MG; 40MG	A070947	002	Mar 04, 1987	Mar	CMS1
----	--	-------	------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

>D>	AB	WATSON LABS	25MG; 25MG	A087398	001		May	DISC
>A>		@	25MG; 25MG	A087398	001		May	DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL
MICARDIS HCT

AB		BOEHRINGER INGELHEIM	12.5MG; 40MG	N021162	001	Nov 17, 2000	Feb	CFTG
AB			12.5MG; 80MG	N021162	002	Nov 17, 2000	Feb	CFTG
AB	+		25MG; 80MG	N021162	003	Apr 19, 2004	Feb	CFTG

AB		ALEMBIC PHARMS LTD	12.5MG; 40MG	A203010	001	Feb 25, 2014	Feb	NEWA
AB			12.5MG; 80MG	A203010	002	Feb 25, 2014	Feb	NEWA
AB			25MG; 80MG	A203010	003	Feb 25, 2014	Feb	NEWA
AB		MYLAN PHARMS INC	12.5MG; 40MG	A091648	001	Feb 25, 2014	Feb	NEWA
AB			12.5MG; 80MG	A091648	002	Feb 25, 2014	Feb	NEWA
AB			25MG; 80MG	A091648	003	Feb 25, 2014	Feb	NEWA

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE							
AB	TORRENT PHARMS LTD	12.5MG;40MG	A201192	001	Feb 25, 2014	Feb	NEWA
AB		12.5MG;80MG	A201192	002	Feb 25, 2014	Feb	NEWA
AB		25MG;80MG	A201192	003	Feb 25, 2014	Feb	NEWA

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL							
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
AA	PADDOCK LLC	5MG/5ML;60MG/5ML	A204658	001	Apr 29, 2014	Apr	NEWA
AA	+ CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Apr	CFTG

HYDROCORTISONE

CREAM;TOPICAL							
HYDROCORTISONE							
	@ TARO	1%	A086155	001		Mar	DISC
LOTION;TOPICAL							
ALA-CORT							
	@ CROWN LABS	1%	A083201	001		Mar	DISC
NUTRACORT							
	@ DOW PHARM	1%	A080443	003		Mar	DISC

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL							
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%							
	@ VINTAGE PHARMS	1%;1%	A089440	001	May 17, 1988	Feb	CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL							
EXALGO							
AB	MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010	Apr	CFTG
AB		12MG	N021217	002	Mar 01, 2010	Apr	CFTG
AB		16MG	N021217	003	Mar 01, 2010	Apr	CFTG
HYDROMORPHONE HYDROCHLORIDE							
AB	ACTAVIS LABS FL INC	8MG	A202144	001	May 12, 2014	Apr	NEWA
AB		12MG	A202144	002	May 12, 2014	Apr	NEWA
AB		16MG	A202144	003	May 12, 2014	Apr	NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL							
HYDROXYCHLOROQUINE SULFATE							
>D> AB	WATSON LABS	200MG	A040133	001	Nov 30, 1995	May	DISC
>A>	@	200MG	A040133	001	Nov 30, 1995	May	DISC

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR							
MAKENA							
>D>	+ KV PHARM	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	May	CAHN
>A>	+ LUMARA HEALTH INC	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	May	CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL							
HYDROXYZINE HYDROCHLORIDE							
>D> AB	WATSON LABS	10MG	A081149	001	Mar 18, 1994	May	DISC
>A>	@	10MG	A081149	001	Mar 18, 1994	May	DISC
>D> AB		25MG	A081150	001	Mar 18, 1994	May	DISC
>A>	@	25MG	A081150	001	Mar 18, 1994	May	DISC
>D> AB		50MG	A081151	001	Mar 18, 1994	May	DISC
>A>	@	50MG	A081151	001	Mar 18, 1994	May	DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL							
HYDROXYZINE PAMOATE							
>D> AB	WATSON LABS	EQ 25MG HCL	A081165	001	Jul 31, 1991	May	DISC
>A>	@	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991	May	DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS
BONIVA

AP	+	ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Feb CFTG
AP		SUN PHARM INDS LTD	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	Feb NEWA

IBUPROFEN

TABLET; ORAL
IBUPROFEN

>D>	AB	WATSON LABS	400MG	A070436	001	Aug 21, 1985	May DISC
>A>		@	400MG	A070436	001	Aug 21, 1985	May DISC
>D>	AB		600MG	A070437	001	Aug 21, 1985	May DISC
>A>		@	600MG	A070437	001	Aug 21, 1985	May DISC

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

>D>	AB	WATSON LABS	1.25MG	A074585	001	Sep 26, 1996	May DISC
>A>		@	1.25MG	A074585	001	Sep 26, 1996	May DISC
>D>	AB		2.5MG	A074585	002	Sep 26, 1996	May DISC
>A>		@	2.5MG	A074585	002	Sep 26, 1996	May DISC

INDOMETHACIN

CAPSULE; ORAL
INDOCIN

>D>		@ ICEUTICA OPERATIONS	25MG	N016059	001		May CAHN
>D>		@	50MG	N016059	002		May CAHN
>A>		@ IROKO PHARMS LLC	25MG	N016059	001		May CAHN
>A>		@	50MG	N016059	002		May CAHN

TIVORBEX

IROKO PHARMS LLC 20MG
+ 40MG

N204768	001	Feb 24, 2014	Feb NEWA
N204768	002	Feb 24, 2014	Feb NEWA

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

AB		MYLAN PHARMS INC	75MG	A202139	001	Mar 20, 2014	Mar NEWA
----	--	------------------	------	---------	-----	--------------	----------

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS
NOVOLOG FLEXTOUCH

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Feb NEWA
---	------------------	------------------------------	---------	-----	--------------	----------

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS
LEVEMIR FLEXTOUCH

+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	005	Oct 31, 2013	Feb NEWA
---	------------------	------------------------------	---------	-----	--------------	----------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE

AN	+	MYLAN SPECLT	0.02%	A074755	001	Jan 10, 1997	Mar CAHN
----	---	--------------	-------	---------	-----	--------------	----------

SPRAY, METERED; NASAL
IPRATROPIUM BROMIDE

>D>	AB	DEY	0.021MG/SPRAY	A075552	001	Mar 31, 2003	May CAHN
>D>	AB		0.042MG/SPRAY	A075553	001	Mar 31, 2003	May CAHN
>A>	AB	MYLAN SPECLT	0.021MG/SPRAY	A075552	001	Mar 31, 2003	May CAHN
>A>	AB		0.042MG/SPRAY	A075553	001	Mar 31, 2003	May CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

>A>	AP	MUSTAFA NEVZAT ILAC	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May CAHN
>A>	AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May CAHN
>D>	AP	MYLAN INSTITUTIONAL	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May CAHN
>D>	AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May CAHN

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE

AN PIRAMAL ENT 99.9% A074502 001 Jun 27, 1995 Feb CAHN

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

+ AUXILIUM PHARMS LLC 40MG N019790 001 Sep 02, 1988 Apr CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL
ISOSORBIDE MONONITRATE

AB ANI PHARMS INC 20MG A075147 001 Nov 27, 1998 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

>D> AB ACTAVIS ELIZABETH 30MG A075306 001 Dec 31, 1998 May DISC
>A> @ 30MG A075306 001 Dec 31, 1998 May DISC
>D> AB 60MG A075306 002 Dec 31, 1998 May DISC
>A> @ 60MG A075306 002 Dec 31, 1998 May DISC

ISRADIPINE

CAPSULE; ORAL
ISRADIPINE

>D> @ MIKAH PHARMA 2.5MG A077169 001 Apr 24, 2006 May CMFD
>A> AB 2.5MG A077169 001 Apr 24, 2006 May CMFD
@ 2.5MG A077169 001 Apr 24, 2006 Feb DISC
>D> @ 5MG A077169 002 Apr 24, 2006 May CMFD
>A> AB 5MG A077169 002 Apr 24, 2006 May CMFD
@ 5MG A077169 002 Apr 24, 2006 Feb DISC
>D> WATSON LABS 2.5MG A077317 001 Jan 05, 2006 May CTEC
>A> AB 2.5MG A077317 001 Jan 05, 2006 May CTEC
2.5MG A077317 001 Jan 05, 2006 Feb CTEC
>D> + 5MG A077317 002 Jan 05, 2006 May CTEC
>A> AB + 5MG A077317 002 Jan 05, 2006 May CTEC
+ 5MG A077317 002 Jan 05, 2006 Feb CTEC

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR

AP + PAR STERILE PRODUCTS EQ 10MG BASE/ML N016812 001 Apr CAHN
AP + EQ 50MG BASE/ML N016812 002 Apr CAHN
AP + EQ 100MG BASE/ML N016812 003 Apr CAHN

KETOCONAZOLE

TABLET; ORAL
NIZORAL

AB + JANSSEN PHARMS 200MG N018533 001 Mar CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC
ACUVAIL

AT + ALLERGAN 0.45% N022427 001 Jul 22, 2009 Jan CFTG

KETOROLAC TROMETHAMINE
@ AKORN 0.45%

AT 0.45% A203376 001 Feb 10, 2014 Feb DISC
A203376 001 Feb 10, 2014 Jan NEWA

>A> KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

>A> SOLUTION; IRRIGATION
>A> OMIDRIA

>A> + OMEROS EQ 4.24MG BASE/ML; EQ 12.4MG N205388 001 May 30, 2014 May NEWA
BASE/ML

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
LAMIVUDINE AND ZIDOVUDINE

AB HETERO LABS LTD V 150MG; 300MG A203259 001 Feb 03, 2014 Jan NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

>D>	AB	ACTAVIS TOTOWA	25MG	A 078669	001	Apr 08, 2011	May	DISC
>A>		@	25MG	A 078669	001	Apr 08, 2011	May	DISC
>D>	AB		100MG	A 078669	002	Apr 08, 2011	May	DISC
>A>		@	100MG	A 078669	002	Apr 08, 2011	May	DISC
>D>	AB		150MG	A 078669	003	Apr 08, 2011	May	DISC
>A>		@	150MG	A 078669	003	Apr 08, 2011	May	DISC
>D>	AB		200MG	A 078669	004	Apr 08, 2011	May	DISC
>A>		@	200MG	A 078669	004	Apr 08, 2011	May	DISC

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

>A>	AB	ALEMBIC PHARMS LTD	5MG	A 201168	001	Jun 12, 2014	May	NEWA
>A>	AB		25MG	A 201168	002	Jun 12, 2014	May	NEWA

LANSOPRAZOLE

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

@ ANI PHARMS INC

@

15MG

30MG

A 078730 001 Oct 15, 2010 Jan CAHN

A 078730 002 Oct 15, 2010 Jan CAHN

LETROZOLE

TABLET; ORAL

LETROZOLE

>D>	AB	ACTAVIS TOTOWA	2.5MG	A 090292	001	Jul 13, 2011	May	DISC
>A>		@	2.5MG	A 090292	001	Jul 13, 2011	May	DISC

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

>D>	+	ABBVIE ENDOCRINE INC	3.75MG/VIAL	N 020011	001	Oct 22, 1990	May	DISC
>A>		@	3.75MG/VIAL	N 020011	001	Oct 22, 1990	May	DISC
>A>		+	3.75MG	N 020011	002	Oct 26, 1995	May	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

>D>	AN	DEY	EQ 0.0103% BASE	A 077800	001	Mar 15, 2013	May	CAHN
>D>	AN		EQ 0.021% BASE	A 077800	002	Mar 15, 2013	May	CAHN
>D>	AN		EQ 0.042% BASE	A 077800	003	Mar 15, 2013	May	CAHN
>A>	AN	MYLAN SPECLT	EQ 0.0103% BASE	A 077800	001	Mar 15, 2013	May	CAHN
>A>	AN		EQ 0.021% BASE	A 077800	002	Mar 15, 2013	May	CAHN
>A>	AN		EQ 0.042% BASE	A 077800	003	Mar 15, 2013	May	CAHN
>D>	AN	WATSON LABS INC	EQ 0.0103% BASE	A 077756	003	Apr 09, 2008	May	DISC
>A>		@	EQ 0.0103% BASE	A 077756	003	Apr 09, 2008	May	DISC
>D>	AN		EQ 0.021% BASE	A 077756	001	Apr 09, 2008	May	DISC
>A>		@	EQ 0.021% BASE	A 077756	001	Apr 09, 2008	May	DISC
>D>	AN		EQ 0.042% BASE	A 077756	002	Apr 09, 2008	May	DISC
>A>		@	EQ 0.042% BASE	A 077756	002	Apr 09, 2008	May	DISC

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

	AB	VINTAGE PHARMS	250MG	A 077319	001	Mar 20, 2009	Feb	CAHN
	AB		500MG	A 077319	002	Mar 20, 2009	Feb	CAHN
	AB		750MG	A 077319	003	Mar 20, 2009	Feb	CAHN
>D>	AB	WATSON LABS INC	1GM	A 078797	001	Jan 15, 2009	May	DISC
>A>		@	1GM	A 078797	001	Jan 15, 2009	May	DISC

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	AB	VINTAGE PHARMS	500MG	A 201464	001	May 25, 2012	Feb	CAHN
	AB		750MG	A 201464	002	May 25, 2012	Feb	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA		L PERRIGO CO	2.5MG/5ML	A 091263	001	Nov 07, 2011	Jan	CAHN
----	--	--------------	-----------	----------	-----	--------------	-----	------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>D>	AB	SANDOZ	5MG	A 090486	001	Mar 26, 2013	May	DISC
-----	----	--------	-----	----------	-----	--------------	-----	------

	TABLET;ORAL							
	LEVOCETIRIZINE DIHYDROCHLORIDE							
>A>	@	5MG		A090486	001	Mar 26, 2013	May	DISC
	<u>LEVOFLOXACIN</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	LEVOFLOXACIN							
>D>	AT	HI TECH PHARMA	0.5%	A076826	001	Feb 10, 2011	May	CAHN
>A>	AT	WATSON LABS INC	0.5%	A076826	001	Feb 10, 2011	May	CAHN
	<u>LEVORPHANOL TARTRATE</u>							
	TABLET;ORAL							
	LEVORPHANOL TARTRATE							
	+	ROXANE	2MG	A074278	001	Mar 31, 2000	Feb	CRLD
	<u>LIDOCAINE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	LIDOCAINE HYDROCHLORIDE							
AP		AGILA SPECLTS	2%	A202242	001	Apr 11, 2014	Mar	NEWA
	LIDOPEN							
	@	MERIDIAN MEDCL TECHN	10%	N017549	001		Mar	DISC
	XYLOCAINE PRESERVATIVE FREE							
	+	FRESENIUS KABI USA	10%	N016801	003		Mar	CTEC
	JELLY;TOPICAL							
	ANESTACON							
	@	DSM PHARMS INC	2%	A080429	001		Jan	CAHN
	GLYDO							
AT		SAGENT PHARMS	2%	A201094	001	Apr 28, 2014	Apr	NEWA
	LIDOCAINE HYDROCHLORIDE							
>D>	AT	HI TECH PHARMA	2%	A040837	001	Mar 23, 2011	May	CAHN
>A>	AT	WATSON LABS INC	2%	A040837	001	Mar 23, 2011	May	CAHN
	SOLUTION;TOPICAL							
	LIDOCAINE HYDROCHLORIDE							
AT		IGI LABS INC	4%	A204494	001	Mar 12, 2014	Feb	NEWA
	SYSTEM;INTRADERMAL							
	ZINGO							
		POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	Mar	CMFD
	<u>LIDOCAINE; PRILOCAINE</u>							
	CREAM;TOPICAL							
	EMLA							
>D>	AB	+ OAK PHARMS	2.5%;2.5%	N019941	001	Dec 30, 1992	May	CAHN
>A>	AB	+ WATSON LABS INC	2.5%;2.5%	N019941	001	Dec 30, 1992	May	CAHN
	<u>LIOTHYRONINE SODIUM</u>							
	INJECTABLE;INJECTION							
	TRIOSTAT							
AP	+	PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Apr	CAHN
	<u>LORAZEPAM</u>							
	TABLET;ORAL							
	LORAZEPAM							
>D>	AB	WATSON LABS	1MG	A071118	001	Jul 24, 1986	May	DISC
>A>	@		1MG	A071118	001	Jul 24, 1986	May	DISC
	<u>LOTEPREDNOL ETABONATE</u>							
	GEL;OPHTHALMIC							
	LOTEMAX							
	+	BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012	Feb	CAHN
	<u>LULICONAZOLE</u>							
	CREAM;TOPICAL							
	LUZU							
	+	MEDICIS	1%	N204153	001	Nov 14, 2013	Jan	CRLD
	<u>MALATHION</u>							
	LOTION;TOPICAL							
	MALATHION							
	@	MYLAN PHARMS INC	0.5%	A078743	001	Mar 06, 2009	Mar	DISC

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

>D> AA WATSON LABS 25MG A 085740 001 May DISC
 >A> @ 25MG A 085740 001 May DISC

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

@ USL PHARMA 10MG A 088484 001 Jul 26, 1984 Mar DISC

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

>A> AB VINTAGE PHARMS LLC 250MG A 091608 001 Jun 02, 2014 May NEWA

MELOXICAM

TABLET; ORAL

MELOXICAM

>D> @ YABAO BIOPHARMS 7.5MG A 077933 001 Jul 19, 2006 May CAHN
 >D> @ 15MG A 077933 002 Jul 19, 2006 May CAHN
 >A> @ YABAO PHARM 7.5MG A 077933 001 Jul 19, 2006 May CAHN
 >A> @ 15MG A 077933 002 Jul 19, 2006 May CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

>D> AP WATSON LABS 50MG/ML A 073444 001 Mar 17, 1992 May DISC
 >A> @ 50MG/ML A 073444 001 Mar 17, 1992 May DISC
 >D> AP 100MG/ML A 073445 001 Mar 17, 1992 May DISC
 >A> @ 100MG/ML A 073445 001 Mar 17, 1992 May DISC
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE
 @ INTL MEDICATION 10MG/ML A 081309 001 Aug 30, 1993 Mar DISC
 >D> AP WATSON LABS 10MG/ML A 073443 001 Mar 17, 1992 May DISC
 >A> @ 10MG/ML A 073443 001 Mar 17, 1992 May DISC

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

>D> AA WATSON LABS 50MG A 040186 001 Jun 30, 1997 May DISC
 >A> @ 50MG A 040186 001 Jun 30, 1997 May DISC
 >D> AA 100MG A 040186 002 Jun 30, 1997 May DISC
 >A> @ 100MG A 040186 002 Jun 30, 1997 May DISC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPIVACAINE HYDROCHLORIDE

>D> AP WATSON LABS 1% A 088769 001 Nov 20, 1984 May DISC
 >A> @ 1% A 088769 001 Nov 20, 1984 May DISC
 >D> AP 2% A 088770 001 Nov 20, 1984 May DISC
 >A> @ 2% A 088770 001 Nov 20, 1984 May DISC

MERCAPTOPYRINE

SUSPENSION; ORAL

PURIXAN

+ NOVA LABS LTD 20MG/ML N 205919 001 Apr 28, 2014 Apr NEWA

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

+ FOREST LABS INC 1GM N 021252 002 Nov 05, 2004 Apr CAHN
 @ 500MG N 021252 001 Jan 05, 2001 Apr CAHN

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

>D> AN + DEY 0.4% A 071786 001 Aug 05, 1988 May CAHN
 >D> AN + 0.6% A 070804 001 Aug 17, 1987 May CAHN
 >A> AN + MYLAN SPECLT 0.4% A 071786 001 Aug 05, 1988 May CAHN
 >A> AN + 0.6% A 070804 001 Aug 17, 1987 May CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>D>	AB	ALVOGEN	1GM	A 076033	003	Jan 24, 2002	May	CAHN
>D>	AB		500MG	A 076033	001	Jan 24, 2002	May	CAHN
>D>	AB		850MG	A 076033	002	Jan 24, 2002	May	CAHN
>A>	AB	ATLAS PHARMS LLC	1GM	A 076033	003	Jan 24, 2002	May	CAHN
>A>	AB		500MG	A 076033	001	Jan 24, 2002	May	CAHN
>A>	AB		850MG	A 076033	002	Jan 24, 2002	May	CAHN
>D>	AB	WATSON LABS	1GM	A 075979	003	Jan 24, 2002	May	DISC
>A>		@	1GM	A 075979	003	Jan 24, 2002	May	DISC
>D>	AB		500MG	A 075979	001	Jan 24, 2002	May	DISC
>A>		@	500MG	A 075979	001	Jan 24, 2002	May	DISC
>D>	AB		850MG	A 075979	002	Jan 24, 2002	May	DISC
>A>		@	850MG	A 075979	002	Jan 24, 2002	May	DISC

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

+		SALIX PHARMS INC	1GM	N 021748	002	Jun 03, 2005	Feb	CTEC
			500MG	N 021748	001	Jun 03, 2005	Feb	CTEC
+		SANTARUS INC	1GM	N 021748	002	Jun 03, 2005	Mar	CAHN
			500MG	N 021748	001	Jun 03, 2005	Mar	CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB		TEVA PHARMS USA	500MG;EQ 15MG BASE	A 091155	001	Mar 10, 2014	Feb	NEWA
AB			850MG;EQ 15MG BASE	A 091155	002	Mar 10, 2014	Feb	NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

AB		SB PHARMCO	1GM;EQ 2MG BASE	N 021410	004	Aug 25, 2003	Apr	CFTG
AB	+		1GM;EQ 4MG BASE	N 021410	005	Aug 25, 2003	Apr	CFTG
AB			500MG;EQ 2MG BASE	N 021410	002	Oct 10, 2002	Apr	CFTG
AB			500MG;EQ 4MG BASE	N 021410	003	Oct 10, 2002	Apr	CFTG

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

AB		TEVA	1GM;EQ 4MG BASE	A 077337	004	May 07, 2014	Apr	NEWA
AB			1GM;EQ 2MG BASE	A 077337	003	May 07, 2014	Apr	NEWA
AB			500MG;EQ 2MG BASE	A 077337	001	May 07, 2014	Apr	NEWA
AB			500MG;EQ 4MG BASE	A 077337	002	May 07, 2014	Apr	NEWA

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

+		ASTRAZENECA AB	1GM;EQ 2.5MG BASE	N 200678	003	Nov 05, 2010	Apr	CAHN
			1GM;EQ 5MG BASE	N 200678	002	Nov 05, 2010	Apr	CAHN
			500MG;EQ 5MG BASE	N 200678	001	Nov 05, 2010	Apr	CAHN

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB		ANI PHARMS INC	25MG	A 040001	001	Jun 30, 1993	Jan	CAHN
AB			50MG	A 040001	002	Jun 30, 1993	Jan	CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB		VINTAGE PHARMS	5MG	A 202068	001	Mar 07, 2012	Feb	CAHN
AB			10MG	A 202068	002	Mar 07, 2012	Feb	CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

>D>	AA	WATSON LABS	500MG	A 085180	001		May	DISC
>A>		@	500MG	A 085180	001		May	DISC
>D>	AA		750MG	A 085192	001		May	DISC
>A>		@	750MG	A 085192	001		May	DISC
		ROBAXIN						
AA	+	AUXILIUM PHARMS LLC	500MG	N 011011	004		Apr	CAHN
		ROBAXIN-750						
AA	+	AUXILIUM PHARMS LLC	750MG	N 011011	006		Apr	CAHN

METHOHEXITAL SODIUM

INJECTABLE; INJECTION
BREVITAL SODIUM

+	PAR STERILE PRODUCTS	2.5GM/VIAL		N011559	002		Apr	CAHN
	@	5GM/VIAL		N011559	003		Apr	CAHN
+		200MG/VIAL		N011559	004	Dec 21, 2012	Apr	CAHN
+		500MG/VIAL		N011559	001		Apr	CAHN

METHOXSALLEN

CAPSULE; ORAL
METHOXSALLEN

>A>	AB	STRIDES ARCOLAB LTD	10MG	A202687	001	Jun 05, 2014	May	NEWA
		OXSORALEN-ULTRA						
>D>	+	DOW PHARM	10MG	N019600	001	Oct 30, 1986	May	CTEC
>A>	AB	+	10MG	N019600	001	Oct 30, 1986	May	CTEC

METHSCOPOLAMINE BROMIDE

TABLET; ORAL
METHSCOPOLAMINE BROMIDE

AA		VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Feb	CAHN
AA			5MG	A040624	002	Dec 28, 2006	Feb	CAHN

METHYLDOPA

TABLET; ORAL
METHYLDOPA

AB		MYLAN	250MG	A070076	002	Apr 18, 1985	Apr	CMS1
----	--	-------	-------	---------	-----	--------------	-----	------

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION
METHERGINE

AP	+	EDISON THERAPS LLC	0.2MG/ML	N006035	004		Feb	CAHN
		TABLET; ORAL						
		METHERGINE						
AB	+	EDISON THERAPS LLC	0.2MG	N006035	003		Feb	CAHN

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB		COREPHARMA	5MG	A091159	001	Mar 12, 2014	Feb	NEWA
AB			10MG	A091159	002	Mar 12, 2014	Feb	NEWA
AB			20MG	A091159	003	Mar 12, 2014	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	WATSON LABS	20MG	A040410	001	Feb 09, 2001	May	DISC
>A>		@	20MG	A040410	001	Feb 09, 2001	May	DISC

METRONIDAZOLE

GEL; VAGINAL
METRONIDAZOLE

		VALEANT PHARM NORTH	1.3%	N205223	001	Mar 24, 2014	Mar	NEWA
--	--	---------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL
METRONIDAZOLE

AB		UNICHEM LABS LTD	250MG	A203458	001	Jan 22, 2014	Jan	NEWA
AB			500MG	A203458	002	Jan 22, 2014	Jan	NEWA
		@ VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	Apr	CAHN
		@	500MG	A070039	001	Jan 29, 1985	Apr	CAHN
>D>	AB	WATSON LABS	250MG	N018764	001	Sep 17, 1982	May	DISC
>A>		@	250MG	N018764	001	Sep 17, 1982	May	DISC
>D>	AB		500MG	N018764	002	Dec 20, 1982	May	DISC
>A>		@	500MG	N018764	002	Dec 20, 1982	May	DISC
AB		WATSON LABS INC	500MG	A070044	001	Feb 08, 1985	Mar	CAHN

MICONAZOLE

TABLET; BUCCAL
ORAVIG

+	BIOALLIANCE PHARMA	50MG		N022404	001	Apr 16, 2010	Apr	CAHN
---	--------------------	------	--	---------	-----	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

AP	BEDFORD LABS	EQ 1MG BASE/ML	A 075421	002	Jun 20, 2000	Apr	CAHN
AP		EQ 5MG BASE/ML	A 075421	001	Jun 20, 2000	Apr	CAHN

MILTEFOSINE

CAPSULE; ORAL
IMPAVIDO

	PALADIN THERAP	50MG	N 204684	001	Mar 19, 2014	Mar	NEWA
--	----------------	------	----------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
DYNACIN

>D>	AB	MEDICIS	EQ 75MG BASE	A 063067	002	Sep 15, 1999	May	CAHN
>A>	AB		EQ 75MG BASE	A 063067	002	Sep 15, 1999	May	CAHN
>D>	AB		EQ 100MG BASE	A 063067	001	Jul 31, 1990	May	CAHN
>A>	AB		EQ 100MG BASE	A 063067	001	Jul 31, 1990	May	CAHN

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION
MIVACURIUM CHLORIDE

	@ AGILA SPECLTS	EQ 2MG BASE/ML	A 078562	001	Apr 30, 2009	Feb	CAHN
--	-----------------	----------------	----------	-----	--------------	-----	------

MODAFINIL

TABLET; ORAL
MODAFINIL

AB	APOTEX INC	100MG	A 077667	001	Feb 03, 2014	Jan	NEWA
AB		200MG	A 077667	002	Feb 03, 2014	Jan	NEWA

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION
ASMANEX HFA

	MERCK SHARP DOHME	0.10MG/INH	N 205641	001	Apr 25, 2014	Apr	NEWA
+		0.20MG/INH	N 205641	002	Apr 25, 2014	Apr	NEWA

POWDER; INHALATION

ASMANEX TWISTHALER

	MERCK SHARP DOHME	0.11MG/INH	N 021067	002	Feb 01, 2008	Mar	CAHN
+		0.22MG/INH	N 021067	001	Mar 30, 2005	Mar	CAHN

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL
NASONEX

>A>	+	MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N 020762	001	Oct 01, 1997	May	CAHN
>D>	+	SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY	N 020762	001	Oct 01, 1997	May	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
AVINZA

AB2	KING PHARMS LLC	30MG	N 021260	001	Mar 20, 2002	Mar	CAHN
AB2		45MG	N 021260	005	Dec 18, 2008	Mar	CAHN
AB2		60MG	N 021260	002	Mar 20, 2002	Mar	CAHN
AB2		75MG	N 021260	006	Dec 18, 2008	Mar	CAHN
AB2		90MG	N 021260	003	Mar 20, 2002	Mar	CAHN
AB2	+	120MG	N 021260	004	Mar 20, 2002	Mar	CAHN

INJECTABLE; INJECTION

MORPHINE SULFATE

>D>	AP	WATSON LABS	0.5MG/ML	A 073373	001	Sep 30, 1991	May	DISC
>A>		@	0.5MG/ML	A 073373	001	Sep 30, 1991	May	DISC
>D>	AP		0.5MG/ML	A 073375	001	Sep 30, 1991	May	DISC
>A>		@	0.5MG/ML	A 073375	001	Sep 30, 1991	May	DISC
>D>	AP		1MG/ML	A 073374	001	Sep 30, 1991	May	DISC
>A>		@	1MG/ML	A 073374	001	Sep 30, 1991	May	DISC
>D>	AP		1MG/ML	A 073376	001	Sep 30, 1991	May	DISC
>A>		@	1MG/ML	A 073376	001	Sep 30, 1991	May	DISC

SOLUTION; ORAL

MORPHINE SULFATE

AA	CARACO	10MG/5ML	A 201011	001	Feb 05, 2014	Jan	NEWA
AA		20MG/5ML	A 201011	002	Feb 05, 2014	Jan	NEWA

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
EMBEDA

	ALPHARMA PHARMS	20MG;0.8MG	N022321	001	Aug 13, 2009	Mar	CAHN
		30MG;1.2MG	N022321	002	Aug 13, 2009	Mar	CAHN
		50MG;2MG	N022321	003	Aug 13, 2009	Mar	CAHN
+		60MG;2.4MG	N022321	004	Aug 13, 2009	Mar	CAHN
		80MG;3.2MG	N022321	005	Aug 13, 2009	Mar	CAHN
		100MG;4MG	N022321	006	Aug 13, 2009	Mar	CAHN

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

	AVELOX						
AB	+	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Feb CFTG
		MOXIFLOXACIN HYDROCHLORIDE					
AB		AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632	001	Mar 04, 2014	Feb NEWA
AB		DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Feb NEWA
AB		TEVA PHARMS USA	EQ 400MG BASE	A077437	001	Feb 18, 2014	Feb NEWA
AB		TORRENT PHARMS LTD	EQ 400MG BASE	A200160	001	Apr 03, 2014	Mar NEWA

NAFCILLIN SODIUM

INJECTABLE;INJECTION
NAFCILLIN SODIUM

AP		AGILA SPECLTS	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Mar NEWA
AP			EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Mar NEWA
AP		ANTIBIOTICE	EQ 1GM BASE/VIAL	A090560	001	Oct 03, 2011	Jan CPOT
AP			EQ 2GM BASE/VIAL	A090560	002	Oct 03, 2011	Jan CPOT
AP		ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011	Feb CAHN
AP			EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011	Feb CAHN
AP			EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Feb CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION
NALOXONE HYDROCHLORIDE

AP		MYLAN INSTITUTIONAL	0.4MG/ML	A204997	001	Mar 06, 2014	Feb NEWA
		SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
		EVZIO					
	+	KALEO INC	0.4MG/0.4ML	N205787	001	Apr 03, 2014	Apr NEWA

NAPROXEN

TABLET;ORAL

	NAPROXEN						
	@	DAVA PHARMS INC	250MG	A074410	001	Apr 28, 1995	Feb DISC
	@		375MG	A074410	002	Apr 28, 1995	Feb DISC
	@		500MG	A074410	003	Apr 28, 1995	Feb DISC
>D>	AB	WATSON LABS	250MG	A074457	001	May 31, 1995	May DISC
>A>		@	250MG	A074457	001	May 31, 1995	May DISC
>D>	AB		375MG	A074457	002	May 31, 1995	May DISC
>A>		@	375MG	A074457	002	May 31, 1995	May DISC
>D>	AB		500MG	A074457	003	May 31, 1995	May DISC
>A>		@	500MG	A074457	003	May 31, 1995	May DISC

NAPROXEN SODIUM

TABLET;ORAL
NAPROXEN SODIUM

>D>	AB	WATSON LABS	EQ 250MG BASE	A074455	001	May 31, 1995	May DISC
>A>		@	EQ 250MG BASE	A074455	001	May 31, 1995	May DISC
>D>	AB		EQ 500MG BASE	A074455	002	May 31, 1995	May DISC
>A>		@	EQ 500MG BASE	A074455	002	May 31, 1995	May DISC

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL
NARATRIPTAN

AB		APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Jan CAIN
AB			EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Jan CAIN
AB		SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan CAIN

NEVIRAPINE

TABLET; ORAL		NEVIRAPINE					
AB	STRIDES ARCOLAB LTD	200MG	A078195	001	May 22, 2012	Jan	CAHN
TABLET, EXTENDED RELEASE; ORAL		NEVIRAPINE					
AB	APOTEX INC	400MG	A205258	001	Apr 03, 2014	Mar	NEWA
AB	SANDOZ	400MG	A203411	001	Apr 03, 2014	Mar	NEWA
AB	VIRAMUNE XR						
AB	+ BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar	CFTG

NIACIN

TABLET, EXTENDED RELEASE; ORAL		NIACIN					
AB	LUPIN LTD	1GM	A090446	001	Mar 20, 2014	Mar	NEWA
AB		500MG	A090860	001	Mar 20, 2014	Mar	NEWA
AB		750MG	A090892	001	Mar 20, 2014	Mar	NEWA
AB	SUN PHARMA GLOBAL	1GM	A200484	002	Apr 23, 2014	Apr	NEWA
AB		500MG	A200484	001	Apr 23, 2014	Apr	NEWA
AB		750MG	A201273	001	Apr 23, 2014	Apr	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL		CARDENE						
AB	CHIESI USA INC	20MG	N019488	001	Dec 21, 1988	Apr	CAHN	
AB	+	30MG	N019488	002	Dec 21, 1988	Apr	CAHN	
NICARDIPINE HYDROCHLORIDE								
AB	ANI PHARMS INC	20MG	A074439	001	Dec 10, 1996	Jan	CAHN	
AB		20MG	A074540	001	Oct 28, 1996	Jan	CAHN	
AB		30MG	A074439	002	Dec 10, 1996	Jan	CAHN	
AB		30MG	A074540	002	Oct 28, 1996	Jan	CAHN	
>D>	AB	WATSON LABS	20MG	A074670	001	Oct 28, 1996	May	DISC
>A>	@	20MG	A074670	001	Oct 28, 1996	May	DISC	
>D>	AB		30MG	A074670	002	Oct 28, 1996	May	DISC
>A>	@	30MG	A074670	002	Oct 28, 1996	May	DISC	
CAPSULE, EXTENDED RELEASE; ORAL		CARDENE SR						
+	CHIESI USA INC	30MG	N020005	001	Feb 21, 1992	Apr	CAHN	
	@	45MG	N020005	002	Feb 21, 1992	Apr	CAHN	
+		60MG	N020005	003	Feb 21, 1992	Apr	CAHN	
INJECTABLE; INJECTION		CARDENE						
AP	+ CHIESI USA INC	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Apr	CAHN	
NICARDIPINE HYDROCHLORIDE								
AP	LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Jan	CAHN	
INJECTABLE; INTRAVENOUS		CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER						
+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr	CAHN	
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER								
+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr	CAHN	
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER								
+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008	Apr	CAHN	
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER								
+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Apr	CAHN	

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL		NIFEDIPINE					
AB2	TWI PHARMS INC	30MG	A203126	001	Apr 03, 2014	Mar	NEWA
AB2		60MG	A203126	002	Apr 03, 2014	Mar	NEWA
AB2		90MG	A203126	003	Apr 03, 2014	Mar	NEWA

NIMODIPINE

CAPSULE; ORAL		NIMODIPINE					
AB	THEPHARMANETWORK LLC	30MG	A090103	001	Apr 07, 2014	Mar	NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL
NITROGLYCERIN

>D>	AB1	KREMERS URBAN PHARMS	0.2MG/HR	A075115	001	Aug 10, 2004	May	DISC
>A>		@	0.2MG/HR	A075115	001	Aug 10, 2004	May	DISC
>D>	AB1		0.4MG/HR	A075115	002	Aug 10, 2004	May	DISC
>A>		@	0.4MG/HR	A075115	002	Aug 10, 2004	May	DISC
		OINTMENT; INTRA-ANAL RECTIV						
	+	FOREST LABS INC	0.4%	N021359	001	Jun 21, 2011	Apr	CAHN

NIZATIDINE

CAPSULE;ORAL
NIZATIDINE

	AB	@ ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002	Jan	CAHN
	AB		150MG	A075668	001	Sep 12, 2002	Jan	CAHN
	AB	@	300MG	A075461	002	Jul 08, 2002	Jan	CAHN
	AB		300MG	A075668	002	Sep 12, 2002	Jan	CAHN

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION;ORAL
AVENTYL

		RANBAXY	EQ 10MG BASE/5ML	N014685	001		Apr	CTNA
		AVENTYL HYDROCHLORIDE						
		@ RANBAXY	EQ 10MG BASE/5ML	N014685	001		Apr	DISC
		NORTRIPTYLINE HYDROCHLORIDE						
AA	+	PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	Apr	CRLD

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

	AB	AUROBINDO PHARMA LTD	5MG	A203708	001	May 15, 2014	Apr	NEWA
	AB		10MG	A203708	002	May 15, 2014	Apr	NEWA
	AB		15MG	A203708	003	May 15, 2014	Apr	NEWA
	AB		20MG	A203708	004	May 15, 2014	Apr	NEWA
	AB	MYLAN PHARMS INC	5MG	A202285	001	May 12, 2014	Apr	NEWA
	AB		10MG	A202285	002	May 12, 2014	Apr	NEWA
	AB		15MG	A202285	003	May 12, 2014	Apr	NEWA
	AB		20MG	A202285	004	May 12, 2014	Apr	NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
LOVAZA

	AB	+	SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Mar	CFTG
			OMEGA-3-ACID ETHYL ESTERS						
	AB		TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Mar	NEWA
			OMTRYG						
		+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Apr	NEWA

>A> OMEGA-3-CARBOXYLIC ACIDS

>A> CAPSULE;ORAL
>A> EPANOVA

>A>		+	ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	May	NEWA
-----	--	---	--------------------	---	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
ZEGERID

	AB		SANTARUS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb	CAHN
	AB	+		40MG;1.1GM	N021849	002	Feb 27, 2006	Feb	CAHN
			FOR SUSPENSION;ORAL ZEGERID						
	AB		SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb	CAHN
	AB	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb	CAHN

ONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

@ LANNETT EQ 2MG BASE/ML

A 090116 001 Apr 14, 2010 Jan DISC

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

AB IPCA LABS LTD EQ 4MG BASE

A 203761 001 Jan 23, 2014 Jan NEWA

AB EQ 8MG BASE

A 203761 002 Jan 23, 2014 Jan NEWA

ORPHENADRINE CITRATEINJECTABLE; INJECTION
ORPHENADRINE CITRATE

>D> AP WATSON LABS 30MG/ML

A 087062 001

May DISC

>A> @ 30MG/ML

A 087062 001

May DISC

OXACILLIN SODIUMINJECTABLE; INJECTION
OXACILLIN SODIUM

@ ISTITUTO BIO ITA SPA EQ 1GM BASE/VIAL

A 062798 001 Dec 11, 1995 Feb CAHN

@ EQ 2GM BASE/VIAL

A 062798 002 Dec 11, 1995 Feb CAHN

@ EQ 125MG BASE/VIAL

A 062798 003 Dec 11, 1995 Feb CAHN

@ EQ 250MG BASE/VIAL

A 062798 004 Dec 11, 1995 Feb CAHN

@ EQ 500MG BASE/VIAL

A 062798 005 Dec 11, 1995 Feb CAHN

OXALIPLATININJECTABLE; IV (INFUSION)
OXALIPLATIN

AP SUN PHARMA GLOBAL 50MG/10ML (5MG/ML)

A 202922 001 Apr 08, 2014 Mar NEWA

AP 100MG/20ML (5MG/ML)

A 202922 002 Apr 08, 2014 Mar NEWA

OXANDROLONETABLET; ORAL
OXANDRIN

AB CREALTA PHARMS LLC 2.5MG

N 013718 001

Jan CAHN

AB + 10MG

N 013718 002 Nov 05, 2001 Jan CAHN

OXAPROZINTABLET; ORAL
OXAPROZIN

>D> AB WATSON LABS 600MG

A 075848 001 Feb 09, 2001 May DISC

>A> @ 600MG

A 075848 001 Feb 09, 2001 May DISC

OXAZEPAMCAPSULE; ORAL
OXAZEPAM

@ IVAX SUB TEVA PHARMS 10MG

A 070943 001 Aug 03, 1987 Apr DISC

@ 15MG

A 070944 001 Aug 03, 1987 Apr DISC

@ 30MG

A 070945 001 Aug 03, 1987 Apr DISC

>D> AB WATSON LABS 10MG

A 072952 001 Sep 28, 1990 May DISC

>A> @ 10MG

A 072952 001 Sep 28, 1990 May DISC

>D> AB 15MG

A 072953 001 Sep 28, 1990 May DISC

>A> @ 15MG

A 072953 001 Sep 28, 1990 May DISC

>D> AB 30MG

A 072954 001 Sep 28, 1990 May DISC

>A> @ 30MG

A 072954 001 Sep 28, 1990 May DISC

OXCARBAZEPINETABLET; ORAL
OXCARBAZEPINE

@ ANI PHARMS INC 150MG

A 078005 001 Dec 11, 2007 Jan CAHN

@ 300MG

A 078005 002 Dec 11, 2007 Jan CAHN

@ 600MG

A 078005 003 Dec 11, 2007 Jan CAHN

OXYBUTYNINFILM, EXTENDED RELEASE; TRANSDERMAL
OXYBUTYNIN

AB BARR LABS DIV TEVA 3.9MG/24HR

A 090526 001 Mar 04, 2014 Feb NEWA

OXYTROL

AB + WATSON LABS (UTAH) 3.9MG/24HR

N 021351 002 Feb 26, 2003 Feb CFTG

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

>A>	AA	COASTAL PHARMS	100MG/5ML	A204092	001	Jun 05, 2014	May	NEWA
TABLET;ORAL								
OXECTA								
>A>		ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	May	CAHN
>A>			7.5MG	N202080	002	Jun 17, 2011	May	CAHN
>D>		KING PHARMS R AND D	5MG	N202080	001	Jun 17, 2011	May	CAHN
>D>			7.5MG	N202080	002	Jun 17, 2011	May	CAHN
OXYCODONE HYDROCHLORIDE								
>A>	AB	AMNEAL PHARMS	5MG	A203638	001	Jun 03, 2014	May	NEWA
>A>	AB		10MG	A203638	002	Jun 03, 2014	May	NEWA
>A>	AB		15MG	A203638	003	Jun 03, 2014	May	NEWA
>A>	AB		20MG	A203638	004	Jun 03, 2014	May	NEWA
>A>	AB		30MG	A203638	005	Jun 03, 2014	May	NEWA

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

>D>	AP	+ BAXTER HLTHCARE CORP	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		May	CAHN
>D>	AP		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	May	CAHN
>A>	AP	+ HIKMA MAPLE	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		May	CAHN
>A>	AP		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	May	CAHN
PITOCIN								
AP		+ PAR STERILE PRODUCTS	10USP UNITS/ML (10USP UNITS/ML)	N018261	001		Apr	CAHN
AP			100USP UNITS/10ML (10USP UNITS/ML)	N018261	002	Jul 27, 2007	Apr	CAHN
			500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012	Apr	CAHN

SOLUTION;NASAL

SYNTOCINON

@ RETROPHIN INC

40USP UNITS/ML

N012285 001

Feb CAHN

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

@ MN PHARMS

30MG/VIAL

A078300 001

Mar 10, 2009

Jan DISC

@

90MG/VIAL

A078300 002

Mar 10, 2009

Jan DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

ULTRESA

>D>		APTALIS PHARMA US	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012	May	CAHN
>D>			41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012	May	CAHN
>D>		+	46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012	May	CAHN
>A>		FOREST LABS INC	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012	May	CAHN
>A>			41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012	May	CAHN
>A>		+	46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012	May	CAHN

ZENPEP

APTALIS PHARMA US

218,000USP UNITS; 40,00USP UNITS;

136,000 USP UNITS

N022210 007

Mar 25, 2014

Mar NEWA

FOREST LABS INC

218,000USP UNITS; 40,00USP UNITS;

136,000 USP UNITS

N022210 007

Mar 25, 2014

Apr CAHN

16,000USP UNITS;3,000USP UNITS;10,000USP UNITS

N022210 005

Jun 15, 2011

Apr CAHN

55,000USP UNITS;10,000USP UNITS;34,000USP UNITS

N022210 002

Aug 27, 2009

Apr CAHN

82,000USP UNITS;15,000USP UNITS;51,000USP UNITS

N022210 003

Aug 27, 2009

Apr CAHN

27,000USP UNITS;5,000USP UNITS;17,000USP UNITS

N022210 001

Aug 27, 2009

Apr CAHN

109,000USP UNITS;20,000USP UNITS;68,000USP UNITS

N022210 004

Aug 27, 2009

Apr CAHN

+

136,000USP UNITS;25,000USP UNITS;85,000USP UNITS

N022210 006

Jul 13, 2011

Apr CAHN

TABLET;ORAL

VIOKACE

FOREST LABS INC

39,150USP UNITS;10,440USP UNITS;39,150USP UNITS

N022542 001

Mar 01, 2012

Apr CAHN

TABLET;ORAL
VIOKACE

+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Apr CAHN
	FOREST RES INST INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar CAHN
+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	PERRIGO R AND D	EQ 20MG BASE	A203024	001	May 07, 2014	Apr NEWA
----	-----------------	--------------	---------	-----	--------------	----------

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

AB	BANNER PHARMACAPS	1MCG	A202539	001	Mar 27, 2014	Mar NEWA
AB		2MCG	A202539	002	Mar 27, 2014	Mar NEWA
AB		4MCG	A202539	003	Mar 27, 2014	Mar NEWA

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL
PAXIL

@	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN
@		EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN
@		EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN
@		EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN

SUSPENSION;ORAL

PAXIL

AB	+ APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN
----	-----------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

PAXIL

AB	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020031	001	Dec 29, 1992	Jan CAHN
AB		EQ 20MG BASE	N020031	002	Dec 29, 1992	Jan CAHN
AB		EQ 30MG BASE	N020031	003	Dec 29, 1992	Jan CAHN
AB	+	EQ 40MG BASE	N020031	005	Dec 29, 1992	Jan CAHN
	@	EQ 50MG BASE	N020031	004	Dec 29, 1992	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

PAXIL CR

AB	APOTEX TECHNOLOGIES	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
AB		EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
AB	+	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

@	AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Apr CAHN
+		20MG	N018976	004	Jan 05, 1989	Apr CAHN

PENICILLIN G POTASSIUM

INJECTABLE;INJECTION
PENICILLIN G POTASSIUM

AP	ISTITUTO BIO ITA SPA	5,000,000 UNITS/VIAL	A065448	001	Aug 18, 2009	Feb CAHN
AP		20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Feb CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION
PENTAM

>D>	AP	+	FRESENIUS KABI USA	300MG/VIAL	N019264	001	Oct 16, 1984	May CTEC
>A>		+		300MG/VIAL	N019264	001	Oct 16, 1984	May CTEC
>D>			PENTAMIDINE ISETHIONATE					
>D>	AP		WATSON LABS	300MG/VIAL	A074303	001	Aug 17, 1995	May DISC
>A>		@		300MG/VIAL	A074303	001	Aug 17, 1995	May DISC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

>D>	AB		WATSON LABS	400MG	A075107	001	Sep 04, 1998	May DISC
>A>		@		400MG	A075107	001	Sep 04, 1998	May DISC

PERINDOPRIL ERBUMINE

TABLET; ORAL							
PERINDOPRIL ERBUMINE							
AB	ANI PHARMS INC	2MG	A 078138	001	Nov 10, 2009	Jan	CAHN
AB		4MG	A 078138	002	Nov 10, 2009	Jan	CAHN
AB		8MG	A 078138	003	Nov 10, 2009	Jan	CAHN

PERPHENAZINE

TABLET; ORAL							
PERPHENAZINE							
	@ ANI PHARMS INC	8MG	A 089456	001	Sep 10, 1987	Apr	CAHN
	@ TEVA PHARMS USA	2MG	A 089707	001	Sep 10, 1987	Apr	CAHN
	@	4MG	A 089708	001	Sep 10, 1987	Apr	CAHN
	@	16MG	A 089457	001	Sep 10, 1987	Apr	CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL							
PHENDIMETRAZINE TARTRATE							
AA	ELITE LABS INC	35MG	A 040762	001	Jan 28, 2008	Apr	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL							
PHENTERMINE HYDROCHLORIDE							
AA	INVAGEN PHARMS	15MG	A 202858	001	Feb 14, 2014	Feb	NEWA
AA		30MG	A 202858	002	Feb 14, 2014	Feb	NEWA
AA		30MG	A 204414	001	May 05, 2014	Apr	NEWA
AA		37.5MG	A 202846	001	Feb 05, 2014	Jan	NEWA
TABLET; ORAL							
PHENTERMINE HYDROCHLORIDE							
AA	INVAGEN PHARMS	37.5MG	A 202942	001	Feb 05, 2014	Jan	NEWA
>D>	@ MIKAH PHARMA	37.5MG	A 040190	001	May 30, 1997	May	CMFD
>A>	AA	37.5MG	A 040190	001	May 30, 1997	May	CMFD

PHENYTOIN

TABLET, CHEWABLE; ORAL							
PHENYTOIN							
AB	TARO	50MG	A 200565	001	Apr 17, 2014	Apr	NEWA

PHENYTOIN SODIUM

CAPSULE; ORAL							
EXTENDED PHENYTOIN SODIUM							
	@ ANI PHARMS INC	100MG EXTENDED	A 040435	001	Jun 20, 2003	Apr	CAHN
	@	100MG EXTENDED	A 089441	001	Dec 18, 1986	Jan	CAHN
PROMPT PHENYTOIN SODIUM							
	@ ANI PHARMS INC	100MG PROMPT	A 080259	001		Jan	CAHN

PINDOLOL

TABLET; ORAL							
PINDOLOL							
AB	MUTUAL PHARM	5MG	A 074063	001	Jan 27, 1994	Feb	CMFD
AB		10MG	A 074063	002	Jan 27, 1994	Feb	CMFD
AB	MYLAN PHARMS INC	5MG	A 074019	001	Sep 03, 1992	Feb	CTEC
AB	+	10MG	A 074019	002	Sep 03, 1992	Feb	CTEC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL							
PIOGLITAZONE HYDROCHLORIDE							
AB	LUPIN LTD	EQ 15MG BASE	A 204133	001	Apr 07, 2014	Mar	NEWA
AB		EQ 30MG BASE	A 204133	002	Apr 07, 2014	Mar	NEWA
AB		EQ 45MG BASE	A 204133	003	Apr 07, 2014	Mar	NEWA

PIPERACILLIN SODIUM

INJECTABLE; INJECTION							
PIPERACILLIN							
+	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A 065114	001	Nov 14, 2003	Feb	CAHN
+		EQ 3GM BASE/VIAL	A 065114	002	Nov 14, 2003	Feb	CAHN
+		EQ 4GM BASE/VIAL	A 065114	003	Nov 14, 2003	Feb	CAHN
+		EQ 40GM BASE/VIAL	A 065157	001	Jul 12, 2004	Feb	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A 065523	001	May 31, 2011	Feb	CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A 065523	002	May 31, 2011	Feb	CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A 065523	003	May 31, 2011	Feb	CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A 090498	001	May 31, 2011	Feb	CAHN

PIROXICAM

CAPSULE; ORAL
PIROXICAM

>D>	AB	WATSON LABS	10MG	A 074287	001	May 16, 1996	May	DISC
>A>		@	10MG	A 074287	001	May 16, 1996	May	DISC
>D>	AB		10MG	A 074460	001	Sep 29, 1995	May	DISC
>A>		@	10MG	A 074460	001	Sep 29, 1995	May	DISC
>D>	AB		20MG	A 074287	002	May 16, 1996	May	DISC
>A>		@	20MG	A 074287	002	May 16, 1996	May	DISC
>D>	AB		20MG	A 074460	002	Sep 29, 1995	May	DISC
>A>		@	20MG	A 074460	002	Sep 29, 1995	May	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION; ORAL
CO-LAV

	@	VINTAGE PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A 073428	001	Jan 28, 1992	Feb	CAHN
		GO-EVAC						
	@	VINTAGE PHARMS	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A 073433	001	Apr 28, 1992	Feb	CAHN

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL
CUROSURF

+		CHIESI USA INC	80MG/ML	N 020744	001	Nov 18, 1999	Apr	CAHN
---	--	----------------	---------	----------	-----	--------------	-----	------

POSACONAZOLE

SOLUTION; IV (INFUSION)
NOXAFIL

+		MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N 205596	001	Mar 13, 2014	Mar	NEWA
---	--	-------------------	------------------------	----------	-----	--------------	-----	------

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

	@	INTL MEDICATION	2MEQ/ML	A 083163	001		Mar	DISC
--	---	-----------------	---------	----------	-----	--	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

>A>	AB	STRIDES ARCOLAB LTD	0.125MG	A 202702	001	Jun 03, 2014	May	NEWA
>A>	AB		0.25MG	A 202702	002	Jun 03, 2014	May	NEWA
>A>	AB		0.5MG	A 202702	003	Jun 03, 2014	May	NEWA
>A>	AB		0.75MG	A 202702	004	Jun 03, 2014	May	NEWA
>A>	AB		1MG	A 202702	005	Jun 03, 2014	May	NEWA
>A>	AB		1.5MG	A 202702	006	Jun 03, 2014	May	NEWA

TABLET, EXTENDED RELEASE; ORAL
MIRAPEX ER

AB	+	BOEHRINGER INGELHEIM	0.375MG	N 022421	001	Feb 19, 2010	Jan	CFTG
AB			0.75MG	N 022421	002	Feb 19, 2010	Jan	CFTG
AB			1.5MG	N 022421	003	Feb 19, 2010	Jan	CFTG
AB			2.25MG	N 022421	006	Jun 17, 2011	Jan	CFTG
AB			3MG	N 022421	004	Feb 19, 2010	Jan	CFTG
AB			3.75MG	N 022421	007	Jun 17, 2011	Jan	CFTG
AB			4.5MG	N 022421	005	Feb 19, 2010	Jan	CFTG
		PRAMIPEXOLE DIHYDROCHLORIDE						
AB		ANCHEN PHARMS	0.375MG	A 202206	001	Feb 06, 2014	Jan	NEWA
AB			0.75MG	A 202206	002	Feb 06, 2014	Jan	NEWA
AB			1.5MG	A 202206	003	Feb 06, 2014	Jan	NEWA
AB			2.25MG	A 202206	004	Feb 06, 2014	Jan	NEWA
AB			3MG	A 202206	005	Feb 06, 2014	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

AB		3.75MG	A202206	006	Feb 06, 2014	Jan NEWA
AB		4.5MG	A202206	007	Feb 06, 2014	Jan NEWA

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS
SYMLIN

	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Feb CAHN
+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Feb CAHN
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Feb CAHN

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVASTATIN SODIUM

AB	SANDOZ	10MG	A076397	003	Oct 23, 2006	Apr CMFD
AB		20MG	A076397	002	Oct 23, 2006	Apr CMFD
AB		40MG	A076397	001	Oct 23, 2006	Apr CMFD

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	+ BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10% VASOCIDIN	A074449	001	Dec 29, 1995	Feb CRLD
	@ NOVARTIS	EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988	Feb DISC

PRIMAQUINE PHOSPHATE

TABLET;ORAL
PRIMAQUINE

AB	+ SANOFI AVENTIS US	EQ 15MG BASE	N008316	001		Jan CFTG
AB	ALVOGEN INC	EQ 15MG BASE	A203924	001	Feb 03, 2014	Jan NEWA
AB	BAYSHORE PHARMS LLC	EQ 15MG BASE	A204476	001	Feb 25, 2014	Feb NEWA

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PROCAINAMIDE HYDROCHLORIDE

@	ANI PHARMS INC	1GM	A040111	001	Dec 13, 1996	Jan CAHN
@		250MG	A088958	001	Dec 02, 1985	Jan CAHN
@		500MG	A088959	001	Dec 02, 1985	Jan CAHN
@		500MG	A088974	001	Jul 22, 1985	Mar CAHN
@		750MG	A089438	001	Mar 23, 1987	Jan CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL
PHENERGAN

@	DELCOR ASSET CORP	50MG	N011689	001		Apr CAHN
---	-------------------	------	---------	-----	--	----------

TABLET;ORAL
PHENERGAN

>D>	@ DELCOR ASSET CORP	12.5MG	N007935	002		May CAHN
	@	12.5MG	N007935	002		Apr CAHN
>D>	@	25MG	N007935	003		May CAHN
	@	25MG	N007935	003		Apr CAHN
>D>	@	50MG	N007935	004		May CAHN
	@	50MG	N007935	004		Apr CAHN
>A>	@ SHIONOGI INC	12.5MG	N007935	002		May CAHN
>A>	@	25MG	N007935	003		May CAHN
>A>	@	50MG	N007935	004		May CAHN

AB	SANDOZ	25MG	A084176	003		Apr CMS1
----	--------	------	---------	-----	--	----------

PROPAFENONE HYDROCHLORIDE

TABLET;ORAL
PROPAFENONE HYDROCHLORIDE

AB	ANI PHARMS INC	150MG	A076550	001	Apr 23, 2004	Jan CAHN
AB		225MG	A076550	002	Apr 23, 2004	Jan CAHN
AB		300MG	A076550	003	Apr 23, 2004	Jan CAHN

PROPRANOLOL HYDROCHLORIDE

SOLUTION;ORAL
HEMANGEOL

+ PIERRE FABRE DERMA 4.28MG/ML N205410 001 Mar 14, 2014 Mar NEWA

TABLET;ORAL

INDERAL

@ WYETH PHARMS INC 40MG N016418 002 Jan DISC

@ 60MG N016418 009 Oct 18, 1982 Jan DISC

@ 80MG N016418 004 Jan DISC

PROPRANOLOL HYDROCHLORIDE

@ ANI PHARMS INC 90MG A071977 001 Apr 06, 1988 Jan CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

@ ANI PHARMS INC 50MG A080215 001 Jan CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

>D> BX WATSON LABS 324MG A087810 001 Sep 29, 1982 May DISC

>A> @ 324MG A087810 001 Sep 29, 1982 May DISC

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

AB + LILLY 60MG N020815 001 Dec 09, 1997 Feb CFTG

RALOXIFENE HYDROCHLORIDE

AB TEVA PHARMS USA 60MG A078193 001 Mar 04, 2014 Feb NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB ACCORD HLTHCARE INC 1.25MG A202392 001 Apr 15, 2014 Mar NEWA

AB 2.5MG A202392 002 Apr 15, 2014 Mar NEWA

AB 5MG A202392 003 Apr 15, 2014 Mar NEWA

AB 10MG A202392 004 Apr 15, 2014 Mar NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

AP + COVIS INJECTABLES EQ 25MG BASE/ML N019090 001 Oct 19, 1984 Apr CAHN

ZANTAC IN PLASTIC CONTAINER

@ COVIS INJECTABLES EQ 1MG BASE/ML N019593 002 Sep 27, 1991 Apr CAHN

@ EQ 50MG BASE/100ML N019593 001 Dec 17, 1986 Apr CAHN

TABLET, EFFERVESCENT;ORAL

ZANTAC 25

@ GLAXO GRP LTD EQ 25MG BASE N020251 003 Apr 01, 2004 Feb DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

>D> AB WATSON LABS INC EQ 0.5MG BASE A201823 001 Jul 01, 2013 May DISC

>A> @ EQ 0.5MG BASE A201823 001 Jul 01, 2013 May DISC

>D> AB EQ 1MG BASE A201823 002 Jul 01, 2013 May DISC

>A> @ EQ 1MG BASE A201823 002 Jul 01, 2013 May DISC

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB ACTAVIS TOTOWA 0.5MG A090008 001 Jan 22, 2014 Jan NEWA

AB 1MG A090008 002 Jan 22, 2014 Jan NEWA

AB 2MG A090008 003 Jan 22, 2014 Jan NEWA

AB AUROBINDO PHARMA LTD 0.5MG A203820 001 Jan 22, 2014 Jan NEWA

AB 1MG A203820 002 Jan 22, 2014 Jan NEWA

AB 2MG A203820 003 Jan 22, 2014 Jan NEWA

AB MYLAN PHARMS INC 1MG A090252 002 Jan 22, 2014 Jan NEWA

AB 2MG A090252 003 Jan 22, 2014 Jan NEWA

AB PADDOCK LLC 1MG A201189 002 Jan 22, 2014 Jan NEWA

AB 2MG A201189 003 Jan 22, 2014 Jan NEWA

AB SANDOZ 1MG A078555 002 Jan 22, 2014 Jan NEWA

TABLET;ORAL							
REPAGLINIDE							
AB		2MG		A078555	003	Jan 22, 2014	Jan NEWA
<u>RIFABUTIN</u>							
CAPSULE;ORAL							
MYCOBUTIN							
AB	+	PHARMACIA AND UPJOHN	150MG	N050689	001	Dec 23, 1992	Feb CFTG
RIFABUTIN							
AB		LUPIN LTD	150MG	A090033	001	Feb 24, 2014	Feb NEWA
<u>RISEDRONATE SODIUM</u>							
TABLET;ORAL							
ACTONEL							
>D>	+	WARNER CHILCOTT LLC	150MG	N020835	005	Apr 22, 2008	May CTEC
>A>	AB	+	150MG	N020835	005	Apr 22, 2008	May CTEC
RISEDRONATE SODIUM							
>A>	AB	APOTEX INC	75MG	A090877	002	Jun 10, 2014	May NEWA
>A>	AB		150MG	A090877	003	Jun 10, 2014	May NEWA
>A>	AB	MYLAN PHARMS INC	75MG	A200477	004	Jun 10, 2014	May NEWA
>A>	AB		150MG	A200477	005	Jun 10, 2014	May NEWA
>A>	AB	SUN PHARMA GLOBAL	75MG	A090886	004	Jun 10, 2014	May NEWA
>A>	AB		150MG	A090886	005	Jun 10, 2014	May NEWA
<u>RISPERIDONE</u>							
SOLUTION;ORAL							
RISPERIDONE							
AA		ANI PHARMS INC	1MG/ML	A076440	001	Jan 30, 2009	Jan CAHN
TABLET;ORAL							
RISPERIDONE							
AB		CARACO	0.25MG	A078036	001	Mar 10, 2014	Feb NEWA
AB			0.5MG	A078036	002	Mar 10, 2014	Feb NEWA
AB			1MG	A078036	003	Mar 10, 2014	Feb NEWA
AB			2MG	A078036	004	Mar 10, 2014	Feb NEWA
AB			3MG	A078036	005	Mar 10, 2014	Feb NEWA
AB			4MG	A078036	006	Mar 10, 2014	Feb NEWA
<u>RIZATRIPTAN BENZOATE</u>							
TABLET;ORAL							
RIZATRIPTAN BENZOATE							
AB		MACLEODS PHARMS LTD	EQ 5MG BASE	A203147	001	Feb 11, 2014	Jan NEWA
AB			EQ 10MG BASE	A203147	002	Feb 11, 2014	Jan NEWA
<u>SAXAGLIPTIN HYDROCHLORIDE</u>							
TABLET;ORAL							
ONGLYZA							
>A>		ASTRAZENECA AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009	May CAHN
>A>	+		EQ 5MG BASE	N022350	002	Jul 31, 2009	May CAHN
>D>		BRISTOL MYERS SQUIBB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009	May CAHN
>D>	+		EQ 5MG BASE	N022350	002	Jul 31, 2009	May CAHN
<u>SIMEPREVIR SODIUM</u>							
CAPSULE;ORAL							
OLYSIO							
+		JANSSEN RES AND DEV	EQ 150MG BASE	N205123	001	Nov 22, 2013	Feb CAIN
<u>SODIUM FLUORIDE F-18</u>							
INJECTABLE;INTRAVENOUS							
SODIUM FLUORIDE F-18							
AP		UCSF RODIOPHARM	10-200mCi/ML	A204437	001	Mar 13, 2014	Mar NEWA
<u>SODIUM POLYSTYRENE SULFONATE</u>							
POWDER;ORAL, RECTAL							
SODIUM POLYSTYRENE SULFONATE							
AA		EPIC PHARMA LLC	453.6GM/BOT	A202333	001	Mar 19, 2014	Mar NEWA

SOLIFENACIN SUCCINATE

TABLET; ORAL		SOLIFENACIN SUCCINATE					
AB	TEVA PHARMS USA	5MG		A 091464	001	Apr 02, 2014	Mar NEWA
AB		10MG		A 091464	002	Apr 02, 2014	Mar NEWA
VESICARE							
AB	ASTELLAS	5MG		N 021518	001	Nov 19, 2004	Mar CFTG
AB	+	10MG		N 021518	002	Nov 19, 2004	Mar CFTG

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION		ACCRETROPIN					
	@ EMERGENT	5MG/ML (5MG/ML)		N 021538	001	Jan 23, 2008	Feb CAHN

SPIRONOLACTONE

TABLET; ORAL		SPIRONOLACTONE					
AB	JUBILANT LIFE	25MG		A 203253	001	Apr 23, 2014	Apr NEWA
AB		50MG		A 203253	002	Apr 23, 2014	Apr NEWA
AB		100MG		A 203253	003	Apr 23, 2014	Apr NEWA
AB	ORION CORP ORION	25MG		A 202187	001	Mar 06, 2014	Feb NEWA
AB		50MG		A 202187	002	Mar 06, 2014	Feb NEWA
AB		100MG		A 202187	003	Mar 06, 2014	Feb NEWA

SUCRALFATE

SUSPENSION; ORAL		CARAFATE					
	+ FOREST LABS INC	1GM/10ML		N 019183	001	Dec 16, 1993	Apr CAHN
TABLET; ORAL		CARAFATE					
AB	+ FOREST LABS INC	1GM		N 018333	001		Apr CAHN

SULFASALAZINE

TABLET; ORAL		SULFASALAZINE					
>D>	AB WATSON LABS	500MG		A 087197	001		May DISC
>A>	@	500MG		A 087197	001		May DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS		IMITREX STATDOSE					
>D>	+ GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N 020080	002	Feb 01, 2006	May CTEC
>A>	BX +	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N 020080	002	Feb 01, 2006	May CTEC
SUMATRIPTAN SUCCINATE							
AP	AGILA SPECLTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A 203322	001	Apr 14, 2014	Mar NEWA
AB	DR REDDYS LABS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A 090495	001	Jan 29, 2014	Jan NEWA
SUMAVEL DOSEPRO							
>A>	BX + ZOGENIX INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N 022239	002	Nov 26, 2013	May NEWA
SYSTEM; IONTOPHORESIS		ZECUITY					
>D>	+ NUPATHE	EQ 6.5MG BASE/4HR		N 202278	001	Jan 17, 2013	May CAHN
>A>	+ TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR		N 202278	001	Jan 17, 2013	May CAHN

SUNITINIB MALATE

CAPSULE; ORAL		SUNITINIB MALATE					
AB	MYLAN PHARMS INC	EQ 12.5MG BASE		A 201275	001	Jan 30, 2014	Jan NEWA
AB		EQ 25MG BASE		A 201275	002	Jan 30, 2014	Jan NEWA
AB		EQ 37.5MG BASE		A 201275	003	Jan 30, 2014	Jan NEWA
AB		EQ 50MG BASE		A 201275	004	Jan 30, 2014	Jan NEWA
SUTENT							
AB	CPPI CV	EQ 12.5MG BASE		N 021938	001	Jan 26, 2006	Jan CFTG
AB		EQ 25MG BASE		N 021938	002	Jan 26, 2006	Jan CFTG
AB		EQ 37.5MG BASE		N 021938	004	Mar 31, 2009	Jan CFTG
AB	+	EQ 50MG BASE		N 021938	003	Jan 26, 2006	Jan CFTG

TACROLIMUSCAPSULE;ORAL
TACROLIMUS

>D>	AB	WATSON LABS	EQ 5MG BASE	A 090402	001	Jul 01, 2010	May	DISC
>A>		@	EQ 5MG BASE	A 090402	001	Jul 01, 2010	May	DISC

TAFLUPROSTSOLUTION/DROPS;OPHTHALMIC
ZIOPTAN

+	OAK PHARMS INC	0.0015%	N 202514	001	Feb 10, 2012	Apr	CAHN
---	----------------	---------	----------	-----	--------------	-----	------

TASIMELTEONCAPSULE;ORAL
HETLIOZ

+	VANDA PHARMS INC	20MG	N 205677	001	Jan 31, 2014	Jan	NEWA
---	------------------	------	----------	-----	--------------	-----	------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR>D> SOLUTION;INJECTION, ORAL
>D> TECHNELITE

>D>	+	LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N 017771	001		May	DISC
>A>		@	0.0083-2.7 CI/GENERATOR	N 017771	001		May	DISC

>D> TECHNETIUM TC 99M GENERATOR

>D>	@	GE HEALTHCARE	830-16600mCi/GENERATOR	N 017693	001		May	CDFR
-----	---	---------------	------------------------	----------	-----	--	-----	------

>D> ULTRA-TECHNEKOW FM

>D>	+	MALLINCKRODT	0.25-3 CI/GENERATOR	N 017243	002		May	DISC
>A>		@	0.25-3 CI/GENERATOR	N 017243	002		May	DISC

SOLUTION;INTRAVENOUS
TECHNELITE

>A>	+	LANTHEUS MEDCL	1-20 CI/GENERATOR	N 017771	002	Feb 12, 2014	May	NEWA
>A>		@	0.0083-2.7 CI/GENERATOR	N 017771	001		May	CDFR

ULTRA-TECHNEKOW FM

>A>	+	MALLINCKRODT	1-19 CI/GENERATOR	N 017243	003	Feb 18, 2014	May	NEWA
>A>		@	0.25-3 CI/GENERATOR	N 017243	002		May	CDFR

SOLUTION;INTRAVENOUS, ORAL
TECHNETIUM TC 99M GENERATOR

>A>	+	GE HEALTHCARE	68-2703mCi/GENERATOR	N 017693	002	Dec 13, 2013	May	NEWA
>A>		@	830-16600mCi/GENERATOR	N 017693	001		May	CDFR

TEMAZEPAMCAPSULE;ORAL
TEMAZEPAM

>D>	AB	WATSON LABS	15MG	A 071446	001	May 21, 1993	May	DISC
>A>		@	15MG	A 071446	001	May 21, 1993	May	DISC
>D>	AB		30MG	A 071447	001	May 21, 1993	May	DISC
>A>		@	30MG	A 071447	001	May 21, 1993	May	DISC

TEMOZOLOMIDECAPSULE;ORAL
TEMOZOLOMIDE

AB	SUN PHARMA GLOBAL	5MG	A 201742	001	Feb 12, 2014	Feb	NEWA
AB		20MG	A 201742	002	Feb 12, 2014	Feb	NEWA
AB		100MG	A 201742	003	Feb 12, 2014	Feb	NEWA
AB		140MG	A 201742	004	Feb 12, 2014	Feb	NEWA
AB		180MG	A 201742	005	Feb 12, 2014	Feb	NEWA
AB		250MG	A 201742	006	Feb 12, 2014	Feb	NEWA

TERAZOSIN HYDROCHLORIDECAPSULE;ORAL
HYTRIN

@	ABBOTT	EQ 1MG BASE	N 020347	001	Dec 14, 1994	Apr	DISC
@		EQ 2MG BASE	N 020347	002	Dec 14, 1994	Apr	DISC
@		EQ 5MG BASE	N 020347	003	Dec 14, 1994	Apr	DISC
@		EQ 10MG BASE	N 020347	004	Dec 14, 1994	Apr	DISC

TERAZOSIN HYDROCHLORIDE

AB	+	SANDOZ	EQ 2MG BASE	A 074823	002	Mar 30, 1998	Apr	CRLD
----	---	--------	-------------	----------	-----	--------------	-----	------

TABLET;ORAL
HYTRIN

@	ABBOTT	EQ 1MG BASE	N 019057	001	Aug 07, 1987	Apr	DISC
@		EQ 2MG BASE	N 019057	002	Aug 07, 1987	Apr	DISC
@		EQ 5MG BASE	N 019057	003	Aug 07, 1987	Apr	DISC
@		EQ 10MG BASE	N 019057	004	Aug 07, 1987	Apr	DISC

TESAMORELIN ACETATE

	POWDER; SUBCUTANEOUS						
	EGRIFTA						
>D>	@ EMD SERONO	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	May	CAHN
>D>	+	EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	May	CAHN
>A>	@ THERATECHNOLOGIES	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	May	CAHN
>A>	+	EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	May	CAHN

TESTOSTERONE

>A>	GEL, METERED; NASAL						
>A>	NATESTO						
>A>	+	TRIMEL BIOPHARMA SRL 5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	May	NEWA
	TABLET, EXTENDED RELEASE; BUCCAL						
	STRIANT						
	+	AUXILIUM PHARMS LLC 30MG	N021543	001	Jun 19, 2003	Apr	CAHN

TESTOSTERONE UNDECANOATE

	INJECTABLE; INTRAMUSCULAR						
	AVEED						
	+	ENDO PHARMS INC 750MG/3ML (250MG/ML)	N022219	001	Mar 04, 2014	Mar	NEWA

THEOPHYLLINE

	TABLET, EXTENDED RELEASE; ORAL						
	THEOCHRON						
	@	CARACO 300MG	A087400	002	Jan 11, 1983	Jan	DISC

THIAMINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	THIAMINE HYDROCHLORIDE						
>D> AP	WATSON LABS	100MG/ML	A080571	001		May	DISC
>A>	@	100MG/ML	A080571	001		May	DISC
>D>	+	200MG/ML	A080571	002		May	DISC
>A>	@	200MG/ML	A080571	002		May	DISC

THIORIDAZINE HYDROCHLORIDE

	CONCENTRATE; ORAL						
	THIORIDAZINE HYDROCHLORIDE						
	@	ANI PHARMS INC 100MG/ML	A089603	001	Nov 09, 1987	Feb	CAHN
	TABLET; ORAL						
	THIORIDAZINE HYDROCHLORIDE						
	@	ANI PHARMS INC 10MG	A088270	001	Apr 14, 1983	Feb	CAHN
	@	10MG	A088493	001	May 17, 1985	Feb	CAHN
	@	15MG	A088271	001	Apr 14, 1983	Feb	CAHN
	@	25MG	A088272	001	Apr 14, 1983	Feb	CAHN
	@	50MG	A088194	001	Apr 14, 1983	Feb	CAHN
	@	100MG	A088273	001	Oct 03, 1983	Feb	CAHN
	@	100MG	A088456	001	May 17, 1985	Feb	CAHN

THIOTHIXENE

	CAPSULE; ORAL						
	THIOTHIXENE						
>D> AB	WATSON LABS	2MG	A070601	001	Jun 05, 1987	May	DISC
>A>	@	2MG	A070601	001	Jun 05, 1987	May	DISC
>D> AB		5MG	A070602	001	Jun 05, 1987	May	DISC
>A>	@	5MG	A070602	001	Jun 05, 1987	May	DISC

TIMOLOL

	SOLUTION/DROPS; OPHTHALMIC						
	BETIMOL						
	+	OAK PHARMS AKORN EQ 0.25% BASE	N020439	001	Mar 31, 1995	Apr	CAHN
	+	EQ 0.5% BASE	N020439	002	Mar 31, 1995	Apr	CAHN

TOBRAMYCIN

	SOLUTION; INHALATION						
	BETHKIS						
		CHIESI USA INC 300MG/4ML	N201820	001	Oct 12, 2012	Apr	CAHN
	TOBRAMYCIN						
>A> AN		AKORN INC 300MG/5ML	A201422	001	May 28, 2014	May	NEWA

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

>D>	AP	WATSON LABS INC	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989	May	DISC
>A>		@	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989	May	DISC

TOPIRAMATE

CAPSULE, DELAYED RELEASE; ORAL
QUDEXY XR

		UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Mar	NEWA
			50MG	N205122	002	Mar 11, 2014	Mar	NEWA
			100MG	N205122	003	Mar 11, 2014	Mar	NEWA
			150MG	N205122	004	Mar 11, 2014	Mar	NEWA
		+	200MG	N205122	005	Mar 11, 2014	Mar	NEWA

CAPSULE, EXTENDED RELEASE; ORAL
QUDEXY XR

		UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Apr	CDFR
			50MG	N205122	002	Mar 11, 2014	Apr	CDFR
			100MG	N205122	003	Mar 11, 2014	Apr	CDFR
			150MG	N205122	004	Mar 11, 2014	Apr	CDFR
		+	200MG	N205122	005	Mar 11, 2014	Apr	CDFR

TABLET; ORAL

TOPIRAMATE

>D>	AB	WATSON LABS	25MG	A077643	001	Mar 27, 2009	May	DISC
>A>		@	25MG	A077643	001	Mar 27, 2009	May	DISC
>D>	AB		50MG	A077643	002	Mar 27, 2009	May	DISC
>A>		@	50MG	A077643	002	Mar 27, 2009	May	DISC
>D>	AB		100MG	A077643	003	Mar 27, 2009	May	DISC
>A>		@	100MG	A077643	003	Mar 27, 2009	May	DISC
>D>	AB		200MG	A077643	004	Mar 27, 2009	May	DISC
>A>		@	200MG	A077643	004	Mar 27, 2009	May	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

AP		INNOPHARMA LICENSING	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Apr	CAHN
----	--	----------------------	------------------	---------	-----	--------------	-----	------

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

AB		ALLIED PHARMA INC	50MG	A202075	001	Nov 28, 2011	Apr	CAHN
AB		AUROBINDO PHARMA LTD	50MG	A203494	001	Mar 31, 2014	Mar	NEWA
>D>	AB	WATSON LABS	50MG	A075962	001	Jun 24, 2002	May	DISC
>A>		@	50MG	A075962	001	Jun 24, 2002	May	DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION
TRANEXAMIC ACID

AP		ACIC FINE CHEMS	100MG/ML	A202436	001	Feb 11, 2014	Jan	NEWA
----	--	-----------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL
TRANEXAMIC ACID

AB		APOTEX INC	650 MG	A202286	001	Jan 27, 2014	Jan	NEWA
----	--	------------	--------	---------	-----	--------------	-----	------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC
IZBA

>A>									
>A>		+	ALCON LABS INC	0.003%	N204822	001	May 15, 2014	May	NEWA
			TRAVOPROST						
		+	PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb	CRLD

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HYDROCHLORIDE

>D>	AB	WATSON LABS	50MG	A070857	001	Oct 10, 1986	May	DISC
>A>		@	50MG	A070857	001	Oct 10, 1986	May	DISC
>D>	AB		100MG	A070858	001	Oct 10, 1986	May	DISC
>A>		@	100MG	A070858	001	Oct 10, 1986	May	DISC

TRETINOIN

GEL; TOPICAL

RETIN-A-MICRO

+ VALEANT INTL 0.08% N020475 003 Jan 28, 2014 Jan NEWA

SOLUTION; TOPICAL

RETIN-A

+ VALEANT INTL 0.05% N016921 001 Feb CTEC

TRETINOIN

@ WOCKHARDT 0.05% A075260 001 Jan 25, 1999 Feb DISC

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

KENALOG-10

>D> AB APOTHECON 10MG/ML N012041 001 May CTEC

>A> 10MG/ML N012041 001 May CTEC

KENALOG-40

>D> AB + APOTHECON 40MG/ML N014901 001 May CTEC

>A> + 40MG/ML N014901 001 May CTEC

TRIAMCINOLONE ACETONIDE

>D> AB SANDOZ 10MG/ML A090166 001 May 27, 2009 May DISC

>A> @ 10MG/ML A090166 001 May 27, 2009 May DISC

>D> AB SANDOZ CANADA INC 40MG/ML A090164 001 Jun 01, 2009 May DISC

>A> @ 40MG/ML A090164 001 Jun 01, 2009 May DISC

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

@ TARO 0.1% A089129 001 Aug 14, 1986 Mar DISC

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

>D> AB WATSON LABS 0.125MG A074445 001 Oct 20, 1995 May DISC

>A> @ 0.125MG A074445 001 Oct 20, 1995 May DISC

>D> AB 0.25MG A074445 002 Oct 20, 1995 May DISC

>A> @ 0.25MG A074445 002 Oct 20, 1995 May DISC

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

>D> AA WATSON LABS 2MG A040184 001 Feb 06, 1998 May DISC

>A> @ 2MG A040184 001 Feb 06, 1998 May DISC

>D> AA 5MG A040184 002 Feb 06, 1998 May DISC

>A> @ 5MG A040184 002 Feb 06, 1998 May DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TIGAN

>D> AP + JHP PHARMS 100MG/ML N017530 001 May CAHN

>A> AP + PAR STERILE PRODUCTS 100MG/ML N017530 001 May CAHN

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+ GLAXO GRP ENGLAND EQ 62.5MCG BASE/INH N205382 001 Apr 30, 2014 Apr NEWA

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+ GLAXOSMITHKLINE EQ 0.0625MG BASE/INH; EQ 0.025MG BASE/INH N203975 001 Dec 18, 2013 Apr CAHN

>D> UREA C-13

>D> FOR SOLUTION; ORAL

>D> BREATHTEK UBT FOR H-PYLORI

>D> + OTSUKA AMERICA EQ 75MG / POUCH N020586 002 May 10, 2001 May DISC

>A> @ EQ 75MG / POUCH N020586 002 May 10, 2001 May DISC

URSODIOL

	TABLET;ORAL							
	URSO 250							
AB	FOREST LABS INC	250MG		N020675	001	Dec 10, 1997	Apr	CAHN
	URSO FORTE							
AB	+ FOREST LABS INC	500MG		N020675	002	Jul 21, 2004	Apr	CAHN

VALACYCLOVIR HYDROCHLORIDE

	TABLET;ORAL							
	VALACYCLOVIR HYDROCHLORIDE							
AB	APOTEX INC	EQ 1GM BASE		A090500	002	Apr 04, 2014	Mar	NEWA
AB		EQ 500MG BASE		A090500	001	Apr 04, 2014	Mar	NEWA
AB	CIPLA LTD	EQ 1GM BASE		A077135	002	May 24, 2010	Jan	CAHN
AB		EQ 500MG BASE		A077135	001	May 24, 2010	Jan	CAHN
AB	WATSON LABS INC	EQ 1GM BASE		A090370	002	Mar 16, 2011	Apr	CAHN
AB		EQ 500MG BASE		A090370	001	Mar 16, 2011	Apr	CAHN

VALPROIC ACID

	SYRUP;ORAL							
	VALPROIC ACID							
AA	ANI PHARMS INC	250MG/5ML		A073178	001	Aug 25, 1992	Jan	CAHN

VANCOMYCIN HYDROCHLORIDE

	CAPSULE;ORAL							
	VANCOCIN HYDROCHLORIDE							
>A>	AB	SHIRE VIROPHARM INC	EQ 125MG BASE	N050606	001	Apr 15, 1986	May	CAHN
>A>	AB	+	EQ 250MG BASE	N050606	002	Apr 15, 1986	May	CAHN
>D>	AB	VIROPHARMA	EQ 125MG BASE	N050606	001	Apr 15, 1986	May	CAHN
>D>	AB	+	EQ 250MG BASE	N050606	002	Apr 15, 1986	May	CAHN
	INJECTABLE;INJECTION							
	VANCOMYCIN HYDROCHLORIDE							
AP	AGILA SPECLTS	EQ 10GM BASE/VIAL		A091554	001	Sep 19, 2011	Feb	CAHN
>A>	AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May	CAHN
>A>	AP		EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May	CAHN
>D>	AP	MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May	CAHN
>D>	AP		EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May	CAHN

VASOPRESSIN

	SOLUTION;IV (INFUSION)							
	VASOSTRICT							
	+	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr	NEWA

VECURONIUM BROMIDE

	INJECTABLE;INJECTION							
	VECURONIUM BROMIDE							
>D>	AP	WATSON LABS	10MG/VIAL	A074334	001	Aug 31, 1995	May	DISC
>A>		@	10MG/VIAL	A074334	001	Aug 31, 1995	May	DISC
>D>	AP		20MG/VIAL	A074334	002	Aug 31, 1995	May	DISC
>A>		@	20MG/VIAL	A074334	002	Aug 31, 1995	May	DISC

VERAPAMIL HYDROCHLORIDE

	TABLET;ORAL							
	VERAPAMIL HYDROCHLORIDE							
AB	MYLAN	80MG		A071483	002	Feb 15, 1989	Apr	CMS1
>D>	AB	WATSON LABS	40MG	A072923	001	Jun 29, 1993	May	DISC
>A>		@	40MG	A072923	001	Jun 29, 1993	May	DISC
>D>	AB		80MG	A070855	001	Sep 24, 1986	May	DISC
>A>		@	80MG	A070855	001	Sep 24, 1986	May	DISC
>D>	AB		80MG	A071366	001	Oct 01, 1986	May	DISC
>A>		@	80MG	A071366	001	Oct 01, 1986	May	DISC
>D>	AB		120MG	A070856	001	Sep 24, 1986	May	DISC
>A>		@	120MG	A070856	001	Sep 24, 1986	May	DISC
>D>	AB		120MG	A071367	001	Oct 01, 1986	May	DISC
>A>		@	120MG	A071367	001	Oct 01, 1986	May	DISC

>A>	<u>VORAPAXAR SULFATE</u>							
>A>	TABLET;ORAL							
>A>	ZONTIVITY							
>A>	+	MERCK SHARP DOHME	EQ 2.5MG BASE	N204886	001	May 08, 2014	May	NEWA

WARFARIN SODIUM

	INJECTABLE; INJECTION						
	COUMADIN						
	@ BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995	Mar	DISC
	TABLET; ORAL						
	COUMADIN						
AB	BRISTOL MYERS SQUIBB	1MG	N009218	022	Mar 01, 1990	Apr	CMFD
	@	1MG	N009218	022	Mar 01, 1990	Mar	DISC
AB		2MG	N009218	013		Apr	CMFD
	@	2MG	N009218	013		Mar	DISC
AB		2.5MG	N009218	018		Apr	CMFD
	@	2.5MG	N009218	018		Mar	DISC
AB		3MG	N009218	025	Nov 18, 1996	Apr	CMFD
	@	3MG	N009218	025	Nov 18, 1996	Mar	DISC
AB		4MG	N009218	023	Aug 24, 1993	Apr	CMFD
	@	4MG	N009218	023	Aug 24, 1993	Mar	DISC
AB		5MG	N009218	007		Apr	CMFD
AB		6MG	N009218	026	Nov 18, 1996	Apr	CMFD
	@	6MG	N009218	026	Nov 18, 1996	Mar	DISC
AB		7.5MG	N009218	016		Apr	CMFD
	@	7.5MG	N009218	016		Mar	DISC
AB	+	10MG	N009218	005		Apr	CMFD

ZICONOTIDE ACETATE

	INJECTABLE; INTRATHECAL						
	PRIALT						
	@ JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Feb	CAIN

ZIDOVUDINE

	INJECTABLE; INJECTION						
	ZIDOVUDINE						
	@ LIAONING CHENGDA	10MG/ML	A204538	001	Nov 26, 2013	Mar	DISC

ZILEUTON

	TABLET; ORAL							
	ZYFLO							
	@ CHIESI USA INC	300MG	N020471	001	Dec 09, 1996	Apr	CAHN	
	+	600MG	N020471	003	Dec 09, 1996	Apr	CAHN	
	TABLET, EXTENDED RELEASE; ORAL							
	ZYFLO CR							
	+	CHIESI USA INC	600MG	N022052	001	May 30, 2007	Apr	CAHN

ZOLEDRONIC ACID

	INJECTABLE; IV (INFUSION)							
	ZOLEDRONIC ACID							
>A>	AP	AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	May	NEWA

ZOLMITRIPTAN

	TABLET; ORAL						
	ZOLMITRIPTAN						
AB	INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar	NEWA
AB		5MG	A204284	002	Apr 09, 2014	Mar	NEWA
AB	TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014	Feb	NEWA
AB		5MG	A090861	002	Mar 04, 2014	Feb	NEWA

ZOLPIDEM TARTRATE

	TABLET; ORAL							
	ZOLPIDEM TARTRATE							
	@ VIVIMED LABS	5MG	A076062	001	Apr 23, 2007	Apr	CAHN	
	@	10MG	A076062	002	Apr 23, 2007	Apr	CAHN	
>D>	AB	WATSON LABS	5MG	A077773	001	Apr 23, 2007	May	DISC
>A>		@	5MG	A077773	001	Apr 23, 2007	May	DISC
>D>	AB		10MG	A077773	002	Apr 23, 2007	May	DISC
>A>		@	10MG	A077773	002	Apr 23, 2007	May	DISC

ZONISAMIDE

	CAPSULE; ORAL						
	ZONISAMIDE						
AB	ANI PHARMS INC	25MG	A077639	001	Dec 22, 2005	Jan	CAHN
	@	25MG	A077641	003	Dec 22, 2005	Jan	CAHN
AB		50MG	A077639	002	Dec 22, 2005	Jan	CAHN

	CAPSULE;ORAL								
	ZONISAMIDE								
	@	50MG	A077641	002	Dec 22, 2005	Jan	CAHN		
AB		100MG	A077639	003	Dec 22, 2005	Jan	CAHN		
	@	100MG	A077641	001	Dec 22, 2005	Jan	CAHN		
	@ SANDOZ	25MG	A077644	001	Dec 22, 2005	Feb	DISC		
	@	50MG	A077644	002	Dec 22, 2005	Feb	DISC		
	@	100MG	A077644	003	Dec 22, 2005	Feb	DISC		

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DRIXORAL PLUS

@ SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987	Feb DISC
-------------------	----------------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014	Feb NEWA
---------------	-----	---------	-----	--------------	----------

	10MG	A202277	004	Mar 11, 2014	Feb NEWA
--	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES

IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014	Feb NEWA
---------------	-----	---------	-----	--------------	----------

	10MG	A202277	003	Mar 11, 2014	Feb NEWA
--	------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ CARACO	5MG	A077631	004	Jan 11, 2008	Feb DISC
----------	-----	---------	-----	--------------	----------

@	10MG	A077631	003	Jan 11, 2008	Feb DISC
---	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CARACO	5MG	A077631	001	Jan 11, 2008	Feb DISC
----------	-----	---------	-----	--------------	----------

@	10MG	A077631	002	Jan 11, 2008	Feb DISC
---	------	---------	-----	--------------	----------

CIMETIDINE

TABLET;ORAL

CIMETIDINE

>D>	WATSON LABS	200MG	A075425	001	Jul 29, 1999	May DISC
-----	-------------	-------	---------	-----	--------------	----------

>A>	@	200MG	A075425	001	Jul 29, 1999	May DISC
-----	---	-------	---------	-----	--------------	----------

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Jan CRLD
---------------	-----------	---------	-----	--------------	----------

DISOPHROL

@ SCHERING PLOUGH	6MG;120MG	N013483	004	Sep 13, 1982	Jan DISC
-------------------	-----------	---------	-----	--------------	----------

DRIXORAL

@ SCHERING PLOUGH	6MG;120MG	N013483	003	Sep 13, 1982	Jan DISC
-------------------	-----------	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+ BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014	Jan NEWA
------------------	------------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

NEXIUM

ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Apr CMS2
----------------	--------------	---------	-----	--------------	----------

NEXIUM 24HR

+ ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Apr CTNA
------------------	--------------	---------	-----	--------------	----------

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

>D>	WATSON LABS	10MG	A075404	001	Nov 28, 2001	May DISC
-----	-------------	------	---------	-----	--------------	----------

>A>	@	10MG	A075404	001	Nov 28, 2001	May DISC
-----	---	------	---------	-----	--------------	----------

IBUPROFEN

SUSPENSION;ORAL

CHILDREN'S ELIXSURE

>D>	ALTERNA TCHP LLC	100MG/5ML	N021604	001	Jan 07, 2004	May CAHN
-----	------------------	-----------	---------	-----	--------------	----------

>A>	MOBERG PHARMA NORTH	100MG/5ML	N021604	001	Jan 07, 2004	May CAHN
-----	---------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Mar NEWA
---------------	-------	---------	-----	--------------	----------

>D>	WATSON LABS	200MG	A070435	001	Mar 05, 1986	May DISC
-----	-------------	-------	---------	-----	--------------	----------

>A>	@	200MG	A070435	001	Mar 05, 1986	May DISC
-----	---	-------	---------	-----	--------------	----------

MINOXIDIL

AEROSOL, FOAM;TOPICAL
WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 002 Feb 28, 2014 Feb NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 5 MAY 2014

NO MAY 2014 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2014 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	6488962	Jun 20, 2020	DP		NP	Mar 11, 2017
	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8653061	Aug 24, 2025	U-1373			
	>A> 8722738	Apr 06, 2032	U-1373			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jan 24, 2019	DP U-1006		NPP	Jan 22, 2017
	6514980	Jan 24, 2019	DP U-1484			
	7223387	May 13, 2023	DP U-1006			
	7223387	May 13, 2023	DP U-1484			
	RE39264	Aug 02, 2016	DP U-1006			
	RE39264	Aug 02, 2016	DP U-1484			
<u>ADAPALENE - ADAPALENE</u>						
A 200298 001					PC	Oct 25, 2014
<u>ADAPALENE - DIFFERIN</u>						
N 021753 001	>A> 8703820	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	>A> 8709392	Sep 15, 2026	DP U-1078			
<u>ADENOSINE - ADENOSINE</u>						
A 077425 001					PC	Mar 22, 2014
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	8664215	Oct 05, 2029	U-1493			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 001	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 002	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 003	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 001	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 002	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 003	8618172	Jul 13, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRINA HCT</u>						
N 022107 004	8618172	Jul 13, 2028	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001 >A>	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002 >A>	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003 >A>	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jan 23, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8645160	Jun 18, 2029	U-1485			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200		I-681	Mar 03, 2017
	6413980	Dec 22, 2019	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1167			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 001	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 005	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	>A> 8722679	Oct 19, 2024	DP			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	>A> 8722679	Oct 19, 2024	DP			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001					NP	Oct 03, 2016
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	>A> 5683677	Nov 04, 2014	DP			
	>A> 5776432	Jul 07, 2015	DP	U-645		
	>A> 6446627	Dec 18, 2017	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	>A> 5683677	Nov 04, 2014	DP			
	>A> 5776432	Jul 07, 2015	DP	U-645		
	>A> 6446627	Dec 18, 2017	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	8546428	Mar 19, 2029	DS DP U-1321			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8663699	Jun 03, 2029	U-124			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE</u>						
A 201615 001					PC	Sep 27, 2014
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8263054	Jan 15, 2023	U-1277			
	8632760	Jan 15, 2023	U-1487			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001					ODE	Jun 20, 2015
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8669290	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8613947	Apr 30, 2032	DP U-976			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8616196	Apr 07, 2029	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8616196	Apr 07, 2029	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8658198	Dec 03, 2027	DP U-1494			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	Sep 27, 2028	DP U-1280			
	8269128	May 26, 2026	DP U-1280			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP		ODE	Apr 29, 2021
	7964592	Jan 13, 2027	DS DP			
	>A> 8039474	Jun 29, 2030	DS DP			
	8039479	Jun 29, 2030	DS DP			
	>A> 8377921	Nov 20, 2027		U-1179		
	>A> 8703787	Feb 02, 2032		U-1179		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Oct 11, 2031	DP U-257		NP	Aug 27, 2015
	>A> 8716264	Jan 13, 2024	DP U-257			
	>A> 8716264*PED	Jul 13, 2024				
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	8003353	Jun 11, 2024	U-817			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001					I-682	Apr 04, 2017
					I-683	Apr 04, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512	002				I-682	Apr 04, 2017
					I-683	Apr 04, 2017
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	001				I-678	Jan 08, 2017
					ODE	Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	002				I-678	Jan 08, 2017
					ODE	Jan 09, 2021
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883	001				>A> NCE	May 23, 2019
					>A> GAIN	May 23, 2024
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250	001	8663685	Jan 18, 2025	U-1030		
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	001	>A> 6414126	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		>A> 6515117	Oct 04, 2020	DS DP U-493		
		>A> 6936590	Oct 04, 2020	U-493		
		>A> 7851502	Aug 19, 2028	DP		
		>A> 7919598	Dec 16, 2029	DS		
		>A> 8221786	Mar 21, 2028	DP		
		>A> 8361972	Mar 21, 2028	U-493		
		>A> 8501698	Jun 20, 2027	DP U-493		
		>A> 8716251	Mar 21, 2028	DP		
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	002	>A> 6414126	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		>A> 6515117	Oct 04, 2020	DS DP U-493		
		>A> 6936590	Oct 04, 2020	U-493		
		>A> 7851502	Aug 19, 2028	DP		
		>A> 7919598	Dec 16, 2029	DS		
		>A> 8221786	Mar 21, 2028	DP		
		>A> 8361972	Mar 21, 2028	U-493		
		>A> 8501698	Jun 20, 2027	DP U-493		
		>A> 8716251	Mar 21, 2028	DP		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	001	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	002	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	003	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	004	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	005	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	006	8597876	Jun 23, 2019	U-1305		
		8597876*PED	Dec 23, 2019			
<u>DASATINIB - SPRYCEL</u>						
N 021986	001	8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	002	8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	003	8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	004	8680103	Feb 04, 2025	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	8680103	Feb 04, 2025	DP			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
>A>	8722084	Oct 15, 2023	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
>A>	8722084	Oct 15, 2023	DP			
>A>	8722084*PED	Apr 15, 2024				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					M-61 PED	Jun 17, 2016 Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078992 003					PC	May 18, 2014
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	>A> RE38115	Jan 26, 2016	DP	Y		
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8679544	Apr 23, 2030	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8679544	Apr 23, 2030	DP			
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	6287594	Jan 15, 2019	DP			
	8623920	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	>A> 8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
>A>	8741956	Jul 10, 2029	U-1435			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352 001					NC	Jan 17, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8709478	Apr 07, 2024	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	8715724	Feb 03, 2028	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	8617597	Feb 08, 2030	DP			
<u>DROXIDOPA - NORTHERA</u>						
N 203202 001					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 002					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 003					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 003					PC	Jun 09, 2014
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	>A> 8716264	Jan 03, 2024	DP U-257			
	>A> 8716264*PED	Jul 03, 2024				
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	>A> 8716264	Jan 13, 2024	DP U-257			
	>A> 8716264*PED	Jul 13, 2024				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	>A> 8716264	Jan 13, 2024	DP U-257			
	>A> 8716264*PED	Jul 13, 2024				
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001					NPP PED	Mar 20, 2017 Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002					NPP PED	Mar 20, 2017 Sep 20, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTECAVIR - BARACLUDE</u>						
N 021798	001				NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655	001	5690960	Nov 25, 2014	DP U-1509	>A> RTO	Mar 28, 2017
		5714504	Feb 03, 2015	DP U-1509		
		5877192	May 27, 2014	U-1509		
		5900424	May 04, 2016	DS U-1509		
		6369085	May 25, 2018	DS DP U-1509		
		6428810	Nov 03, 2019	DP U-1509		
		6875872	May 27, 2014	DS		
		7411070	May 25, 2018	DS		
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689	001	5877192	May 27, 2014	U-643	D-138	Mar 04, 2017
		5877192	May 27, 2014	U-1495	I-679	Mar 04, 2017
		5877192*PED	Nov 27, 2014			
		6143771	May 27, 2014	DP U-643		
		6143771	May 27, 2014	DP U-1495		
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689	002	5877192	May 27, 2014	U-643	D-138	Mar 04, 2017
		5877192	May 27, 2014	U-1495	I-679	Mar 04, 2017
		5877192*PED	Nov 27, 2014			
		6143771	May 27, 2014	DP U-643		
		6143771	May 27, 2014	DP U-1495		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667	001	6667050	Apr 06, 2019	DP U-1		
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190	001				ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529	002	8722037	Dec 26, 2028	DP		
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	001	8617598	Sep 27, 2022	DP		
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	002	8617598	Sep 27, 2022	DP		
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	003	8617598	Sep 27, 2022	DP		
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200	001	8216180	Jan 12, 2028	DP		
		8439864	Mar 25, 2028	DP		
<u>EZETIMIBE - ZETIA</u>						
N 021445	001	7612058	Oct 30, 2025	U-1027		
		7612058	Oct 30, 2025	U-1173		
		7612058*PED	Apr 30, 2026			
<u>FENTANYL - SUBSYS</u>						
N 202788	001	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
<u>FENTANYL - SUBSYS</u>						
N 202788	002	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
<u>FENTANYL - SUBSYS</u>						
N 202788	003	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
<u>FENTANYL - SUBSYS</u>						
N 202788	004	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
<u>FENTANYL - SUBSYS</u>						
N 202788	005	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	6599498	Jun 30, 2023	DS DP			
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677 001	7907135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - FLUOCINONIDE</u>						
A 090256 001					PC	Jul 13, 2014
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	>A> 8691185	Jan 24, 2023	U-336			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	>A> 8691185	Jan 24, 2023	U-336			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8147461	Oct 15, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001					NP	May 10, 2016
<u>FORMOTEROL FUMARATE - PERFORMIST</u>						
N 022007 001	>A> 8623922	Jun 22, 2021	DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	6054430	May 24, 2014	DS		NP	Jan 28, 2017
	6342476	May 24, 2014	U-441			
	6362161	May 24, 2014	DS			
	7199098	May 24, 2014	DS			
	8232250	Aug 19, 2030	U-441			
	8367605	May 24, 2014	DS			
	8399413	Sep 06, 2030	U-441			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	8642012	Sep 22, 2030	U-1383			
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP U-1087			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6228398	Nov 01, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-680	Feb 12, 2017
	8476284	Dec 28, 2026	U-1491		ODE	Feb 12, 2021
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8703780	Dec 28, 2026	U-1491			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	>A> 8735452	Sep 30, 2029	U-981			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NP	Jul 26, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	>A> 8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	>A> 8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	>A> 8716271	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	>A> 8716271	Dec 18, 2026	U-1440			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8679069	Apr 12, 2025	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8679069	Apr 12, 2025	DP			
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001	5310912	Feb 25, 2015	DS			
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946 001	>A> 8735393	Dec 04, 2018	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8648107	May 28, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001					>A> NP	May 30, 2017
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jun 14, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jun 14, 2028	DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	Aug 23, 2027	U-1503			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	8618135	Mar 07, 2025	U-1316			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8697686	Dec 20, 2025	DS DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	7052679	Oct 26, 2021	DP			
	7537009	Oct 28, 2024	DP			
	8074644	Jul 25, 2022	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001 >A>	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002 >A>	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003 >A>	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004 >A>	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005 >A>	5532372	Jul 02, 2018	DS			
	>A> 8729085	May 26, 2026	DP			
<u>MENOTROPINS (FSH; LH) - MENOPUR</u>						
N 021663 001					>A> D-139	Feb 19, 2017
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919 001					ODE	Apr 28, 2021
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8668931	Sep 19, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-134	May 24, 2016
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
N 205223 001					NP	Mar 24, 2017
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684 001					NCE ODE	Mar 19, 2019 Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008	8722650	Jun 24, 2025	U-1078			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002					NP	Feb 28, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 001	>A> 5889015	Jan 27, 2014	U-645			
	>A> 5889015*PED	Jul 27, 2014				
	>A> 6057307	Jan 27, 2014	DP U-645			
	>A> 6057307*PED	Jul 27, 2014				
	>A> 6068832	Aug 27, 2017	DP U-645			
	>A> 6365581	Jan 27, 2014	U-645			
	>A> 6365581*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 002	>A> 5889015	Jan 27, 2014	U-645			
	>A> 5889015*PED	Jul 27, 2014				
	>A> 6057307	Jan 27, 2014	DP U-645			
	>A> 6057307*PED	Jul 27, 2014				
	>A> 6068832	Aug 27, 2017	DP U-645			
	>A> 6365581	Jan 27, 2014	U-645			
	>A> 6365581*PED	Jul 27, 2014				
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 001	>A> 6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 002	>A> 6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 003	>A> 6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 004	>A> 6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 005	>A> 6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 006	>A> 6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	>A> 7682633	Jun 19, 2027	U-1510			
	>A> 8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	>A> 7682633	Jun 19, 2027	U-1510			
	>A> 8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	>A> 7682633	Jun 19, 2027	U-1510			
	>A> 8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	>A> 7682633	Jun 19, 2027	U-1510			
	>A> 8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	>A> 7682633	Jun 19, 2027	U-1510			
	>A> 8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	>A> 7682633	Jun 19, 2027	U-1510			
	>A> 8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MYCOPHENOLIC ACID - MYCOPHENOLIC ACID</u>						
A 091248 001					PC	Jul 07, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	>A> 7731686	Jun 10, 2026	DP			
	>A> 7731690	Jan 15, 2025	DP			
	>A> 7749194	Oct 30, 2028	DP			
	>A> 7918823	Nov 23, 2024	DP			
	>A> 7947017	Mar 12, 2028	DP			
	>A> 8016788	Mar 21, 2025	DP			
	>A> 8021344	Nov 02, 2029	DP			
	>A> 8206360	Feb 27, 2027	DP			
	>A> 8223610	Apr 10, 2029	DP			
	>A> 8231573	Nov 25, 2028	DP			
	>A> 8313466	Nov 23, 2024	DP			
	>A> 8361029	Nov 23, 2024	DP			
	>A> 8425462	Nov 23, 2024	DP			
	>A> 8608698	Nov 23, 2024	DP			
	>A> 8627816	Feb 04, 2032	DP			
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 203411 001					PC	Oct 12, 2014
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 205258 001					PC	Oct 12, 2014
<u>NIACIN - NIACIN</u>						
A 076250 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 002					PC	Mar 19, 2014
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8663680	Feb 13, 2020	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002					M-132 PED	Dec 21, 2013 Jun 21, 2014
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					M-132 PED	Dec 21, 2013 Jun 21, 2014
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545 001	5641805	Jun 06, 2015	U-765	Y		
	5641805*PED	Dec 06, 2015				
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	>A> 5792795	May 13, 2016	DP			
	>A> 5948818	May 13, 2016	DP			
	>A> 7960370	Feb 07, 2025	DP			
	>A> 8383678	Feb 07, 2025	DP U-1511			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Mar 01, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8637540	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8637540	Nov 26, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	5202333	Apr 13, 2015	DS DP U-528		>A> I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			>A> M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		>A> PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			>A> PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	>A> 8729094	Jan 30, 2024	DP U-528			
	>A> 8729094*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	5202333	Apr 13, 2015	DS DP U-901		>A> I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			>A> M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		>A> PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			>A> PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8658663	Apr 06, 2029	DS DP U-904			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Apr 20, 2019	DP			
	8685441	Jan 13, 2019	U-665			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8626531	Oct 23, 2020			U-1361	
	8673939	May 15, 2023			U-1360	
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8626531	Oct 23, 2020			U-1361	
	8673939	May 15, 2023			U-1360	
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8626531	Oct 23, 2020			U-1361	
	8673939	May 15, 2023			U-1360	
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8626531	Oct 23, 2020			U-1361	
	8673939	May 15, 2023			U-1360	
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	5661151	Jul 19, 2019	DS DP U-1454			
	5703079	Aug 26, 2014	DS DP U-1454			
	8410077	Mar 13, 2029	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	8679533	Sep 08, 2029	DP U-219			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	8679533	Sep 08, 2029	DP U-219			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8338489	Oct 16, 2028	U-1496		NP ODE	Mar 14, 2017 Mar 14, 2021
<u>RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE</u>						
A 078193 001					PC	Sep 24, 2014
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022		U-257		
	7435734	Oct 21, 2022		U-257		
	7754731	Mar 11, 2029	DS DP	U-257		
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 001					>A> I-685	May 29, 2017
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 002					>A> I-685	May 29, 2017
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Jul 08, 2029	DS DP			
	8680124	Jul 20, 2028		U-1506		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001 >A>	8518949	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8642573	Oct 02, 2029		U-1481		
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8618142	Mar 08, 2024	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001 >A>	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002 >A>	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003 >A>	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004 >A>	8722693	Jun 12, 2028	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005 >A>	8722693	Jun 12, 2028	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP		NPP	Apr 23, 2017
	7566462*PED	May 16, 2026			ODE	Dec 13, 2014
	7566714	Nov 17, 2024		U-989	PED	Jun 13, 2015
	7566714*PED	May 17, 2025			PED	Oct 23, 2017
	7612073	Nov 17, 2024		U-1010		
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024		U-1156		
	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 17, 2015				
	8067416	Nov 17, 2024		U-989		
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	RE43797	Nov 17, 2024		U-1156		
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-134	May 24, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	002				M-134	May 24, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845	001				D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473	001				D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109	001				D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SIROLIMUS - SIROLIMUS</u>						
A 201676	003				PC	Jul 15, 2014
<u>SODIUM OXYBATE - XYREM</u>						
N 021196	001	>A> 8731963	Dec 17, 2022	U-1110		
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671	001	8618076	Dec 11, 2030	DS DP U-1470		
		8633309	Mar 26, 2029	DS DP U-1470		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	008	8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	009	8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	010	8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923	001	8618141	Feb 11, 2023	U-1480		
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239	001	6174304	Dec 13, 2015	DP		
		6251091	Dec 09, 2016	DP		
		6280410	Mar 27, 2017	DP		
		6681810	Dec 13, 2015	DP		
		8241243	Aug 10, 2023	DP		
		8491524	Nov 21, 2022	DP		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	5856529	Dec 09, 2017	DS DP U-1486	NCE ODE	Jan 31, 2019 Jan 31, 2021
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710	001				PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710	002				PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710	003				PC	Jul 07, 2014
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277	001	8623868	Feb 21, 2023	DP		
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088	001	5362718	Feb 15, 2019	DS DP	Y	
		5362718*PED	Aug 15, 2019			
		>A> 8722700	Jul 25, 2023	DP		
		>A> 8722700*PED	Jan 25, 2024			
		RE44768	Feb 15, 2019	DS DP		
		RE44768*PED	Aug 15, 2019			
<u>TESTOSTERONE - NATESTO</u>						
N 205488	001				>A> NP	May 28, 2017
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219	001	7718640	Mar 14, 2027	DP	NP	Mar 05, 2017
		8338395	Feb 27, 2026	U-1500		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	8626531	Oct 23, 2020	U-1465			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6645963	Nov 16, 2018	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001					M-135	Feb 21, 2017
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5753677	May 19, 2020	U-978			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	8652527	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAVOPROST - IZBA</u>						
N 204822 001	>A> 8722735	Oct 10, 2029	DP		>A> NP	May 15, 2017
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	8653137 8658694	Sep 05, 2028 Sep 05, 2028	U-1437 U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	8653137 8658694	Sep 05, 2028 Sep 05, 2028	U-1437 U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	8653137 8658694	Sep 05, 2028 Sep 05, 2028	U-1437 U-1437			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	>A> 5873360	Feb 23, 2016	DP			
	>A> 7488827	Apr 27, 2025	DS DP			
	>A> 7498440	Apr 27, 2025	DS DP			
	>A> 8113199	Oct 23, 2027	DP			
	>A> 8161968	Feb 05, 2028	DP			
	>A> 8183257	Jul 27, 2025			U-1476	
	>A> 8201556	Feb 05, 2029	DP			
	>A> 8309572	Apr 27, 2025			U-1476	
	>A> 8534281	Aug 10, 2029	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	>A> 8201556	Feb 05, 2029	DP		NP	Dec 18, 2016
<u>UROFOLLITROPIN - BRAVELLE</u>						
N 021289 001					>A> D-139	Feb 19, 2017
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	8642608	Feb 06, 2022	U-1490			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	8613950	Dec 23, 2028	DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	8673921	Jun 05, 2022	DS DP			
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	>A> 7235567	Jun 13, 2021	DS DP		>A> NCE	May 08, 2019
	>A> 7304078	Apr 06, 2024	DS DP	U-1512		
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	8450372	Mar 18, 2028	U-892			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	>A> 8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	>A> 8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	>A> 8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	>A> 8722684	Nov 11, 2030	DS DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003	6750237	Nov 28, 2020	DP			
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020	DP			
	7220767*PED	May 28, 2021				

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>